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Colorectal cancer (CRC) is a common disease in all western countries. In Finland, 3360 new CRC 
patients were diagnosed in the year 2016. The incidence of CRC continues to rise in countries in 
which screening has not been launched; the diagnostic delay for CRC could be longer than that for 
other common malignancies. The CRC treatment process has been revolutionised over the past years, 
and the prognosis of CRC has improved, but we lack information regarding the prognostic and 
predictive factors that would help us to optimise the therapy for an individual patient. In addition, 
with improved survival rates, both acute and long-term toxicities require more attention. 
Hypertension (HTN) is a well-recognised adverse event that is associated with all drugs involved in 
anti-VEGF (vascular endothelial growth factor) inhibition. The first study discussed in this thesis 
investigated whether HTN could act as a surrogate marker for efficacy during bevacizumab-
containing therapy. We had 101 consecutive patients with mCRC, who had been treated with 
bevacizumab-containing palliative chemotherapy. We observed that patients who developed any 
grade of HTN showed a significantly improved response rate (RR) (30 vs. 20%; P= .025), median 
progression-free survival (mPFS) (10.5 vs. 5.3 months; P= .008), and median overall survival (mOS) 
(25.8 vs. 11.7 months; P< .001), compared to normotensive patients. In a multivariate landmark 
survival analysis, the development of HTN within 3 months after the start of therapy was an 
independent predictor of survival (HR 0.53; P= .007), along with the presence of other known mCRC 
prognostic factors. The significant association between HTN and treatment outcome was independent 
of the treatment line. According to our results, treatment-associated HTN might predict the outcome 
of bevacizumab-containing chemotherapy in mCRC patients and could potentially be utilized as a 
biomarker for continued care. However, our data require validation in large prospective studies. 
Though the prevalence of Helicobacter pylori (H. pylori) has decreased in Finland, it continues to be 
a major public health problem worldwide. The role of the H. pylori infection as a confounding 
gastrointestinal comorbidity in the diagnosis of CRC is not well known, and it is not established 
whether H. pylori infection worsens chemotherapy-induced gastrointestinal toxicity. It is known that 
the diagnosis of CRC can be delayed owing to the misinterpretation of symptoms by both a patient 
and doctor and owing to the comorbidities present. In the second sub-study, we studied the role of 
different symptoms and H. pylori for diagnostics in seventy-nine radically operated stage II-IV CRC 
patients. Of these, thirty-seven patients (47%) were H. pylori-seronegative at the baseline and forty-
two (53%) were seropositive. We observed that diagnosis was significantly delayed in patients who 
presented with functional dyspeptic symptoms (7.5 vs. 5 months; P= .035), but it was not delayed in 
patients with anaemia, bowel symptoms, occlusion, blood in the stool, infection, and hypolactasia. 
Likewise, the H. pylori infection was associated with a delay in diagnostics. The median time from 
CRC symptom onset to surgery in H. pylori-infected patients was significantly longer, as compared 
to that in non-infected individuals (6 vs. 5 months; P= .012). All patients were treated with 5-
fluorouracil (5-FU)-based adjuvant chemotherapy. H. pylori seropositivity at the baseline was not 
associated with oro-gastrointestinal toxicity during chemotherapy. In conclusion, dyspeptic 
symptoms and the presence of H. pylori infection at the baseline delayed the initial diagnosis of CRC, 
which highlights the importance of thorough diagnostics. However, there is no association 
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between H. pylori infections and gastrointestinal adverse events during 5-FU-based adjuvant 
chemotherapy. Therefore, the eradication of H. pylori infections before providing 5-FU-based 
adjuvant chemotherapy cannot be routinely recommended.  
The association between survival and adverse events in several types of cancer and especially those 
related to targeted therapies has been established, but data for CRC patients, and notably for those 
with early-stage CRC, are limited. In the third sub-study, we assessed whether adverse events could 
predict disease-free survival (DFS) or OS in stage II-III CRC patients. We pooled material from two 
prospective clinical trials and studied 1033 stage II-III CRC patients treated with 5-FU-based adjuvant 
chemotherapy. Adverse events of interest included haematological (leukopenia, neutropenia, 
thrombocytopenia) and non-haematological (e.g., mucositis, diarrhoea, nausea/vomiting, hand-foot 
syndrome) events. Any grade of neutropenia was associated with improved DFS (HR 0.76 CI95% 0.61-
0.95), while any grade of nausea/vomiting was associated with improved DFS (HR 0.74 CI95% 0.59-
0.92) and OS (HR 0.58 CI95% 0.45-0.75), and mucositis was associated with improved DFS (HR 0.70 
CI95% 0.56-0.88) and OS (HR 0.67 CI95% 0.52-0.88). Patients experiencing all three of these adverse 
events had the best outcome, whereas patients reporting no adverse events had the worst survival 
rates. According to our results, adverse events related to treatment with adjuvant 5-FU chemotherapy 
in early stage CRC patients, especially non-haematological adverse events, are strongly associated 
with the prediction of improved DFS and OS. Our findings require validation in large prospective 
trials, but if established, adverse events could guide the clinician in bringing about dose modifications, 
to maximize the treatment efficacy, while ensuring a lesser level of toxicity.  
The use of oxaliplatin in the adjuvant setting reduces the risk of death 20% in stage III CRC patients. 
The major adverse event associated with oxaliplatin-based regimens is peripheral neuropathy, but the 
prevalence of acute and long-term neuropathy is not well established, especially in a subarctic 
climate, such as that observed in Finland. It is not well known whether there is a difference in the 
neuropathy observed with two standard regimens, i.e., oxaliplatin with capecitabine (CAPOX) and 
infusional 5-FU (FOLFOX), and whether long-term neuropathy influences the quality of life (QOL). 
In the fourth sub-study, we analysed the prevalence of oxaliplatin-induced acute and long-term 
neuropathy during and after treatment with CAPOX and FOLFOX and studied the effect of long-term 
neuropathy on QOL in a real-life patient population. One hundred and forty-four early stage CRC 
patients (72 CAPOX patients and 72 matched FOLFOX controls) were identified and evaluated for 
acute neuropathy (according to NCI-CTCAEv3.0) during adjuvant treatment. Ninety-two long-term 
survivors responded to QOL (EORTC QLQ-C30) and chemotherapy-induced peripheral neuropathy 
(EORTC CIPN-20) questionnaires and were prospectively evaluated for long-term neuropathy. Any 
grade of neuropathy was found to be present in 69% of patients at 4.2 years, at the median follow-up. 
Though neuropathy grade 2-4 did not influence the global health status, it was associated with 
decreased physical functioning (P= .031), role functioning (P= .040), and more diarrhoea (P= .021) 
in QLQ-C30 items. There were no differences in acute or long-term neuropathy between CAPOX- 
and FOLFOX-treated patients, and no seasonal variation was observed. We noted a significant 
association between acute and long-term neuropathy. Grade 0-1 acute neurotoxicity was significantly 
worsened to grade 2-4 long-term neuropathy in 36%, or 5 out of 14 patients. The ECOG 1 
performance status at the baseline was a significant risk factor for long-term neuropathy. According 
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to our results, long-term neuropathy is observed after therapy in a significant proportion of patients 
and is severe in some patients, but it does not impair global health status. At least in a subarctic 
climate such as that in Finland, long-term neuropathy is not preventable in all patients with a reduction 
in the duration of therapy, but the performance status might predict the risk of long-term neuropathy. 




CRC is the third most common cancer worldwide after lung- and breast cancer, and is the second 
most common cancer in Europe (Bray et al., 2018). In addition, it is the second most common cause 
of cancer-related death after lung cancer in the western world and Europe. In 2018, there were 1.8 
million new CRC patients diagnosed worldwide, of which 499 667 were diagnosed in Europe and 
694 000 died worldwide due to CRC; of these, 242 483 were from Europe. There has been an increase 
in the awareness about CRC in the general population, along with screening programmes that have 
been launched in several countries (Jones et al., 2010a). Nevertheless, the patient- or doctor-related 
diagnostic delays for CRC could sometimes be long (Korsgaard et al., 2008). Symptoms of CRC can 
be vague, and diagnostics can be confounded by other comorbidities, because of which the clinician 
needs to be vigilant (Walter et al., 2016).  
The prognosis for CRC has constantly improved during the past two decades and overall 5-year 
survival rates currently exceed 60% (Allemani et al., 2018). Concerning early stage CRC, prognosis 
has improved due to the use of improved surgical techniques and 5-FU and oxaliplatin based adjuvant 
therapies in high-risk stage II and stage III patients (Andre et al., 2004b; Labianca et al., 2013). 
However, biological agents such as bevacizumab and epidermal growth factor receptor inhibitors 
(EGFR-inhibitors) that improved outcomes in mCRC patients have failed in adjuvant trials  (Alberts 
et al., 2012; Allegra et al., 2011; de Gramont et al., 2012; Taieb et al., 2014). Recent studies in the 
adjuvant setting have mainly focused on optimizing the delivery and duration of the therapy, but we 
need tools to develop a specialised adjuvant therapy for each individual. The majority, i.e., 70-75% 
of patients, have local, early-stage disease at diagnosis. Despite the improvement in survival rates, 
there is still room for improvement, as it has been estimated that around 30%, even up to 50% of 
patients treated with a curative intent have ultimately relapsed, which emphasizes the need for 
improvements to be made in adjuvant therapy (Schmoll et al., 2012).  
Evidence of an underlying, multifactorial biological background, which leads to the development of 
different CRC subtypes that are associated with different clinical courses and treatment responses, is 
rapidly increasing. From a historical perspective, 5-FU-based chemotherapy alone was the treatment 
for mCRC for three decades (Machover, 1997). The prognosis of the untreated disease is 
approximately 2-6 months (Sorbye et al., 2009), and with the use of the single agent 5-FU, survival 
improved up to 12 months. After irinotecan and oxaliplatin were introduced for clinical use, 
combination chemotherapies improved the mOS up to 20 months (Goldberg, 2005; Tournigand et al., 
2004). Today, the mOS exceeds 30 months in clinical trials, with the use of biological agents (Van 
Cutsem et al., 2016). Approximately 10-15% of patients with metastatic disease survive for more than 
five years (Ahmed et al., 2013; Cronin et al., 2018a).  
Almost two thirds of CRC patients treated with curative intent were alive five years after the 
diagnosis, and they represent the third most common group of cancer survivors after prostate and 
breast cancer patients (Bray et al., 2018). Because of the improved prognosis, the prevalence of CRC 
survivors is likely to increase over the coming decades. Therefore, though it is important to study 
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acute adverse events, we also need to study long-term toxicities and what kind of impact those may 
have on the QOL in CRC survivors.  
CRC is a heterogeneous malignancy and the course of the disease and treatment outcome can vary 
widely between individuals. We still have very few tools for optimizing treatments on an individual 
basis. In clinical practice, the TNM mainly guide the decision regarding the adjuvant therapy. In 
mCRC patients, only RAS mutations act as negative predictive markers for therapy by excluding 
patients not benefitting from EGFR- inhibitors. We need validated biomarkers that would be reliable 
in everyday clinical practice, to select precision medicines for each patient. We also need to 
understand which patient would benefit more from continuous treatment, as we are currently exposing 
some patients to toxicities without any benefit.  
Even though we live in the era of tailored individual cancer therapies, we estimate the dose of 
available drugs based on the body-surface-area (BSA) (Gurney, 2002). It is especially well recognised 
that during treatment with 5-FU, significant level of variation is observed in the metabolism of 
individuals (Saif et al., 2009); thus, we currently treat some patients without sufficient dose-intensity, 
thereby compromising the optimal outcome, while exposing other patients to excessive toxicity. It is 
questionable whether we are optimally exploiting the standard drugs available at present. Instead of 
carrying out intensive research on new agents, it might be worth to shift some focus towards toxicity-
based and pharmacokinetically guided dose escalation.  
This thesis was conducted to investigate some clinically relevant issues in this field. Since we lack 
knowledge about predictive factors in the treatment of CRC, we were interested in studying whether 
typical, treatment-related adverse events were associated with treatment outcomes and if they could 
act as useful predictive factors. We were also interested in studying if evidence regarding H. Pylori 
colonisation interferes with CRC diagnostics and if it increases acute gastrointestinal toxicity during 
5-FU-based adjuvant chemotherapy. Finally, long-term neuropathy after oxaliplatin-based adjuvant 






5. REVIEW OF THE LITERATURE 
5.1 Epidemiology  
CRC is a considerable health issue that contributes to a remarkable cancer burden globally, especially 
in the western world, as it mostly affects countries with a high standard of living (Bray et al., 2018). 
In the western world, CRC is the third most common cancer in men, after lung and prostate cancer, 
and the second most common cancer in women after breast cancer, with approximately 1.8 million 
new CRC cases observed worldwide in the year 2018. The statistics are the same for Finland; CRC 
is the third most common cancer in Finland as well, as 3360 patients were diagnosed with CRC in 
the year 2016 (Cancer_registry, 2018).  
In six years, the number of CRC patients has increased by 0.6 million; statistics reported by 
GLOBOCAN from the year 2012 showed that 1.2 million new patients had been diagnosed (Ferlay 
et al., 2014). It is predicted that 3.1 million new CRC cases would be reported globally in 2040 (Bray 
et al., 2018). A significant increase in the incidence of CRC is attributable to the rapidly increasing 
CRC incidence rates in many low- and middle-income countries, especially in Eastern Europe, Asia, 
and South America, as they are adapting western lifestyles (Center et al., 2009). Some stabilising or 
decreasing trends in incidence have been observed in highly developed countries, especially in the 
United States, probably due to systematic screening and early prevention (Ansa et al., 2018). In 
Finland, the incidence of CRC continues to increase (Cancer_registry, 2018). 
With regard to mortality, CRC is the second leading cause of cancer death, both in the United States 
and Europe, including in Finland after lung cancer (Bray et al., 2018; Cronin et al., 2018a). There 
were 0.9 million deaths due to CRC in 2018, and it is predicted that 1.6 million deaths would be 
reported in 2040. In Finland, 1303 individuals died due to CRC in 2016 (Cancer_registry, 2018). 
Mortality trends are showing a decrease in most developed countries, such as Finland, because of an 
improvement in therapeutic options, and because of screening and early detection in some countries 
(Bray et al., 2018; Cancer_registry, 2018; Van Cutsem et al., 2016). 
Prognosis for both early-stage and metastatic CRC has improved during the past twenty years, and 
especially over the past ten years (Allemani et al., 2018; Van Cutsem et al., 2016). The current 5-year 
overall survival rates in Europe exceed 60%, and are among the highest in Finland; 5-year survival 
rates of 64.9 % (CI95% 63.7–66.2) and 64.4 % (CI95% 62.6–66.1) have been observed for rectal and 
colon cancers, respectively, according to recently published statistics (Allemani et al., 2018). Thus, 
the number of CRC survivors has increased globally and in Finland, and represents the third largest 
group of cancer survivors, after the groups of prostate and breast cancer survivors; the prevalence is 
likely to continue to increase in the future (DeSantis et al., 2014). In patients with mCRC, the median 
survival duration in randomized trials exceeds 30 months (Van Cutsem et al., 2016) and 
approximately 10-15% of patients with mCRC survive beyond five years (Ahmed et al., 2013; Cronin 
et al., 2018b). 
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5.2 Risk factors  
Age is a major risk factor for CRC. It is uncommon for the disease to occur before the age of 40, after 
which the risk begins to rise and increases significantly after the age of 50 (Cancersociety_fi, 2018). 
The median age at diagnosis is about 70 years (Jarvinen et al., 2013) . However, according to recent 
data, there has been a steady increase in CRC incidence in groups of individuals with age below 50, 
and even in those with an age of 20, for unexplained reasons (Austin et al., 2014). There is a strong 
association between CRC and the western lifestyle, which is characterized by the high consumption 
of red and processed meat, low dietary intake of fruit, vegetable, and fibre, obesity, smoking, 
excessive use of alcohol, and low physical activity (Grosso et al., 2017; Tuan and Chen, 2016). 
Inflammatory bowel disease is an independent risk factor for CRC, but due to improvements in 
treatments and surveillance, only a minority of patients with inflammatory bowel disease develop 
CRC (Annese et al., 2015).  
It is estimated that about 70-75% of newly diagnosed CRC cases are sporadic without any 
predisposing factors or positive family history, about 5% are attributable to a known, predisposing 
genetic condition and in the rest of the cases there is an underlying, hereditary contribution by not yet 
identified genes. (Brandão and Lage, 2015). The lifetime risk of development of CRC in an “average” 
western individual is about 5-6%, but the risk increases up to 20%, if first- and/or second-degree 
relatives have a history of CRC (Jasperson et al., 2010; Rustgi, 2007).  
The most common genetic condition associated with CRC is the Lynch syndrome (hereditary non-
polyposis colorectal carcinoma, HNPCC), which accounts for about 3-4% of all CRC cases. In a 
patient with Lynch syndrome, the lifetime risk for developing CRC without appropriate follow-up is 
up to 90%, and there is also an increased risk of development of other malignancies, such as 
gynaecological and urogenital (Lynch et al., 2009; Watson et al., 2008). Other genetic conditions 
occur very rarely (Syngal et al., 2015). Only approximately 1% of CRC cases are attributable to 
familial adenomatous polyposis (FAP), and less than 1% of cases occur due to rare polyposis 
syndromes such as MYH-associated polyposis.  
5.3 Pathways in the carcinogenesis of CRC 
CRC is a heterogeneous disease that develops through multiple genetic and epigenetic alterations, 
which can be activated by environmental, inherited, or both factors (Bardhan and Liu, 2013). It is 
thought that CRC develops through two different morphological pathways. The first pathway 
involves the so-called classical adenoma-carcinoma sequence, which begins with premalignant 
lesions that are comprised of conventional adenomas, including tubular or tubulovillous adenomas 
(Fearon and Vogelstein, 1990; Tannapfel et al., 2010). Secondly, there is the so-called serrated 
neoplasia pathway, which begins with the development of sessile or traditional serrated adenomas or 
hyperplastic polyps. These two morphologic pathways are driven by different, partly overlapping 
molecular pathways that can be divided into three groups, depending on the mechanism by which the 
tumour develops (Bae et al., 2016; Nazemalhosseini Mojarad et al., 2013; Worthley and Leggett, 
2010). The first group consists of germline or sporadic mutations in DNA mismatch repair genes, 
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which lead to the development of a DNA microsatellite instability (MSI) phenotype. The second 
group consists of mutations in APC or other genes activating the Wnt pathway, which leads to the 
development of the chromosomal instability (CIN) phenotype. Tumours in the third group develop 
as result of global genome hypermethylation, which lead to the silencing of the tumour suppressor 
gene (CIMP) phenotype. CIMP is associated with the sporadic MSI phenotype (Nazemalhosseini 
Mojarad et al., 2013).  
All the above-mentioned groups have distinct genetic, pathologic, and clinical characteristics. The 
classification of CRC tumours into six different gene expression-based groups has been described, 
and there are three to six subgroups in each group, to classify CRC tumours into subtypes (Guinney 
et al., 2015). To resolve the inconsistencies among these classifications and facilitate their clinical 
translation and utility, an international consortium was formed. Based on a large set of gene 
expression and molecular, mutational, histological, and clinical data, it was possible to identify four 
different consensus molecular subtypes (CMS) of CRC tumours (Guinney et al., 2015). These 
subtypes are: CMS1 (MSI immune subtype including MSI, CIMP-high, hypermutated, and BRAF 
positive subtypes), CMS2 (canonical subtype, WNT/MYC pathway activation, high in somatic copy 
number alterations), CMS3 (metabolic subtype: SCNA/CIMP-low, KRAS mutations, and metabolic 
dysregulation), and CMS4 (mesenchymal subtype with high somatic copy number alterations and 
with prominent transforming growth factor-β, TGF-β, activation, stromal invasion and angiogenesis). 
According to Guinney et al., 14%, 37%, 13%, and 23% of tumours are of the CMS1, CMS2, CMS3, 
and CMS4 type (Guinney et al., 2015). The rest of the tumours are so-called mixed or intermediate 
tumours, and it is not possible to classify them effectively into any of the subtypes. The CMS 
classification system will be further discussed in section 5.11. 
5.4 Symptoms and diagnostics 
The symptoms and prognosis of CRC are directly associated with the growth of the tumour into the 
lumen of the bowel and the stage of the disease, which is determined by the extent of tumour growth 
through the bowel wall into adjacent organs and lymph nodes, and by the presence of distant 
metastases (Brenner et al., 2014; Greene et al., 2002). Classical symptoms that are alarming with 
regard to a CRC diagnosis include changes in bowel habits, especially in combination with an 
increase in the age and tumour bleeding (Glynne-Jones et al., 2017; Labianca et al., 2013). Bleeding 
could be either visible in the stool, especially in distal cancer, or can be microscopic, especially in 
proximal tumours that lead to iron deficiency and microcytic anaemia (John et al., 2011). In some 
instances, CRC presents with bowel obstruction, but weight loss, abdominal pain, and weakness are 
often associated with a more advanced stage. Symptoms and signs of CRC are often vague, non-
specific, and long lasting, and their gradual increase makes the diagnostics challenging. CRC was 
observed to mimic even functional dyspepsia, and demonstrate a variety of symptoms that it might 
present with (O'Reilly and Long, 1987). 
In cancer, early diagnosis is always important. It is important to improve prognosis and diminish 
psychological distress. Since CRC develops from recognizable, precancerous polyps, which can be 
detected and removed before they become cancerous, it has been of interest to screen CRC to detect 
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early-stage disease. Screening was shown to reduce mortality and be cost-effective (Issa and 
Noureddine, 2017). Screening programmes have been launched in some countries, but not in all. In 
Finland, screening was launched, but faecal occult blood screening did not reduce mortality in a pilot 
analysis (Pitkäniemi et al., 2015). The recommended screening method for the average-risk 
population is either an annual or biennial faecal immunochemical test (FIT), sigmoidoscopy every 5 
years, or colonoscopy every 10 years (Bénard et al., 2018; Schoen et al., 2012). The participation rate 
for screening has varied significantly between nations and was 70% in Finland (Pitkäniemi et al., 
2015). As long there is a lack of a nationwide screening program and participation rates are not 
satisfactory, it is not possible to detect pre-cancerous lesions and very early stages of CRC.  
Even though screening programmes and media campaigns have increased general awareness 
regarding CRC (Jones et al., 2010a; Jones et al., 2010b), patient or health care system-related 
diagnostic delays are seen more often in CRC than in other common cancers (Korsgaard et al., 2008; 
Van Hout et al., 2011). One third of patients diagnosed with CRC have three or more consultations 
with a general practitioner before referral, as compared with that of only 17.9% for other cancers in 
a British patient material (Lyratzopoulos et al., 2013). This is mostly due to the vague nature of CRC 
symptoms, but it was shown that even rectal bleeding did not always lead to colonoscopy, if bleeding 
had already been long lasting (Walter et al., 2016).  
The diagnostic delay of CRC can also be associated with other abdominal cancers and gastrointestinal 
comorbidities, and the diagnostic work-up can be confused by those, or terminated too early, due to 
another condition being diagnosed first (Walter et al., 2016). H. pylori, discussed in detail in section 
5.5.1, is most commonly associated with dyspepsia (Malfertheiner et al., 2012). Its prevalence in 
Finland has remarkably decreased over the past decades and the same trend is seen in other western 
countries, as its prevalence is associated with socioeconomic status (Hooi et al., 2017). Globally, 
more than half of the world’s population is infected with H. pylori. Another common gastrointestinal 
complaint is lactose intolerance. Finnish individuals tolerate lactose well, but globally, lactose 
intolerance affects most of the world’s population (Storhaug et al., 2017). Data showing H. pylori and 
lactose intolerance to be confounding comorbidities in CRC diagnostics are scarce. 
5.5 Gut microbiota  
The entire gastrointestinal tract and especially the large intestine harbours an enormous number of 
bacteria, viruses, and fungi (Proctor, 2011). The composition of microbiota is highly dependent on 
lifestyle and environmental factors, and is affected by age. Therefore, there is great variation in 
microbiota, both intra-individually and inter-individually (D'Argenio and Salvatore, 2015; David et 
al., 2014; Perez-Cobas et al., 2013; Yatsunenko et al., 2012). Gut microbiota has a huge metabolic 
capability and has several important metabolic functions, including the production of vitamins, 
synthesis of amino acids, absorption of ions, participation in the conversion of dietary polyphenolic 
compounds, and it is involved in the biotransformation of bile acids (Boleij and Tjalsma, 2012; 
Jandhyala et al., 2015). Together with these metabolic functions, the intestinal microbiota plays a 
fundamental role in the induction, education and function of the immune system (Belkaid and Hand, 
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2014). It maintains the intestinal barrier and is essential in assisting in the generation of an adequate 
immune response to pathogens.  
Several reports support the fact that dysbiosis, i.e., the imbalance in normal intestinal microbiota, 
which could be a consequence of environmental factors, infections, antibiotics, surgery, and 
chemotherapy, plays an essential role in several health conditions, such as obesity, diabetes, 
inflammatory bowel disease, and several autoimmune diseases (Belkaid and Hand, 2014; Blainey et 
al., 2012; Maloy and Powrie, 2011; Osborn and Olefsky, 2012; Turnbaugh et al., 2006; Wu et al., 
2010). In addition, increasing amounts of evidence have shown that microbiota is a promoter and 
modifier in CRC carcinogenesis (Schwabe and Jobin, 2013). Inflammation is an important driver of 
carcinogenesis in CRC and the microbiota is important for modifying inflammatory responses 
(Belkaid and Hand, 2014). There is a complicated network between bacteria with the ability to shape 
a pro-tumorigenic environment, by driving the generation of pro-inflammatory responses and bacteria 
with protective, anti-inflammatory capabilities (Chow et al., 2010; Reinoso Webb et al., 2016). The 
microbiota shared by healthy adults most abundantly includes Firmicutes, Bacteroidetes, and 
Actinobacteria, while Proteobacteria, Fusobacteria, Cyanobacteria, and Verrucomicrobia are 
usually less well represented (D'Argenio and Salvatore, 2015). No single carcinogenic pathogen is 
identified in CRC, but increasing amounts of evidence suggest that some bacteria play an especially 
important role in colorectal carcinogenesis, such as Streptococcus bovis, Bacteroides 
fragilis, Enterococcus faecalis, Clostridium septicum, Fusobacterium spp., and Escherichia coli 
(Chen et al., 2012; Gagniere et al., 2016; Gao et al., 2015).  
The incidence of CRC is strongly associated with a western lifestyle. Gut microbiota is unfavourably 
modified by the lack of physical activity, obesity, and a western diet (Gagniere et al., 2016). CRC is 
associated with the reduced abundance of protective bacteria, such as Clostridium and Roseburia, 
which are important producers of butyrate (Ríos-Covián et al., 2016). Butyrate is the most important 
of all the short chain fatty acids, which are energy sources for colonocytes, and are released by the 
fermentation of complex carbohydrates using colonic bacteria. Butyrate plays a protective role against 
carcinogenesis, by promoting colon motility, improving visceral blood flow, preventing the 
overgrowth of pathogens, reducing inflammation, inducing apoptosis, and inhibiting tumour cell 
progression. The presence of fibre significantly induces the production of short chain fatty acids; 
therefore, a fibre-rich diet is shown to reduce CRC risk (Howe et al., 1992). 
Studies demonstrate that there are differences in the drug metabolism of individuals due to differences 
in their microbiota (Gimenez-Bastida et al., 2018; Li et al., 2016; Scott et al., 2017). The amount of 
data available with regard to chemotherapeutic agents and microbiota is still scarce, but continues 
to increase. Microbiota can mediate treatment efficacy and toxicity by direct enzymatic activity and 
biochemical conversion of a drug (Alexander et al., 2017). Scott et al. explored whether the host 
response to 5-FU can be mediated by bacteria using the nematode Caenorhabditis elegans as a model 
(Scott et al., 2017). C. elegans were colonized with different strains of Escherichia coli and 
investigators observed up to 80-fold changes in the 5-FU efficacy, depending on the bacterial strain 
C. elegans was colonized with. Toxicity was measured in terms of nematode fertility. It was also 
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suggested that bacterial ribonucleotide metabolism is the primary mediator of 5-FU efficacy in C. 
elegans.  
Irinotecan is activated by hydrolysis to form SN-38, an inhibitor of topoisomerase 1 (Mathijssen et 
al., 2001). It is deactivated in the liver by hepatic glucuronidation, producing SN-38G, which is then 
excreted into the gut with bile. Bacterial ß-glucuronidases in the gut lumen have the ability to 
reactivate SN-38G to its active, enterotoxic form, which leads to mucositis (Guthrie et al., 2017). 
There are numerous bacterial ß-glucuronidase isoforms that differ with regard to their substrate 
pharmacokinetics; therefore, there are differences between individuals with regard to the bacterial 
capability to reactivate SN-38G, depending on the presence of specific bacterial ß-glucuronidases and 
glucuronide membrane transporters (Wallace et al., 2015). The characterization of microbiota might 
identify patients at increased risk of developing irinotecan induced mucositis and diarrhoea. It was 
shown that ciprofloxacin and low doses of amoxapine were effective in the suppression of bacterial 
ß-glucuronidase activity and therefore decreased the risk for mucositis (Kodawara et al., 2016; Kong 
et al., 2014).  
Microbiota can also mediate chemotherapeutic efficacy, by regulating the tumour 
microenvironment. In a study by Iida et al., three different cancer cell lines (including a CRC cell 
line) were transplanted under the skin of germ-free mice, mice treated with wide-spectrum 
antibiotics, and conventional mice (Iida et al., 2013). Germ-free mice and mice treated with wide-
spectrum antibiotics lack normal commensal bacteria. After tumour growth, the mice were treated 
with immunotherapy or chemotherapy, using either oxaliplatin or cisplatin. Concerning 
oxaliplatin, reactive oxygen species (ROS) are essential for DNA damage and apoptosis in response 
to platinum compounds (Ozben, 2007). ROS are produced by tumour-infiltrating myeloid cells, but 
their production requires an induction signal from commensal bacteria. It was observed that in germ-
free mice and mice treated with antibiotics, the tumour-infiltrating myeloid-derived cells produced 
lower levels of ROS (Iida et al., 2013). In these mice, the outcome of treatment with oxaliplatin was 
inferior, as compared to that in mice with an intact gut microbiota exhibiting normal microbiota 
mediated ROS production. 
Even some fatal drug interactions during chemotherapy are probably mediated by microbiota 
metabolism, as observed in Japan, where sixteen patients treated with anti-viral drug sorivudine (1-
β-D-arabinofuranosyl-5-(E)-(2-bromovinyl) uracil) and 5-FU died over a 40 day period due to the 
excessive toxicity of 5-FU (Diasio, 1998). It was noted that the Bacteroides species, B. vulgatus, B. 
thetaiotaomicron, B. fragilis, B. uniformis, and B. eggerthii secrete high concentrations of 
phosphorolytic enzymes hydrolysing sorivudine to (E)-5-(2-bromovinyl) uracil (BVU). BVU in 
turn inhibits the DPD enzyme, which leads to the inactivation of 5-FU and these patients died 
because of fatally high 5-FU concentrations.  
 Helicobacter pylori 
Helicobacter pylori (H. pylori) is a gram-negative bacterium colonizing the gastric epithelium and is 
classified as a group I carcinogen since 1994 (Anonymous, 1994; Warren and Marshall, 1983). It 
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does not invade or reside in the colonic mucosa, but is known to move through the colonic lumen, as 
detected by immunohistochemistry in neoplastic colorectal tissue. A majority of infected patients are 
asymptomatic, but H. pylori is a known cofactor in some important gastrointestinal conditions 
(McColl, 2010). It plays a role in the development of duodenal and gastric ulcers. In H. pylori positive 
dyspeptic patients, eradication of the bacterium can lead to long-term relief of symptoms and 
dyspepsia therefore remains an accepted indication for H. pylori eradication (Malfertheiner et al., 
2012). It is the most important risk factor for atrophic gastritis and gastric cancer, as is it estimated 
that the development of almost 90% of all gastric cancers could be attributable to H. pylori infections 
(Herrero et al., 2014). In addition, there is a strong association between gastric MALT lymphomas 
and H. pylori infections, and the eradication of H. pylori could be sufficient to cause the regression 
of most localized gastric MALT lymphomas (Fischbach et al., 2004). Even though the incidence of 
H. pylori infection has been decreasing in many countries, due to improved standards of living, H. 
pylori infection continues to be a major public health problem (Hooi et al., 2017). According to a 
global systematic review, approximately 4.4 billion individuals worldwide were estimated H. pylori 
carriers in 2015. 
Ever since H. pylori was recognised as underlying pathogen in gastric cancer, there has been interest 
in investigating its role in other gastrointestinal malignancies, especially CRC. In 2013, three large 
meta-analyses were performed, and a positive association was observed between H. pylori infection 
and colorectal adenoma or CRC (Chen et al., 2013; Papastergiou et al., 2016; Rokkas et al., 2013; 
Wu et al., 2013). As an example, a study by Rokkas et al. observed a significant relationship between 
H. pylori and colon cancer (OR 1.3, CI95% 1.07-1.59; P= .01) and colon polyps (OR 1.5; CI95% 1.26-
1.79; P= .000) (Rokkas et al., 2013). Sonnenberg et al. have performed the largest case-control study, 
in which biopsies from 156,000 subjects who underwent both colonoscopy and oesophago-gastro-
duodenoscopy were included (Sonnenberg and Genta, 2013). H. pylori-related gastritis occurred more 
frequently among patients with colonic hyperplastic polyps (OR 1.24, CI95% 1.18-1.30), adenomatous 
polyps (OR 1.52, CI95% 1.46-1.57), advanced adenomas (OR 1.80, CI95% 1.69-1.92), villous adenomas 
or adenomas with high-grade dysplasia (OR 1.97, CI95% 1.82-2.14), and adenocarcinomas (OR 2.35, 
CI95% 1.98-2.80). However, no large, randomised, longitudinal studies have been conducted. Cross-
sectional and case-control studies can establish associations, but it is not possible to draw conclusions 
based on them, if causality between H. pylori and CRC exists. 
Several hypotheses have been put forward about pathogenic mechanisms that could explain the 
possible link between a H. pylori infection and colorectal neoplasia (Papastergiou et al., 2016). 
Gastrin is a known trophic factor in the colorectal mucosa and a persistent H. pylori infection elicits 
hypergastrinemia (Renga et al., 1997). It was shown that gastrin was directly mitogenic in either 
normal or neoplastic colonic cells in vitro, and resulted in the hyperproliferation of colonic mucosa 
in transgenic mice. In addition, CRC tumour cells were shown to secrete gastrin (Finley et al., 1993). 
There are several studies reporting the association between elevated serum/plasma gastrin levels, an 
increased risk of colorectal adenoma, and/or CRC, but some studies have disputed these observations 
(Papastergiou et al., 2016). It has also been hypostatized that H. Pylori induced chronic atrophic 
gastritis might contribute to changes in the colorectal microflora, which would lead to dysbiosis (Zou 
et al., 2018). 
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5.6 Therapy options for CRC 
 Early stage disease 
The treatment and prognosis of CRC depends on the stage of disease at diagnosis (Brenner et al., 
2014). In early stage I-III CRC, radical surgery is a crucial mode treatment. In rectal cancer, 
radiotherapy might be provided preoperatively. The options include a long course of chemoradiation 
(50.4/1.8Gy) with capecitabine in patients with more locally advanced disease or a short course of 
radiotherapy (5x5Gy) without chemotherapy, to lower the risk of local recurrence (Benson and 
Venook, 2018b; Glynne-Jones et al., 2017). Palliative surgery of the primary tumour can be 
performed in advanced disease, to prevent complications that would occur later and/or relieve 
possible symptoms, but its impact on survival has not been established clearly.  
The prognosis of colon cancer is most accurately predicted by the TNM stage. Based on the 
surveillance, epidemiology, and end results (SEER) database, which contained information about 
people diagnosed with colon cancer between 2004 and 2014, the 5-year survival rates by stage were:  
stage I  92%,  stage IIa 87%, stage IIb 65%,  stage IIIa 90%, stage IIIb 72%, stage IIIc 53% and for 
stage IV 12% (Anonymous, 2018). For rectal cancer patients 5-year survival rates were: stage I 88%, 
stage IIa 81%, stage IIb 50%, stage IIIa 83%, stage IIIb 72%, stage IIIc 58% and for stage IV 13%. 
As can be seen, the prognosis is better for stage IIIa patients than for IIb which can reflect the routine 
availability of adjuvant therapy for patients with stage III disease, in contrast to stage II. 
Decisions about postoperative treatment after radical surgery are mainly taken after the assessment 
of the pathological tumour stage (Schmoll et al., 2012). In stage I CRC, no adjuvant chemotherapy is 
recommended due to favourable prognosis, but in stage II disease, the decision-making process 
becomes more complex. Treatment with single-agent 5-FU for six months was shown to result in a 
relatively small improvement in survival (absolute 3-5%) in stage II disease (Gray et al., 2004), with 
no additional OS benefit of oxaliplatin (Andre et al., 2004a; Andre et al., 2015a). It is therefore a 
question for which patient adjuvant chemotherapy is justified also considering toxicity and costs. 
According to guidelines in stage II patients presenting with risk factors such as histologically poor 
differentiation, vascular/lymphatic/perineural invasion, tumour obstruction or perforation, T4 tumour 
and less than 12 examined lymph nodes, risk for recurrence is considered increased and in these 
patients adjuvant therapy should be considered (Benson and Venook, 2018a; Benson and Venook, 
2018b; Labianca et al., 2013). Single agent 5-FU is the standard therapy for stage II, but oxaliplatin 
can be considered, based on assessment of individual risk, i.e., in case of a T4 colon tumour.  
Adjuvant chemotherapy after curative resection is recommended for all stage III patients without 
contraindications for therapy (Benson and Venook, 2018a; Labianca et al., 2013). The 5-FU-based 
regimens result in an improvement in DFS to 67%, as compared to that of 55%, observed with surgery 
alone (corresponding to a 30% proportional reduction in risk of recurrence [HR, 0.70; CI95% 0.63-
0.78]); the OS improved from 64% to 71% at 5 years with adjuvant chemotherapy (a 26% 
proportional reduction in risk of death [HR 0.74, CI95% 0.66-0.83]) (Eisenhauer et al., 2009) (Gill et 
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al., 2004). The addition of oxaliplatin increased the absolute 5-year DFS from 6.2 to 7.5% and the 
overall survival from 2.7 to 4.2% in patients with stage III colon cancer (Brenner et al., 2014). 
For rectal cancer patients, the optimal treatment option after surgery has not been well established 
(Benson and Venook, 2018b; Schmoll et al., 2012). It has not been indisputably proven that adjuvant 
chemotherapy results in benefits to the patient, and it is debatable whether it should be given with or 
without oxaliplatin.  
Several multigene assays have been developed to provide prognostic and predictive information to 
support the decision regarding the stage II or III patients to be treated with adjuvant therapy (Benson 
and Venook, 2018a). These assays quantify the expression of tumour genes associated with a risk of 
recurrence, but are not predictive of the efficacy of adjuvant chemotherapy. Thus, data required are 
considered to be insufficient for supporting the use of these assays to guide decisions about adjuvant 
therapy. (Benson and Venook, 2018a).  
 Metastatic disease  
At diagnosis, approximately 20% of patients present with synchronous metastatic disease and 
according to estimations at least 30% of patients treated with curative intent develop metachronous 
distant metastasis (Adam et al., 2015; Van Cutsem et al., 2016). The liver and lung are the most 
common and dominant sites of metastasis in colon cancer and rectal cancer patients, respectively. 
The next most common metastatic sites include the peritoneum, central nervous system, and bone 
(Van Cutsem et al., 2016). 
In the metastatic setting, several approaches and therapeutic options could be considered. The most 
important factors in decision making are the ECOG performance status, liver and kidney function, 
tumour burden, and most importantly, the location of metastasis (Van Cutsem et al., 2016).  
The possibility of achieving curation after the resection of metastasis in oligometastatic disease is a 
crucial therapeutic consideration (Van Cutsem et al., 2016). More than 50% of patients with mCRC 
will develop liver metastasis during the course of the disease, and surgery of patients with liver 
metastasis has remarkably contributed to the improved prognosis of mCRC patients (Van Cutsem et 
al., 2016). The 5-year OS rate for patients after liver resection exceeds 50%, as compared to that of 
10-15% with palliative chemotherapy (Adam et al., 2015; Goldsbury et al., 2018). For patients with 
lung metastasis, 5-year OS rates after resection are 30-50% (Petrella et al., 2017). Peritoneal 
metastases occur in about 20% of patients and are associated with poor prognosis, but some of these 
patients are suitable for cytoreductive surgery. In addition to surgery, hyperthermic intraperitoneal 
chemotherapy (HIPEC) is usually delivered peri-operatively into the abdomen (Cashin et al., 2016; 
Ceelen, 2018; Maillet et al., 2016; Quenet et al., 2018; Verwaal et al., 2008). In ASCO 2018, the 
Prodige 7 trial was presented, in which the results with surgery alone were compared with those of 
surgery with HIPEC (Quenet et al., 2018). There were no differences in survival (OS 41.2 months in 
the non-HIPEC group vs. 41.7 months in the HIPEC group) or relapse-free survival (RFS) (11.1 
months in the non-HIPEC group vs. 13.1 months in the HIPEC group). Hence, it is not established 
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whether HIPEC should be a part of treatment protocols in the future for these patients. In patients 
with non-resectable liver-limited disease, there are several loco-ablative methods available such as 
thermoablation, microwave ablation, stereotactic radiotherapy, and IRE (Van Cutsem et al., 2016). 
These can be curative in part of patients but can be used as a part of palliative therapy as well. 
 
5.7 Chemotherapeutic agents in treatment of CRC 
 Fluorouracil (5-FU) 
 Mechanism of action 
The drug 5-FU is an antimetabolite, anuracil analogue,  which is the cornerstone in the treatment of 
CRC, both in the adjuvant and metastatic settings (Labianca et al., 2013; Longley et al., 2003; Van 
Cutsem et al., 2016). Its use was first based on the observation that rat hepatomas use uracil more 
rapidly than the normal cells (Miura et al., 2010). 5-FU is intracellularly converted into three active 
metabolites, i.e., fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate 
(FdUTP), and fluorouridine triphosphate (FUTP), which disrupt RNA and DNA synthesis, thus 
leading to cell death (Longley et al., 2003). However, the main mechanism of action of 5-FU is the 
irreversible inhibition of thymidylate synthase, which is an essential enzyme required for the 
synthesis of thymidine, a nucleoside required for DNA and RNA replication and repair, the lack of 
which leads to cell death (Longley et al., 2003). The 5-FU metabolite FdUMP binds to the nucleotide-
binding site of thymidylate synthase, forming a stable ternary complex with the enzyme and reduced 
folinate, thereby blocking the binding of the substrate dUMP, which normally binds to it, and inhibits 
the synthesis of pyrimidine thymidine. High intracellular concentrations of reduced folate are 
necessary for the optimal inhibition of thymidylate synthesis; therefore, 5-FU is administered together 
with calcium folinate (leucovorin, LV). LV is an exogenous source of reduced folinate that enhances 
the cytotoxicity of 5-FU. It was demonstrated in several randomised trials with mCRC patients that 
LV caused a significant improvement in the RR, as compared to that observed with single-agent 5-
FU (FU/LV 23% vs. 5-FU 11%, P< .000), but it had no impact on survival. (Anonymous, 1992). 
Before LV, 5-FU was administered with several other less active agents such as levamisole, to 
improve the cytotoxic effects. 
 Bolus 5-FU 
5-FU is active only in the S-phase of the cell cycle and has a short half-life of 10-20 minutes (de 
Gramont and Thirion, 1994). Several ways of dosing, scheduling, and administering of 5-FU have 
been studied, to maximize the cytotoxic effect. Initially, two major treatment strategies were 
developed with 5-FU administered as a bolus shot, but with different dosing and scheduling 
(Machover et al., 1986; Petrelli et al., 1987). A traditional arm in several studies is the so-called Mayo 
regimen, put forward by the North Central Cancer Treatment Group (NCTTG), which consists of the 
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administration of an intravenous bolus containing 370-425 mg/m2 of 5-FU for 3-5 minutes and 
infusion of 10-20 mg/m2 of low-dose LV for five consecutive days within a four week cycle 
(O'Connell, 1989). Another traditional bolus regimen is the Roswell Park regimen, which consists of 
the administration of 500 mg/m2 of a 5-FU bolus with 500 mg/m2 of high-dose LV six times weekly 
for six weeks, after every eight weeks (Haller et al., 2005). Other bolus regimens have also been 
developed to improve tolerability, such as the Nordic FLv regimen, (bolus 5-FU 500 mg/m2 and 
bolus LV 60 mg/m2 days 1 and 2 every 2 weeks), which is traditionally mostly used in Nordic 
countries (Glimelius, 1993).  
Due to toxicity issues that are discussed later, Mayo and Roswell Park are no longer as widely used 
as they were in the beginning of the 5-FU era, but they still are adequate therapy options that have 
been included both in the guidelines of the European Society for Medical Oncology (ESMO) and 
National Comprehensive Cancer Network (NCCN) guidelines (Benson and Venook, 2018a; Benson 
and Venook, 2018b; Van Cutsem et al., 2016). In developing countries, bolus regimens can be of 
importance, since there is no need for central intravenous catheters and infusion pumps for their 
administration, and the costs are lower, as compared to the costs associated with oral 
fluoropyrimidines.  
 Continuous infusion of 5-FU  
Protracted and continuous infusion (CI) regimens were developed to increase the dose intensity of 5-
FU therapy (de Gramont et al., 1997a). It was noted that it was possible to deliver four to five times 
higher doses of 5-FU by infusions, as compared to that delivered in the bolus form. In addition, it was 
shown that an infusional high-dose and bolus 5-FU shot act through different mechanisms that 
enhance each other in vitro. This observation led to the development of combination regimens of 
bolus and infusional 5-FU (Sobrero et al., 1993).  
Several CI regimens have been studied and used. Today, the standard method of delivering infusional 
5-FU can be considered as the so-called de Gramont regimen (LV5FU2), developed by the French 
GERCOD (Groupe d'Etude et de Recherchesur les Cancers de l'Ovaire et Digestifs) group. The de 
Gramont regimen consists of the administration of 400 mg/m2 of a 5-FU bolus and infusion of 
leucovorin 200 mg/m2 for two hours, followed by a 22-hour infusion of 600 mg/m2 of 5-FU for two 
consecutive days. This regimen was further modified in order to improve outcome, toxicity profile, 
and patient convenience (de Gramont et al., 1997b). Today, a widely accepted standard regimen and 
a backbone for combination chemotherapy is the so-called modified or simplified de Gramont 
regimen involving the infusion of 400 mg/m2 of LV, followed by infusion of a 400 mg/m2 bolus of 
5-FU on day 1, after which a continuous infusion of 2400 mg/m2 of 5-FU is performed over 46 hours.  
 Efficacy of 5-FU in mCRC 
Survival in patients with mCRC without any anti-tumoural treatment is expected to be approximately 
two to eight months (Scheithauer et al., 1993; Sorbye et al., 2009). Single agent 5-FU improved 
survival up to approximately 11 months, but survival rates of up to 15 months were reported in some 
studies (de Gramont et al., 1997a; Hansen et al., 1996; Scheithauer et al., 1993). Response rates 
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reported with the 5-FU/LV bolus were modest, but improved significantly with CI regimens, as 
demonstrated in a meta-analysis of nine trials (RR 14% vs 22%, respectively, P= .0002) (Anonymous, 
1998). Another trial compared single agent 5-FU as a protracted infusion or bolus, and in this study, 
RR was 30% in the CI arm and 7% in the bolus arm (P < .001), but there was no difference in survival 
(mOS 11 vs. 10 months, CI and bolus arms, respectively) (de Gramont et al., 1997a). A study of 348 
patients treated with the Mayo regimen or LV5FU2 resulted in a RR of 32.6% in LV5FU2, 14.4% 
with the Mayo regimen (P= .0004) (de Gramont et al., 1997a), and the mPFS was 27.6 weeks for 
patients receiving LV5FU2 and 22.0 for patients receiving Mayo (P= .0012). The mOS was not 
statistically significant between treatment regimens (mOS 62.0 weeks in the LV5FU arm and 56.8 
weeks in the Mayo arm, respectively, P= .067). Thus, CI regimens improve the RR and PFS, but 
since the superiority of either bolus or CI regimens in terms of survival is not clearly proven, the most 
significant difference is the toxicity profile, which favours CI regimens.  
 5-FU in the adjuvant treatment of CRC 
The year 1989 was a turning point in the treatment of CRC, as the North Central Cancer Treatment 
Group (NCCTG) reported that 12 months of treatment with 5-FU combined with levamisole after 
surgery reduced the risk of recurrence by 40% in stage III patients, as compared with that observed 
after surgery alone (Laurie et al., 1989). Another pivotal trial, the Intergroup 0035, studied the use of 
5-FU plus levamisole, levamisole alone, or observation in stage II and III patients demonstrating a 
41% relative reduction in the recurrence rate (P < .0001) (Moertel et al., 1990). It also demonstrated 
a significantly improved survival in patients on the 5-FU/levamisole arm; the median 5-year OS was 
60% for adjuvant chemotherapy, versus that of 46.7% and 49% for the use of observations and 
levamisole alone, respectively (P = .0007). After these results were obtained, postoperative treatment 
with 5-FU and levamisole in stage II and III CRC patients became a new standard in the year 1990.  
In addition to these pivotal trials of the adjuvant era, several trials were performed in the adjuvant 
setting in stage II and III patients, after combining different modulating agents with 5-FU to enhance 
the efficacy of the therapy. For example, the NSABP C-03 trial studied the efficacy of 5-FU/LV, as 
compared to that observed with a combination of methotrexate, alkylating nitrosourea lomustine, and 
5-FU (MOF). The 3-year DFS rate was 73% for patients receiving 5-FU/LV, as compared to that of 
64% for patients receiving MOF (P= .0004), which supports the use of LV in the adjuvant setting 
(Wolmark et al., 1993).  
The NSABP C-04 trial randomized stage II and III patients to receive 5-FU/LV, 5-FU/levamisole, or 
5-FU/LV/levamisole. For stage II patients, the use of 5-FU/LV reduced the risk of recurrence, as 
compared to that observed with 5-FU/levamisole (5-year DFS 75% vs. 71%) and enhanced survival 
(5-year OS 84% vs. 81%) (Wolmark et al., 1999). Stage III patients treated with 5-FU/LV experienced 
a 13% and 10% relative risk reduction, in accordance with the 5-year DFS (57% vs. 53%) and 5-year 
OS (67% vs. 63%), respectively. The combination of LV and levamisole added no further benefits. 
Thus, these findings demonstrated the superiority of 5-FU/LV over that of 5-FU/levamisole as the 
standard of care for stage III patients, also supporting a potential role of 5-FU/LV in stage II disease. 
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The Intergroup study 0089 investigated the effect of biochemical modulation of 5-FU, by comparing 
the 5-FU + low-dose LV, 5-FU + high-dose LV, 5-FU + levamisole, and 5-FU + levamisole + low-
dose LV with each other (Haller et al., 2005). This study included both high-risk stage II and stage 
III patients. There were no statistically significant differences between regimens, in terms of DFS and 
OS. According to these results, the inclusion of levamisole does not improve outcome and high dose 
LV adds no extra benefit, as compared to the benefits observed with the low dose. In addition, this 
study proved that six months of therapy is equal to that for twelve months.  
The GERCOR C96.1 study compared the Mayo regimen with LV5FU2 in stage II and III patients, as 
well as the results obtained with a treatment duration of 24 weeks versus those obtained with a 
treatment duration of 36 weeks (André et al., 2007). The Mayo regimen and LV5FU2 were equal in 
terms of the DFS (HR 1.01 CI95%, 0.81-1.27) and OS (HR 1.02 CI95% 0.77-1.34). There were no 
statistically significant differences in the DFS or OS on providing treatment for a duration of 24 or 
36 weeks 
The PETACC-2 (Pan European trial in adjuvant colon cancer 2 study) study investigated whether 
infusional high dose 5-FU regimens were superior to bolus 5-FU/LV regimens (Kohne et al., 2013). 
Patients were randomised to receive either the Mayo regimen, high dose 5-FU alone (the Spanish 
TTD regimen; day 1, 5-FU, 3500 mg/m2 continuous infusion for 48 h, given weekly during an 8-
week cycle for 3-cycles), high dose 5-FU plus LV (the German AIO regimen; day 1, LV 
500 mg/m2 i.v. 2-h infusion, followed by 5-FU, 2600 mg/m2 i.v. 24-h infusion, given weekly during 
a 6-week cycle for 3-cycles), or the LV5FU2 regimen. There were no significant differences in terms 
of RFS and OS between infusional high dose 5-FU and the Mayo regimens, but the Mayo regimen 
was the most toxic (Kohne et al., 2013).  
 Treatment related adverse events during 5-FU based chemotherapy 
The toxicity of 5-FU is significantly associated with the type of regimen, dose, scheduling, and way 
of administration (Macdonald, 1999). In general, bolus regimens are more toxic than CI regimens. 
Especially higher rates of grade 3-4 leukopenia and stomatitis are associated with the 5-FU bolus, as 
compared with the CI regimen, but the occurrence of the hand foot syndrome (HFS) is significantly 
more frequent with CI regimens (Piedbois et al., 1998). In addition, different dosing and scheduling 
methods used for bolus administration lead to different kinds of toxicity profiles. The Mayo regimen 
is associated with higher rates of any grade 3-4 toxicity than the Roswell Park regimen (55.6% vs. 
40.3%, respectively). Haematological toxicity and stomatitis occur especially more frequently with 
Mayo, but the use of Roswell Park results in more gastrointestinal toxicity (Haller et al., 2005). In the 
PETACC-2 trial, it was observed that grade 3-4 leukopenia (6.9% vs. 2.1%) and stomatitis (9.7% vs. 
3.1%) were significantly more common with Mayo regimens, as compared to those of CI regimens, 
but grade 3-4 HFS was significantly more common in patients receiving a CI regimen (4.2% vs. 0.4%) 
(Köhne et al., 2013). In a subgroup analysis, the occurrence of grade 3-4 diarrhoea was more common 
with TTD (23.3%) and AIO (20.1%), as compared with that for LV5FU2 (3.5%). Thus, LV5FU2 had 
the most favourable toxicity profile, according to this study.  
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55.6           0.9 
1.5             0.6 
5.5             3.3 
2.6             1.8 
16.0           5.4 
19.6           3.6 
3.5             6.3 
14.3           0.3 
 
20        4 
<1              - 
5      1 
15        5 
16      29 
12         - 
<1            <1 
 
 (de Gramont et al., 1997a) (Saini et al., 2003) (Haller et al., 2005) 
 
 Capecitabine 
 Mechanism of action and efficacy 
Capecitabine is an oral fluoropyrimidine, an oral prodrug of 5-FU that presents with a 
pharmacokinetic profile that mimics continuous 5-FU infusion (Miwa et al., 1998; Walko and 
Lindley, 2005). It is orally administered twice daily for 2 weeks, followed by a one-week rest period 
in 3-week cycles (1250 mg/m2 as a monotherapy). The prodrug is absorbed in an intact manner into 
the gastrointestinal tract, because of which it therefore has a bioavailability of nearly 100%. 
Capecitabine is first converted to 5′-deoxy-5-fluorocytidine by hepatic carboxylesterase, 
predominantly in the liver, and then converted to 5′-deoxy-5-fluorouridine by cytosine deaminase, 
both in tumour cells and in the liver; after this enzymatic cascade, it is finally activated to cytotoxic 
5-FU, by thymidine phosphorylase. Thymidine phosphorylase is expressed in the liver and in several 
tumours at higher concentrations than that observed in normal tissues, and because metabolic 
conversion occurs with more specificity in tumour cells, systemic exposure to 5-FU is reduced, but 
the dose-intensity in the tumour cells is improved (Budman et al., 1998; Miwa et al., 1998; Walko 
and Lindley, 2005). 
It was first shown by two large randomised trials in the metastatic setting that there were no significant 
differences in PFS or OS after treatment with capecitabine and the traditional bolus 5-FU (Hoff et al., 
2001; Van Cutsem et al., 2001). However, an integrated analysis of these two trials demonstrated that 




In the adjuvant setting the use of, capecitabine was approved after results from the X-ACT (Xeloda 
in Adjuvant Colon Cancer Therapy) trial were published (Cassidy et al., 2004). In the X-ACT 
(n=1987) trial, patients were randomised to either capecitabine or the traditional Mayo regimen. A 
significant improvement in RFS (HR 0.86, CI95% 0.74–0.99) was noted, but there were no significant 
differences in the DFS (HR 0.87, CI95% 0.75–1.00) or OS (HR 0.84, CI95% 0.69–1.01).  
 Treatment related adverse events during capecitabine containing chemotherapy 
There are no direct head-to-head trials comparing the monotherapy of capecitabine and LV5FU2, but 
capecitabine is demonstrated to have a more improved safety profile than bolus 5-FU/LV, as shown 
in Table 2. A significantly lesser level of diarrhoea, stomatitis, nausea, alopecia, and grade 3-4 
neutropenia were observed, resulting in a lower incidence of neutropenic fever and sepsis being 
reported with capecitabine (Cassidy et al., 2002). HFS was the only adverse event occurring 
significantly more frequently with the use of capecitabine. The X-ACT trial in the adjuvant setting 
reported that any grade of HFS occurred in 62% of patients in the capecitabine arm versus 10% of 
patients in the 5-FU/LV arm (P< .001), grade 1-2 HFS was observed in 44% versus 9% (P< .001) of 
patients, and grade 3 HFS was observed in 17% versus 0.6% (P< .001) of patients receiving 
capecitabine and 5-FU/LV, respectively (Cassidy et al., 2004). The number of dose reductions due to 
adverse events (33.9% vs. 42.2%, P= .0037) was significantly higher in the 5-FU/LV arm and there 
was a significant increase in the number of hospitalizations due to neutropenic infections (11.6% vs. 
18.0%, P< .005) in the 5-FU/LV arm, as compared with that in capecitabine arm.  
Table 2. Toxicities reported, Capecitabine versus FU/LV as a monotherapy 
Study 
Regimen 
(Van Cutsem et al., 2004) 
Capecitabine       Mayo 
% 
(Hoff et al., 2001) 
Capecitabine     Mayo 
% 
(Twelves et al., 2005) 
Capecitabine            Mayo 
% 






2.0                 19.8 
10.7                10.4 
1.3                  13.3 
16.2                  0.3 
 
2.6                   25.9 
15.4                 13.9 
3.0                   16.0 
18.1                    0.7 
 
2                     26 
11                   13 
2                     14 
17                   0.6 
 
 S-1 
S-1 is like capecitabine an oral 5-FU derivate containing a combination of tegafur, gimeracil, and 
oteracil (Shirasaka, 2009). Gimeracil is a potent inhibitor of dihydropyrimidine dehydrogenase 
(DPD) and oteracil inhibits the conversion of 5-FU to active metabolites in the gastrointestinal tract. 
S1 is widely used and studied in the Asian population, but there are remarkable differences in the 
metabolism and toxicity profile of Asian and western populations (Kwakman and Punt, 2016). The 
Dutch Colorectal Cancer Group conducted a randomized, phase III SALTO trial, which had used the 
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primary end point to compare the incidence of HFS between S-1 and capecitabine in the first-line 
treatment of mCRC in the western population (Kwakman et al., 2017). S-1 was associated with a 
significantly lower incidence of HFS, as compared with that of capecitabine, but the level of efficacy 
was equal. The Nordic 9 trial demonstrated that the use of S-1 dose-reduced combination therapy 
with S-1 and oxaliplatin was well-tolerated in older and frail western patients (Winther et al., 2018). 
However, data with regard to S-1 in the treatment of CRC in western population is limited and S-1 is 
therefore not reimbursed in the treatment of CRC in Finland. 
 Dihydropyrimidine dehydrogenase (DPD) 
Less than 15% of administered 5-FU is converted to active metabolites of 5-FU (van Kuilenburg, 
2004). More than 80% of the drug is metabolized and eliminated by an enzyme, dihydropyrimidine 
dehydrogenase (DPD), which is encoded by the DPYD gene. Approximately 2-5% of the white 
population in North America and Europe present with a major mutation in DPYD, leading to the 
partial inactivation of DPD (Henricks et al., 2018; Morel et al., 2006). The complete loss of DPD is 
estimated to be much rarer, encountered only in 0.01-0.1% of the population. Patients with a DPD 
deficiency are at risk of excessive, severe toxicity, in the form of myelosuppression, diarrhoea, 
mucositis, and neurotoxicity if 5-FU is administered; especially in patients with a total loss of DPD, 
treatment can be lethal.  
DPYD is highly polymorphic and several genetic variants have been identified, of which some have 
significant functional consequences with regard to enzymatic activity (van Kuilenburg, 2004). The 
most well studied gene variant is DPD*2A, a single-nucleotide variant at the intron boundary of exon 
14, which results in the production of a truncated protein with virtually no enzyme activity (Wei et 
al., 1996). Other recognised variants that are significantly associated with 5-FU related 
haematological and gastrointestinal toxicity are c.2846A>T, c.1679T>G and c.1236G>A, according 
to a recent meta-analysis (Meulendijks et al., 2015). In patients with a known partial DPD deficiency, 
the dose should be adapted to avoid severe toxicity and in patients with complete DPD deficiency, 
fluoropyrimidines should not be used (Van Cutsem et al., 2016). According to guidelines, if known 
prior to treatment, in patients presenting with DPD*2A or c.1679T>G the 5-FU dose should be 
reduced 50% and in patients with c.2846A>T or c.1236G>A, the dose should be reduced at least 25% 
from the full dose (Caudle et al., 2013; Henricks et al., 2018).  
DPYD gene variants are the best recognised predictive factors for 5-FU related toxicity, but do not 
account for all the observed cases of DPD deficiency or 5-FU toxicity, as other heterozygotic variants 
might play a role in toxicity (Caudle et al., 2013; Rosmarin et al., 2014). In addition, the DPD 
genotype does not faithfully reflect the phenotype, because of the post-transcriptional regulation of 
DPD through gene promoter hypermethylation (van Kuilenburg, 2004). DPD deficiency has been 
detected in 39-61% of patients with severe 5-FU related toxicity, which means that not all of the cases 
with severe toxicity can be explained by DPYD polymorphism. Bocci et al. reported three patients 
who displayed a low drug clearance of 5-FU, but in all three individuals, the DPD activity was intact 
(Bocci et al., 2006).  
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In addition to DPD, several other factors that predicted the sensitivity and toxicity to 5-FU have been 
studied (Van Cutsem et al., 2016). For example, data suggests that decreased levels of thymidylate 
synthase are associated with an improved response and survival with 5-FU (Fukushima et al., 2001; 
Peters et al., 2002). However, according to the guidelines, only DPD is established as a predictor for 
toxicity and efficacy, and DPD testing can be considered in routine clinical practice (Van Cutsem et 
al., 2016). 
 Oxaliplatin 
 Mechanism of action and efficacy 
Oxaliplatin is a diaminocyclohexane platinum compound, which acts by impairing DNA replication, 
leading to cellular apoptosis (Misset et al., 2000). It is widely used in the treatment of mCRC since 
2000, when De Gramont et al published a study with 420 previously untreated mCRC patients 
randomised to LV5FU2 with or without oxaliplatin (de Gramont et al., 2000). Oxaliplatin 
significantly improved the mPFS (9.0 vs. 6.2 months; P= .0003) and RR (50.7% vs. 22.3%; P= .0001). 
Improved mOS was further demonstrated by the NCCTG trial, after comparing the following three 
regimens: FOLFOX, IROX (irinotecan together with oxaliplatin), and the standard IFL (bolus 5-FU 
together with irinotecan) (Goldberg et al., 2004). FOLFOX was superior to IFL with regard to a 
significantly improved RR (45 vs. 31%), time to progression (8.7 vs. 6.9 months), and mOS (19.5 vs. 
15 months). Thus, this study established the efficacy of oxaliplatin in the treatment of mCRC, after 
which it has been studied in various trials using different dosing. The combination of capecitabine 
and oxaliplatin (CAPOX) showed similar activity to FOLFOX in mCRC, in terms of PFS, OS, and 
RR, with a good level of tolerability (Ducreux et al., 2011).  
The use of oxaliplatin in the adjuvant setting is well established by three pivotal trials, i.e., MOSAIC, 
NSABP-C07, and XELOXA. (Andre et al., 2004b). The MOSAIC study, published in 2004, 
randomised 2246 stage II or III CRC patients to receive LV5FU2 alone or with oxaliplatin 
(FOLFOX). The values for DFS at five years were 73.3% and 67.4% in the FOLFOX and LV5FU2 
groups, respectively (P= .003); six-year OS rates were 78.5% and 76.0% in the FOLFOX and 
LV5FU2 groups, respectively (P= .046). Ten-year OS results were published in 2015, which 
demonstrated an even larger benefit in favour of FOLFOX; 10-year OS among all 2,246 patients was 
71.7% in the FOLFOX and 67.1% in the LV5FU2 arm (P= .043), thereby increasing the absolute 
survival benefit in the FOLFOX arm from 2.2% at 6 years to 4.76% at 10 years (Andre et al., 2015a). 
However, no significant OS benefit of oxaliplatin was observed in stage II patients, not even with 
high-risk disease (defined as T4, tumour perforation, or fewer than 10 lymph nodes examined). Ten-
year OS rates for FOLFOX and LV5FU were 75.4% vs. 71.7% (P= .058), respectively, in stage II 
high-risk patients (Andre et al., 2015a). The risk of death was significantly reduced in stage III 
patients (OS 67.1% for FOLFOX and 59.0% for LV5FU, P= .016).  
The NSABP C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen, i.e. 
FLOX regimen, in 2409 patients with stage II or III disease (Yothers et al., 2011). The associated 3- 
and 4-year DFS rates were 71.8% and 67.0% for 5-FU/LV and 76.1% and 73.2% for FLOX, 
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respectively. The HR for DFS was 0.80 (CI95% 0.69-0.93), signifying a 20% reduction in the risk of 
recurrence, in favour of FLOX (P < .004).   
The XELOXA trial comparing the CAPOX and Mayo and Roswell Park regimens in 1886 stage III 
patients demonstrated the benefit of oxaliplatin being independent of the fluoropyrimidine backbone 
(Haller et al., 2011a). No stage II patients were included in this trial. As observed in the MOSAIC 
and NSABP-C07 studies, CAPOX demonstrated DFS benefit in favour of oxaliplatin at 3 years; DFS 
rate was 70.9% with CAPOX and 66.5% with Mayo (HR 0.80 CI95% 0.69-0.93)). The HR for the OS 
for CAPOX, as compared to that for Mayo was 0.87 (CI95% 0.69-0.93). The 5-year OS for CAPOX 
and Mayo were 77.6% and 74.2%, respectively (HR=0.87, CI95% 0.72-1.05).  
The IDEA collaboration investigated whether three months of oxaliplatin based adjuvant therapy is 
non-inferior to that provided for six months (Grothey et al., 2018). The major idea behind the study 
design was to reduce side effects, especially the neuropathy associated with oxaliplatin-containing 
adjuvant therapy. The IDEA collaboration was established in 2007 as a worldwide consortium in 
North America, Europe, and Asia, and it included six individual studies (TOSCA, SCOT, HORG, the 
IDEA France trial, ACHIEVE, CALGB/SWOG 80702). Data from all the six substudies were pooled 
for the final analysis. From a statistical perspective, the study did not meet its end point, as the 
boundary of non-inferiority was not reached. From the clinical perspective, the absolute difference 
between three and six month arms was only 0.9% (74.6% for 3 months vs. 75.5% for 6 months; 
HR=1.07, CI95% 1.00–1.15). Differences were noted in the 3-year DFS between FOLFOX and 
CAPOX regimens, and between patients with T1–3N1 (low-risk) versus T4 or N2 (high-risk) disease. 
In the subset of low-risk patients, the DFS observed with 3 months of CAPOX treatment was non-
inferior to that with 6 months (HR=0.85, CI95% 0.71–1.01), but with regard to FOLFOX, its non-
inferiority could not be proven (HR=1.10, CI95% 0.96–1.26). In high-risk patients with T4 or N2 
disease, DFS after 3 months of FOLFOX treatment was inferior to that of 6 months (HR=1.20, CI95% 
1.07–1.35), but non-inferiority was not proven in the CAPOX arm (HR=1.02, CI95% 0.89–1.17) 
(Grothey et al., 2018).  
According to the current NCCN guidelines, in low-risk patients, the recommended duration of 
adjuvant therapy is 3 months (Benson and Venook, 2018a). In high-risk patients, a duration of 3 to 6 
months can be considered with CAPOX. If FOLFOX is chosen for low-risk patients, the 
recommended duration of therapy is 3 to 6 months, but in high-risk patients, the duration is always 6 
months. ESMO guidelines are awaited. 
 Treatment related adverse events during oxaliplatin containing chemotherapy 
In the MOSAIC trial, FOLFOX was associated with an increased rate of diarrhoea, vomiting, 
neurosensory toxicity, and neutropenia, as compared with that for LV5FU2 (Andre et al., 2004a). The 
NSABPC-07 trial reported higher rates of diarrhoea and nausea with FLOX, as compared to those 
with FU/LV, while the reported rates of vomiting and neutropenia were similar in both regimens 
(Kuebler et al., 2007).  
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The IDEA trial reported a significantly less grade 2 neuropathy in the three month arm, as compared 
to that for six months (17% vs. 48% for FOLFOX; 12% vs. 36%  for CAPOX; P< .0001), as well as 
lower rates of any grade 3-4 adverse events (3% vs. 16% for FOLFOX; 3% vs. 9% for CAPOX; P< 
.0001) (Grothey et al., 2018). Grade 2-4 diarrhoea was also reported less often with a shorter duration 
of therapy (P< .0001 for FOLFOX; P= .01 for CAPOX).  
 Oxaliplatin induced neuropathy  
Oxaliplatin and fluoropyrimidine combination therapy related toxicities are presented in Table 3. The 
most common dose-limiting adverse event associated with the use of oxaliplatin is peripheral 
neuropathy, which is classified into the acute and chronic forms (de Gramont et al., 2000; Giacchetti 
et al., 2000). The underlying mechanism of acute neuropathy involves the dysfunction of nodal axonal 
voltage-gated sodium (Na+) channels resulting from the oxalate chelating effect on both calcium 
(Ca2+) and magnesium (Mg2+) (Beijers et al., 2014). Chronic neuropathy is caused by the 
accumulation of oxaliplatin in the dorsal root ganglia cells, leading to morphological and functional 
changes in the nerves.  
Acute neurotoxicity occurs in nearly all oxaliplatin treated patients and is mostly transient and 
reversible at the beginning of the therapy (Saif and Reardon, 2005). It appears during or shortly after 
oxaliplatin infusion and manifests typically with cold-allodynias, as dysesthesias and/or paraesthesia 
in the distal extremities, with a “stocking-glove” pattern. Acute oxaliplatin-induced neuropathy is 
unique and peculiar, since the sensory symptoms are commonly induced by exposure to cold. Some 
patients present with pharyngo-laryngeal dysesthesia, which causesa feeling of difficulty in breathing. 
Motor nerve function consistently remains unchanged during treatment and it is rare to observe motor 
symptoms, including tetanic spasms, fasciculations, and prolonged muscular contractions. The 
duration of acute neurotoxicity is typically from a day or two up to a week at the beginning of 
treatment, after which it becomes prolonged (Pachman et al., 2015). The intensity of the symptoms 
typically increases from the first cycle to the second cycle, after which the intensity stabilizes, but the 
duration of neuropathic symptoms is extended. 
The most typical presentation of long-term neuropathy involves sensory symptoms, continuous 
tingling or impaired sensations, leading in the worst case to total numbness with a glove-sock-like 
pattern (Pachman et al., 2015; Saif and Reardon, 2005). Sensory ataxia and deficits in fine sensory-
motor coordination are common. Chronic symptoms are not triggered by cold, as much as by the 
symptoms in the acute phase. In a manner similar to that of acute toxicity, chronic toxicity affects 





Table 3. Toxicities reported with oxaliplatin-based regimens 
Study 
Regimen 
De Gramont et al, 2000 
LV5FU2     FOLFOX 
Andre et al, 2004 
LV5FU2    FOLFOX 
Ducreux et al, 2004 
XELOX FOLFOX 
Kuebler et al, 2007 
FU/LV    FLOX 















5.3                11.9 
 
0                   18.2 
 
 
4.7                   41.1 
0.2                     1.8 
3.2                   10.9 
    2.4                     2.7 
    6.6                   10.8 
 
     0.2                  12.4 
 
 
   5                   47 
      0                     6 
      5                   14 
      0                   <1   
     14                    7 
     14                    7 





    19.4       28.3 
 
    32.2       38 
 
      0.7         9 
 
 Excision repair cross-complementation group 1 (ERCC1) 
There is no predictive factor for oxaliplatin that has been proven to predict the toxicity or efficacious 
oxaliplatin treatments. The high excision repair cross-complementation group 1 (ERCC1) protein 
expression levels in immunohistochemistry were shown to be a negative predictive factor for 
platinum-based therapy in lung cancer patients (Olaussen et al., 2007). In CRC, ERCC1 has been 
studied and data suggest that a high expression level of ERRC1 is associated with poor prognosis and 
with a poor response to oxaliplatin based therapy (Qian et al., 2014). However, the data are 
insufficient to recommend the use of ERCC1 protein expression for treatment decisions involving the 
use of oxaliplatin in routine practice (Van Cutsem et al., 2016). 
 Irinotecan 
 Mechanism of action and efficacy 
Irinotecan is a topoisomerase-I inhibitor that causes DNA damage and cell death through the active 
metabolite SN38 (Mathijssen et al., 2001). Two key trials were published with regard to mCRC in 
2000 (Douillard et al., 2000; Saltz et al., 2000). Saltz et al. conducted a trial comparing the use of the 
5-FU bolus either alone or in combination with irinotecan (IFL regimen), and the results revealed a 
significantly longer mPFS (7 months vs. 4.3, P= .004) and mOS (14.8 months vs. 12.6, P= .04) in the 
IFL arm. Similar results were reported by Douillard et al. and based on these trials, irinotecan was 
established as the first-line treatment option in CRC together with 5-FU (Goldberg, 2005).  
IFL was associated with a greater level of toxicity and is no longer the first preference for a regimen. 
Irinotecan with infusional 5-FU/LV was shown to be better tolerated and FOLFIRI treatment is 
currently a widely accepted standard of care (Goldberg, 2005; Tournigand et al., 2001; Tournigand 
et al., 2004; Van Cutsem et al., 2016).  
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In the initial phase III randomised trials, a comparison of the use of irinotecan combined with 
capecitabine (CAPIRI) with that of FOLFIRI revealed various results. In the BICC-C study 
comparing FOLFIRI, IFL, and CAPIRI, both mPFS and mOS were inferior with the use of CAPIRI, 
as compared to that obtained with FOLFIRI (Fuchs et al., 2007). Median PFS was 7.6 months for 
FOLFIRI, 5.9 months for IFL, and 5.8 months for CAPIRI. Median OS was 23.1 months for 
FOLFIRI, 17.6 months for IFL, and 18.9 months for CAPIRI. CAPIRI arm was discontinued in this 
study due to toxicity. Similarly, EORTC 40015 reported inferior outcomes with CAPIRI, as compared 
with those obtained with FOLFIRI, and the study was discontinued following eight deaths unrelated 
to disease progression (Kohne et al., 2008). The higher toxicity associated with CAPIRI in these two 
trials could explain the inferior outcome, but consequently, CAPIRI is not an as widely accepted 
regimen as FOLFIRI. However, after studies by the AIO colorectal study group demonstrated that 
modified schedules of capecitabine and irinotecan regimen were feasible and effective, CAPIRI has 
been included as an option in the ESMO guidelines (Moosmann et al., 2011; Schmiegel et al., 2013; 
Van Cutsem et al., 2016).  
In the adjuvant setting, irinotecan failed to improve DFS and OS, and its use is therefore not 
recommended in the adjuvant setting (Papadimitriou et al., 2011; Saltz et al., 2007; Van Cutsem et 
al., 2005; Ychou et al., 2009). 
 Treatment related adverse events during irinotecan containing chemotherapy 
Typical toxic effects attributable to the use of irinotecan include diarrhoea, nausea, neutropenia, 
alopecia, and cholinergic symptoms (Cunningham et al., 1998). Of these, diarrhoea and neutropenia 
are the most common grade 3–4 toxicities, as detailed in Table 4. Diarrhoea associated with irinotecan 
can be especially severe, even fatal, but is well managed at most times, by following the antidiarrheal 
guidelines and with the intensive and early use of loperamide (Stein et al., 2010). Irinotecan associated 
toxicity is dependent on the underlying fluoropyrimidine backbone, and as mentioned, the IFL 
regimen was first the standard of care after irinotecan was introduced, but it was associated with 
notable toxicity levels; cases with fatal diarrhoea were also reported (Rothenberg et al., 2001). The 
increased risk of toxic death appeared to be confined to cumulative weekly bolus dosing, due to higher 
rates of neutropenia, as compared with that observed for the infusional irinotecan regimens 
(Rothenberg et al., 2001). The phase III randomised BICC-C trial comparing the bolus, infusional, 
and oral fluoropyrimidine backbone with irinotecan was the first to conduct a head-to-head 
comparison of IFL and FOLFIRI, which demonstrated the superior safety and efficacy of FOLFIRI 
(Fuchs et al., 2007). The combination of irinotecan and capecitabine turned out to be more 
complicated, as initial trials reported higher toxicity rates with CAPIRI, as compared with those 
observed with irinotecan plus intravenous 5-FU/LV treatment (Fuchs et al., 2007; Kohne et al., 2008). 
EORTC phase III study 40015 was discontinued prematurely because of excessive toxicity (39% of 
patients experienced grade 3–4 diarrhoea) and mortality (11% treatment related deaths) in patients 
undergoing CAPIRI treatment (Kohne et al., 2008). The BICC-C trial reported higher rates of grade 
3-4 toxicities with CAPIRI, as compared with those observed with FOLFIRI (nausea/vomiting 34% 
vs 17.6%, diarrhoea 47.5% vs 13.9% and dehydration 19.1% vs 5.8%, respectively) (Fuchs et al., 
2007). More recently, CAPIRI studies have reported lower rates of serious toxicities, probably due to 
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increased experience with the regimen and use of modified doses. A phase III study by the Hellenic 
Cooperative Oncology Group that compared CAPIRI plus bevacizumab and FOLFIRI plus 
bevacizumab demonstrated the efficacy of both treatment arms was similar, and there was a generally 
lower incidence of grade 3-4 events and no significant differences in toxicity profiles between the 
two regimens (Pectasides et al., 2012). CAPIRI combination therapy is an option included in the 
ESMO guidelines, if it is ensured that dose adjustment and proper management of side effects would 
be carried out (Van Cutsem et al., 2016).  
Table 4. Toxicities reported with irinotecan-based regimens 
Study 
Regimen 











Salz et al, 2000 
 
IFL     FU/LV 
Douillard et al, 2000 
 
FOLFIRLV5FU2 
Tournigand et al, 
2004 
FOLFIRI  FOLFOX 
Skof et al, 2009 
 
CAPIRI FOLFIRI 
    
 
54               66 
9                 15 
10                4 
2                 17 




29              2 
2                0 
19             10 
0                2 
44             26 
0                5 
2                0 
 
24            44 
0               7 
13             3 
10             1 
14            11 
2             2 
 
4             13 
0             0 
7             6 
0             0 
 
2             4 
 
 UDP glucuronosyltransferase 1 family, polypeptide A1 
The UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) is an enzyme involved in the 
glucuronidation pathway (Strassburg et al., 1998). The gene is a part of a locus encoding several 
UDP-glucuronosyltransferases, and its polymorphism is associated with an increased toxicity to 
irinotecan (nausea, diarrhoea, neutropenia). UGT1A1 is responsible for both bilirubin 
glucuronidation and the glucuronidation of SN-38, which is the active metabolite of irinotecan. In a 
manner similar to that for DPD and 5-FU, several genetic variants of UGT1A1 are associated with 
irinotecan related toxicities (Liu et al., 2014; Zhang et al., 2017). The UGT1A1*28 and UGT1A1*6 
variants are especially associated with irinotecan induced neutropenia and diarrhoea.  
Even though UGT1A1 gene polymorphisms are known to be predictive for irinotecan related toxicity, 
the UGT1A/UGT1A1 status is rarely used in clinical practice as a predictive biomarker of irinotecan 
toxicity and it is not routinely recommended in the NCCN or ESMO guidelines (Benson and Venook, 
2018a; Benson and Venook, 2018b; Van Cutsem et al., 2016). It can be considered for patients with 
elevated bilirubin levels. 
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5.8 Biological agents in the treatment of CRC 
 Anti-angiogenic therapy in colorectal cancer 
The formation of new blood vessels from the pre-existing blood vessels is known as angiogenesis 
(Ferrara et al., 2003). Physiological angiogenesis is required during embryogenesis and in normal 
tissue growth and repair, but angiogenesis is also a hallmark of cancer, since the supply of oxygen 
and nutrients by the vasculature is required for tumour growth (Ferrara et al., 2003). Pathological 
tumour angiogenesis has been in focus in cancer research for years since it can be therapeutically 
targeted. Vascular endothelial growth factors (VEGFs) comprise a large family of growth factors, 
including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PLGF) (Carmeliet, 
2003; Holmes and Zachary, 2005). Of these known growth factors driving angiogenesis, VEGF-A 
has emerged as the single most important regulator of neovascularization. The biological effects of 
VEGFs are mediated by the vascular endothelial growth factor receptors (VEGFRs), such as VEGFR-
1, VEGFR-2, and VEGFR-3 (Jeltsch et al., 2013). This VEGF-VEGFR mediated route is the most 
utilized route for the treatment of CRC, but it is not the only one driving angiogenesis. There are 
several other pathways, such as the fibroblast growth factor (FGF-FGFR) and platelet-derived growth 
factor (PDGF-PDGFR) pathways (Zhao and Adjei, 2015). 
There are several anti-angiogenic drugs that are in clinical use and under development in many types 
of malignancies, but CRC was one of the first solid tumours that benefitted from anti-angiogenic 
therapy. The first soluble VEGF-A ligand, bevacizumab, has been widely used in the treatment of 
CRC since 2004 (Hurwitz et al., 2004). In addition to VEGF/VEGFR ligands, angiogenesis can be 
targeted by oral tyrosine kinase inhibitors that block the intracellular domain of receptors involved in 
angiogenesis (Al-Abd et al., 2017).  
 Bevacizumab 
Bevacizumab is an anti-angiogenic drug and a monoclonal humanized antibody that binds to 
circulating vascular endothelial growth factor A (VEGF-A) (Ferrara et al., 2003). It has been widely 
used in the treatment of mCRC since 2004, after Hurwitz et al had published the results from a trial 
comparing the use of IFL with or without bevacizumab (Hurwitz et al., 2004). In the bevacizumab 
arm, a significant improvement of 4.4 months in the PFS and 4.7 months in the OS were observed. 
Since then, bevacizumab has been studied in several randomised first- and second-line mCRC trials, 
and it has shown efficacy in terms of RR, PFS, and OS benefit in some in combinations with 5-FU, 
capecitabine, irinotecan, and oxaliplatin (Cunningham et al., 2013; Giantonio et al., 2007; Hurwitz et 
al., 2004; Kabbinavar et al., 2008; Saltz et al., 2008; Tebbutt et al., 2010).  
The TML trial demonstrated that continuing with bevacizumab therapy while changing the cytotoxic 
backbone in second-line treatment after progression during a bevacizumab containing regimen 
improved the OS, as compared to that observed after continuing with chemotherapy alone (Bennouna 
et al., 2013). Patients continuing with bevacizumab showed a modest improvement in OS (11.2 vs. 
9.8 months; HR=0.81, P= .0062) The BEBYP trial reported similar results, which suggested that 
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patients pre-treated with bevacizumab in first-line treatment can benefit from subsequent therapies 
that target VEGF (Masi et al., 2015). 
Bevacizumab was studied in the adjuvant setting in AVANT and NSABP C-08 trials, but it failed to 
prolong DFS in both the trials, and is therefore not to be used in the adjuvant setting (Allegra et al., 
2011; de Gramont et al., 2012).  
 Aflibercept 
Aflibercept is a recombinant fusion protein containing VEGF-binding portions from the extracellular 
domains of human VEGF receptors 1 and 2, fused to the Fc portion of human immunoglobulin (Ig)G1. 
It blocks the activity of VEGF-A, VEGF-B, and placental growth factor, (PlGF) by acting as a high-
affinity ligand trap to prevent these ligands from binding to their endogenous receptors (Tseng et al., 
2010). It was first shown in the VELOUR trial (n=1401) that OS improve from 12.1 months in the 
placebo arm to 13.5 months with aflibercept (HR=0.82, CI95% 0.71-0.94) in the second line of 
treatment in patients pre-treated with oxaliplatin based chemotherapy, either with or without 
bevacizumab (Van Cutsem et al., 2012a). Aflibercept also significantly improved the mPFS, which 
was 4.7 with placebo to 6.9 months with the use of aflibercept (HR=0.76, CI95% 0.66-0.87). The RR 
was also improved with aflibercept (11.1% vs. 19.8%, P= .0001). The outcome was not different 
between patients treated or not treated with bevacizumab in the first line. 
 Ramucirumab  
Ramucirumab, a human IgG1 monoclonal antibody, binds specifically to the extracellular domain of 
VEGFR-2 with high affinity (Kong et al., 2017). It prevents the binding of the agonist ligands VEGF-
A, VEGF-C, and VEGF-D, thereby blocking the activation of VEGFR-2. It was approved for second-
line treatment with an irinotecan based regimen, after the RAISE trial (n=1072) demonstrated a 
statistically significant OS benefit for ramucirumab treated patients after first-line therapy with 
oxaliplatin based chemotherapy and bevacizumab (Tabernero et al., 2015). Median OS was 
13.3 months for the ramucirumab group and 11.7 months for the placebo group (HR 0.84, CI95% 0.73–
0.98).  
 Treatment related adverse events during bevacizumab containing therapy 
Typical adverse events reported in initial phase III trials with bevacizumab includedHTN, bleeding, 
arterial thromboembolic events (i.e., cerebral vascular events, myocardial infarction, transient 
ischemic attack, and angina), wound healing complications, proteinuria, and gastrointestinal 
perforations (Hurwitz et al., 2004; Kabbinavar et al., 2008; Strickler and Hurwitz, 2012). These 
toxicities have also been well established in real-life clinical patient populations by three large 
observational studies, i.e., BEAT, ARIES, and BRITE, and are well recognised in clinical practice 
(Bendell et al., 2012; Kozloff et al., 2009; Van Cutsem et al., 2009). BEAT, ARIES, and BRITE 
included almost 5,000 mCRC patients treated using the first or second line of treatment with 
bevacizumab containing chemotherapy, using different chemotherapy backbones. The main grade 3-
5 toxicities observed included HTN (5.3-22%), bleeding (2.2-3.0%), arterial thromboembolic event 
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(1.0-2.3%), GI-perforation (2.0%), wound healing complications (1.0% in all and up to 3.5% in 
postoperative patients), and proteinuria (all grades, 1.0%). These rates are similar to those reported 
in randomised trials (Bendell et al., 2012; Kozloff et al., 2009; Van Cutsem et al., 2009).  
HTN is the most common adverse event reported with the use of bevacizumab. The pathogenesis of 
bevacizumab induced HTN is not yet fully understood (de Jesus-Gonzalez et al., 2012; Syrigos et al., 
2011). It is suggested that HTN is caused by impaired angiogenesis or endothelial dysfunction that is 
associated with bevacizumab. Another theory is that VEGF signal antagonism leads to the inhibition 
of nitric synthase, resulting in decreased levels of nitric oxide, which consequently leads to 
vasoconstriction and a decrease in the renal excretion of sodium resulting in HTN (Syrigos et al., 
2011). HTN rates reportedly vary widely between studies due to the use of different measuring 
protocols (before treatments, between treatments, at home or in hospital) and different baseline 
characteristics of patients between studies (age, underlying HTN etc.). The BRITE trial reported 
about de novo HTN that required medication and the worsening of HTN in already hypertensive 
patients at the baseline in 22% of patients (Kozloff et al., 2009). The BEAT trial reported any grade 
of HTN in 30% and grade 3-4 in 5% of the patients (Van Cutsem et al., 2009); thus, less  than in the 
previous phase III trials, which reported grade 3-5 HTN in up to 16% of patients (Hurwitz et al., 2004; 
Kabbinavar et al., 2008).  
 Molecular Biomarkers for Anti-Angiogenic Therapy  
Despite intensive research, no biomarker is available yet for the identification of patients benefiting 
from anti-angiogenic therapy (Cidon et al., 2016). Genes involved in angiogenesis have been studied 
and they show a relatively high level of variation, ranging from a silent single nucleotide 
polymorphism to functional polymorphisms, but none of the genetic factors has turned out to be a 
reliable predictive factor. Several studies have also analysed circulating molecules, including 
different cytokines and angiogenic factors, such as angiopoietin-2 and VEGF levels (Goede et al., 
2010; Jurgensmeier et al., 2013; Kopetz et al., 2010). The results are partly contradictory, as it was 
observed in biomarker analysis after the use of ramucirumab that high levels of VEGF-D were 
associated with improved outcomes (Tabernero et al., 2018), but data from the AGIT-MAX trial 
reported the opposite with bevacizumab (Weickhardt et al., 2015). Thus, in conclusion, there are no 
biomarkers or factors available for predicting the treatment outcome with anti-angiogenic therapy. 
 Epidermal growth factor (EGFR) inhibitors 
 Cetuximab and panitumumab 
The EGF receptor, a transmembrane glycoprotein, is a member of the tyrosine kinase receptor family, 
which is known to be overexpressed in multiple malignancies, including CRC, and it contributes to 
cell proliferation and survival (Pines et al., 2010).  
EGFR-directed antibodies are examples of a personalised, targeted therapy, the use of which has been 
based on the presence or absence of negative predictive RAS mutations in the tumour cells. In initial 
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trials, the administration of EGFR inhibitors was based on positive EGFR staining by 
immunohistochemistry, but its benefit was limited, as only around 40% of unselected, 
chemorefractory patients responded to it (Cunningham et al., 2004).  
It was then demonstrated that approximately 40% of tumours harbour mutations in the exon 2 (codons 
12 and 13) of the KRAS gene, which predicts the lack of benefit of administered EGFR inhibitors 
(Amado et al., 2008). Douillard et al reported in 2014 about a retrospective analysis of an expanded 
RAS analysis from the PRIME study, which was a trial that compared the use of FOLFOX alone and 
FOLFOX plus panitumumab in first-line treatment (n=1183) (Douillard et al., 2013). This study 
began the “new era” of expanded RAS analysis, the results of which revealed that mutations also 
occurred in KRAS exon 3 (codon 61) and exon 4 (codons 117 and 146), and NRAS gene exon 2 
(codons 12 and 13), exon 3 (codon 61), and exon 4 (codons 117 and 146), which all predict the lack 
of benefit of EGFR-treatment. These other KRAS and NRAS mutations occur in 10-15% of all 
patients (Dietel et al., 2015; Douillard et al., 2013). KRAS and NRAS constitutively activate EGFR 
downstream cell signalling, but this cascade can be blocked by inactivating EGFR in a wild-type 
tumour. Mutations in KRAS or NRAS genes lead to the continuous activation of downstream ERK 
signalling, regardless of EGFR blockade, and bypass EGFR inhibition (Misale et al., 2015). Thus, it 
is possible to exclude patients who do not benefit from treatment, but are exposed to toxicity. It was 
shown by the OPUS trial (n=315), which studied the use of FOLFOX versus FOLFOX and cetuximab 
in first-line treatment that detrimental effects were observed in cetuximab treated RAS mutated 
patients.(Bokemeyer et al., 2011; Bokemeyer et al., 2015). Thus, according to the ESMO and NCCN 
guidelines, it is mandatory to perform a RAS mutation analysis before the administration of EGFR 
inhibitors (Benson and Venook, 2018a; Van Cutsem et al., 2016).  
The anti-EGFR antibodies cetuximab and panitumumab are active in different lines of treatment and 
as single agents or in combination with various chemotherapeutic agents (Benson and Venook, 2018a; 
Benson and Venook, 2018b; Van Cutsem et al., 2016). Cetuximab was first shown to significantly 
improve RR (13% vs. 0%), PFS (3.7 vs. 1.9 months, P<0.001) and OS (9.5 vs. 4.8 months; P<0.001), 
as compared with with the best supportive care (Jonker et al., 2007). The CRYSTAL trial explored 
the use of cetuximab in combination with FOLFIRI for first-line therapy, and demonstrated that there 
was a significant improvement in RR (57.3% vs. 39.7%, P< .001), PFS (9.9 vs. 8.4 months, P= 
.0012), and OS (23.5 vs. 20.0 months, P= .0093) in KRAS wild-type patients that were treated with 
cetuximab plus FOLFIRI, as compared to those treated with FOLFIRI alone (Van Cutsem et al., 
2011). Cetuximab was approved for use in first-line therapy after these results were obtained. The 
results obtained with the use of panitumumab were first studied in comparison to those obtained with 
the best supportive care; it was demonstrated that in KRAS wild-type tumours, there was a significant 
improvement in RR (17% vs. 0%), PFS (12.3 vs. 7.3 weeks), and OS (8.1 vs. 7.6 months, HR 0.67, 
CI95%0.55-0.82) in panitumumab-treated patients, as compared to those obtained with the best 
supportive care (Amado et al., 2008). In the phase III PRIME study, FOLFOX was administered for 
first-line therapy with or without panitumumab, and it resulted in an improved RR in wild-type KRAS 
patients (57% vs. 48%, OR 1.47, CI95% 1.07–2.04). Median PFS for wild-type KRAS patients was 
10.0 vs. 8.6 months (HR=0.80 CI95% 0.67-0.95) and an exploratory analysis of updated survival 
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(>80% OS events) demonstrated a significantly improved mOS in patients with wild-type KRAS 
of 23.8 months vs. 19.4 months (HR=0.83, CI95%0.70–0.98) (Douillard et al., 2014).  
 Treatment related adverse events during therapy containing EGFR-inhibitors 
The major side effect associated with cetuximab treatment is skin toxicity, including acne-like skin 
rashes, dry skin, hair growth disorders, pruritus, and nail changes (Cunningham et al., 2004; Fakih 
and Vincent, 2010). Allergic and anaphylactic reactions are more common with the use of cetuximab 
than with panitumumab. Severe reactions are seen in approximately 3% of patients following 
cetuximab administration, with a fatal outcome observed in 0.1% of patients. 
5.9 Additional drugs available for mCRC treatment 
 Regorafenib 
Regorafenib, an oral multitarget tyrosine kinase inhibitor, targets a large set of kinases, including 
angiogenic and stromal receptor tyrosine kinases (VEGFR-1, -2, -3, TIE2, FGFR-1, PDGFR-β) 
(Crona et al., 2013). It was approved after results from the CORRECT trial (n=760) were published 
(Grothey et al., 2013). The mOS improved from 5.0 months using a placebo to 6.4 months with the 
use of regorafenib (HR= 0.77 CI95% 0.64–0.94) as the last line of treatment in patients refractory to 
all available chemotherapy and biological agents. 
The CORRECT trial reported any adverse event occurring in 93% of patients who were assigned to 
receive regorafenib and 61% of patients in the placebo arm (Grothey et al., 2013). The most 
commonly reported ≥ 3 adverse events included HFS, fatigue, diarrhoea, HTN, and rash or 
desquamation in 17%, 10%, 7%, 7%, and 6% of the patients, respectively. More grade 1-4 toxicities 
were reported in the placebo arm in this study, as compared to those reported for patients receiving 
regorafenib. 
 TAS-102 
TAS-102 is a novel anti-metabolite that was first studied and used in Asia (Lenz et al., 2015). It is an 
oral drug and consists of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine 
phosphorylase inhibitor, tipiracil hydrochloride (Mayer et al., 2015). TAS-102 acts in a manner 
similar to that of 5-FU, by inhibiting thymidylate synthase and incorporating it into DNA, but it was 
shown to be efficacious in 5-FU resistant cell lines in preclinical studies (Lenz et al., 2015). Tipiracil 
hydrochloride prevents the rapid degradation of trifluridine, allowing the maintenance of the adequate 
plasma levels of the active drug. 
TAS-102 was approved in the United States and Europe after results from the RECOURSE trial 
(n=800) were published. The mOS improved from 5.3 months using a placebo to 7.1 months with the 
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use of TAS-102 (HR 0.68, CI95% 0.58-0.81) in heavily pre-treated patients as the last line of treatment 
(Mayer et al., 2015).  
The most frequently observed clinically significant adverse events associated with TAS-102 were 
neutropenia (38%) and leukopenia (21%) (Mayer et al., 2015). Febrile neutropenia was reported in 
4% of the patients receiving TAS-102. 
5.10 Personalized treatment of CRC 
There are several clinically relevant genetic abnormalities that have been identified in many human 
malignancies, which can be therapeutically targeted, for example, BRAF in melanoma, c-KIT in 
GIST, and EGFR in lung cancer (Vogelstein et al., 2013). CRC is an exception, because although the 
genomic landscape of CRC has been extensively studied, there are no abnormalities identified that 
could be therapeutically targeted in every day clinical practice at present.  
RAS mutation status is a negative predictive factor for EGFR-inhibition, but RAS is not a druggable 
mutation. In addition to KRAS and NRAS mutations, BRAF mutations have an impact on decision 
making, and MSI-H and HER2 are emerging as targets for the personalized treatment of CRC.  
Personalized medicine should therefore widely encompass several aspects other than the mutational 
assessment of CRC patients.  
 Individual metabolism 
The recommended doses of cytotoxic agents are determined in dose-finding phase I and phase II 
studies based on BSA, but sample sizes in these studies are small, and therefore insufficient for 
examining individual differences in drug metabolism (Gurney, 2002). In a real-life patient population, 
a standard dose might be insufficient to achieve the appropriate cytotoxic effect in individuals in 
whom the drug elimination process is faster, while in others, the same dose could lead to even fatal 
toxicity. As mentioned previously, mainly due to variations in the DPD enzyme activity, the area-
under-the-curve can vary even up to 100-fold, which results in great variations in the response and 
treatment outcome for individuals treated with 5-FU (Saif et al., 2009). It was shown that with BSA-
based standard dosing, only 20%–30% of patients are within the appropriate dose range, approximately 
40%–60% of patients are below the dose range and therefore remain undertreated, and 10%–20% of 
patients are overdosed (Saif et al., 2009). In a randomised phase III study in mCRC patients, 
pharmacokinetically adjusted 5-FU dosing improved RR from 18.3% to 33.7% (P = .004) and 
numerically mOS from 16 months to 22 months (P = .08) as compared to the BSA dosing (Gamelin 
et al., 2008). Several other studies have also demonstrated that it is possible to reduce toxicities and 
improve treatment outcome if the dose of 5-FU is individually adjusted using pharmacokinetics (Saif 
et al., 2009). 
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 Microsatellite instability 
MSI tumours represent a high level of microsatellite instability and are recognised by the high 
frequency of their mutations, which is attributable to the silencing of different genes in the mismatch 
repair system (MLH1, MSH2, MSH6, PMS2) (Wei et al., 1996). About 80% of cases occur 
sporadically, most commonly due to the epigenetic hypermethylation and silencing of 
the MLH1 promoter area, but about 20% occur because of hereditary germline mutations (Lynch 
syndrome). MSI tumours can be divided into MSI-high (MSI-H) and MSI-low (MSI-L) tumours, 
depending on the extent of instability. MSI-H tumours represent a subset of CRCs with distinct 
clinical and pathological features and are often right-sided, poorly differentiated mucinous tumours 
exhibiting an increased number of tumour infiltrating lymphocytes (Alexander et al., 2001; Jass et 
al., 1998; Smyrk et al., 2001). Approximately 20% and 12% of stage II and stage III tumours, 
respectively, present with MSI (Roth et al., 2010), but in stage IV, a prevalence of 4-8% has been 
reported in the western population (Van Cutsem et al., 2016).  
Increasing amounts of data support the fact that therapy should be tailored according to MSI status, 
both in the adjuvant and metastatic settings (Henricks et al., 2018; Yoshino et al., 2018) and both 
NCCN and Pan-Asian adapted ESMO consensus guidelines support routine MSI testing. Stage II 
MSI-H tumours are consistently associated with a more favourable prognosis, as compared to that of 
microsatellite stable (MSS) tumours with a low risk for recurrence (English et al., 2008; Lombardi et 
al., 2013; O'Reilly and Long, 1987; Ursem et al., 2018). An intact DNA replication error system 
known as the proficient MMR system appears to be necessary to mediate the cytotoxicity of 5-FU, 
and patients with MSI-H tumours do not derive a clear benefit from adjuvant 5-FU treatment (Cai et 
al., 2013). According to the guidelines, stage II MSI-H tumours should not be treated with single 
agent 5-FU in the adjuvant setting due to favourable prognosis, but also due to the limited efficacy of 
single agent 5-FU (Benson and Venook, 2018a; Benson and Venook, 2018b; Labianca et al., 2013). 
In stage III disease, MSI-H appears to have less prognostic value and adjuvant therapy should 
therefore be offered to patients with stage III MSI-H tumours (Benson and Venook, 2018a; Benson 
and Venook, 2018b). MSI-H tumours benefit from the inclusion of oxaliplatin, and if treated, an 
oxaliplatin-containing regimen should be chosen in case of an MMR deficiency (Andre et al., 2015a; 
Benson and Venook, 2018a; Benson and Venook, 2018b; Labianca et al., 2013). Updated 10-year 
results from the MOSAIC trial demonstrates that HRs for DFS and the OS benefit in the FOLFOX4 
arm were 0.48 (CI95% 0.20-1.12) and 0.41 (CI95% 0.16-1.07), respectively, in patients with stage II to 
III dMMR CRC tumours (Andre et al., 2015b). The analysis of pooled data from NCCTG N0147 and 
PETACC8 also showed that MMR deficiency is a favourable prognostic factor for oxaliplatin-
containing adjuvant chemotherapy in stage III CRC (Zaanan et al., 2018). 
There is some contradictory data published with regard to irinotecan and MSI status. In a retrospective 
analysis of the CALGB 89803, which was a study of use of irinotecan in the adjuvant setting, the 5-
year DFS of IFL-treated MSI-H patients was significantly improved, as compared to that for MSS 
patients (Meulendijks et al., 2015), but no benefit was observed in another trial, PETACC-3, which 
studied the use of irinotecan in adjuvant treatment (Klingbiel et al., 2015). The NSABP C-08 trial 
failed to show the benefit of including bevacizumab in the standard FOLFOX regimen for 1 year, 
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during the treatment of stage II/III colon cancer, but in the post hoc analyses, it was observed that 
MSI-H patients derived a statistically significant survival benefit from the addition of bevacizumab 
(Pogue-Geile et al., 2013). However, the data is currently contradictory and insufficient, because of 
which we cannot recommend VEGF-inhibitors in particular for patients with MSI-H tumours (Benson 
and Venook, 2018a; Benson and Venook, 2018b). 
It has been postulated that the biological background for improved prognosis in early stage MSI 
tumours is the mutational load associated with these tumours and the increased lymphocyte 
infiltration, which enhances the host immune response (Smyrk et al., 2001). MSS tumours are 
immunologically “cold”, but MSI-H tumours are “hot” due to a mutational high load being presented 
in an active immune microenvironment and the high expression of various checkpoint molecules (Le 
et al., 2015; Rokkas et al., 2013).  
In the metastatic setting, MSI-H tumours represent a subset of CRCs that derive a benefit from 
immune checkpoint inhibitors (PD1/PD-L1 blockade) during late line treatment, according to phase 
II trials (Le et al., 2015; Overman et al., 2017; Overman et al., 2018), but phase III results are still 
awaited. Le et al. began a new era, as they conducted a phase II trial (n=41) that included both 
colorectal and non-colorectal tumours with or without mismatch-repair deficiencies. All patients were 
treated with pembrolizumab (PD1-inhibitor), after which significantly improved RR values and 
durable responses were seen in patients with MSI-H tumours (Le et al., 2015). The mPFS and mOS 
were not reached in CRC patients with MSI-H tumours, but the values were 2.2 and 5.0 months, 
respectively, for CRC patients with MSS tumours. The RR and PFS rates of CRC patients were 40% 
and 78%, respectively, for patients with MSI-H tumours (n=11), and 0% and 11% for patients with 
MSS (n=21) tumours at 20 weeks. All CRC patients had previously received at least two therapies. 
In CheckMate-142 study 74 MSI-H CRC patients were treated with the PD1 inhibitor nivolumab 
(Overman et al., 2017). At a median follow-up time of 12 months, 23 out of 74 patients had achieved 
an objective response and 51 patients exhibited disease control that lasted for 12 or more weeks. The 
median duration of response was not reached. Further, improved results were even reported by the 
nivolumab plus ipilimumab cohort of CheckMate-142 (Overman et al., 2018).  
Based on the data presented, the Federal Drug Administration (FDA) in the United States has 
approved pembrolizumab, nivolumab, and a combination therapy of nivolumab with ipilimumab, for 
the treatment of MSI-H CRCs in patients that have progressed following fluoropyrimidine, 
oxaliplatin, and irinotecan containing therapy. Approval is awaited in Europe. 
 KRAS and NRAS mutations 
KRAS and NRAS mutations are an example of personalised medicine, as they are negative predictive 
factors for the EGFR-inhibiting antibodies cetuximab and panitumumab in CRC patients (Douillard 
et al., 2013; Douillard et al., 2014; Heinemann et al., 2014; Van Cutsem et al., 2015; Venook et al., 
2014). Patients with tumours that contain these mutations do not benefit from EGFR inhibitors and 
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RAS mutation analysis excludes approximately 50% of patients from this therapy. Data are discussed 
in detail in section 5.8.2.1. 
 Mutation in BRAFV600E  
Another important finding from the study by Douillard et al. was the observation that approximately 
8% of CRCs harbour a mutation in the BRAF gene, most often a point mutation in the V600E 
oncogene, but higher figures (10%) have been presented in a review by Ursem and in two Nordic 
studies (Algars et al., 2017; Douillard et al., 2013; Sorbye et al., 2015; Ursem et al., 2018). KRAS, 
NRAS, and BRAFV600E mutations are usually mutually exclusive, even though some rare exceptions 
have been reported. BRAFV600E-mutant mCRCs are a distinct biologic entity with a dismal prognosis 
that are associated with hypermutated tumours that frequently exhibit a CIMP phenotype and MSI 
(Cremolini et al., 2015b; English et al., 2008). BRAFV600E-mutated CRC tumours are commonly 
refractory to standard chemotherapy regimens, and unlike in melanomas, BRAFV600E mutated CRCs 
do not derive benefits from single agent BRAF-inhibitors (Cremolini et al., 2015b; Kopetz et al., 
2015).  
The TRIBE study evaluated the use of FOLFIRI plus bevacizumab versus FOLFOXIRI (5-FU in 
combination with irinotecan and oxaliplatin) plus bevacizumab as the first-line treatment in 508 
patients, of which 28 patients presented with the BRAFV600E mutation (Cremolini et al., 2015b). Of 
these BRAFV600E mutated patients, 12 patients were assigned to the FOLFIRI arm and 16 patients 
were assigned to the FOLFOXIRI arm. In these BRAFV600E mutated patients, the mOS of patients 
treated with FOLFOXIRI plus bevacizumab was 19.0 months, as compared to that of 10.7 months in 
the FOLFIRI plus bevacizumab arm (HR 0.54 CI95% 0.24–1.20). Although the number of patients 
with BRAFV600E mutations was small, based on this study and the patient series (Loupakis et al., 
2014), FOLFOXIRI plus bevacizumab treatment is considered as a good first-line therapy option for 
patients with BRAFV600E mutations (Van Cutsem et al., 2016). 
To improve the prognosis of BRAFV600E mutated CRCs, several trials have been conducted using the 
EGFR, MEK and BRAF inhibitors. FDA approved the use of encorafenib in combination with 
binimetinib and cetuximab for the treatment of BRAFV600E mutated CRCs in second or later lines of 
treatment, after results from the phase III BEACON trial were published (Cutsem et al., 2018). 
Data indicate that the use of EGFR-inhibitors in BRAFV600E mutated patients is controversial, but 
evidence supporting the fact that these patients do not benefit from anti-EGFR antibodies has been 
accumulating (Pietrantonio et al., 2015; Rowland et al., 2015); both NCCN and ESMO guidelines 
recommend that EGFR inhibitors should not be used in BRAFV600E mutated patients (Benson and 
Venook, 2018a; Benson and Venook, 2018b; Van Cutsem et al., 2016). 
Data suggest that the BRAFV600E mutation is associated with an inferior outcome in stage II and III 
disease as well, especially in MSS tumours, but there is no evidence proving that it can predict 




 Non- BRAFV600E mutations 
Jones at al. described using a dataset of nearly 10,000 patients that 2% of all CRCs and 22% of all 
BRAF mutated patients harboured non- BRAFV600E mutations that can be detected in next generation 
sequencing platforms (Jones et al., 2017b). In their study, non- BRAFV600E mutated tumours were 
associated with a younger age, male gender, and lower-grade tumours, and were more often left-
sided, as compared to BRAFV600E mutated tumours. In the dataset described by Jones et al., patients 
with non-BRAFV600E mutated tumours had a mOS of 60 months, as compared to an mOS of 43 months 
in all RAS wild-type patients, and a mOS of 11 months in the BRAFV600E mutated patients. Another 
small study of 10 patients with BRAF mutations at codons 594 and 596 also found that these 
mutations were associated with an improved prognosis, as compared to that of individuals with the 
BRAFV600E mutation (Cremolini et al., 2015a). According to Jones et al. (Jones et al., 2017a), these 
patients should not be treated as aggressively as BRAFV600E mutated patients, but data regarding non-
BRAFV600E mutations is limited at the moment. 
 Human epidermal growth factor receptor 2 (HER2)  
The overexpression or amplification of HER2 has been reported in around 20% of breast cancers 
(Zhang et al., 2003) and in 7%–34% of gastric cancers (Reichelt et al., 2006). HER2 targeted therapies 
are established treatment strategies used for the treatment of these cancers, and show a significant 
improvement in survival; therefore, HER2 has been of interest also in CRC (Bang et al., 2010; Swain 
et al., 2015).  
HER2 amplifications or mutations are detected in approximately 5% of all CRCs, but its role as a 
biomarker for prognosis remains debatable (Sartore-Bianchi et al., 2016). Instead, HER2 is emerging 
not only as a negative predictor of response to EGFR-inhibitors, but also as a target for therapy 
(Bertotti et al., 2011; Yonesaka et al., 2011). The clinical benefit of dual HER2-inhibition using 
trastuzumab and lapatinib in CRC was first demonstrated in the Italian HERACLES trial (Sartore-
Bianchi et al., 2016). In previous pre-clinical studies, it was demonstrated that HER2 targeted 
monotherapy was inferior to dual inhibition in CRC patients (Leto et al., 2015). In the HERACLES 
trial of 27 eligible patients, 1, 7, and 12 patients achieved CR, PR, and SD, respectively, and this was 
the best response observed in this heavily pre-treated patient population (Sartore-Bianchi et al., 2016).  
 PIK3CA 
The PI3K signalling pathway is involved in the pathogenesis of CRC. |Mutations in PIK3CA exons 
9 and/or 20 are present in 10-20% of CRC patients and are associated with other molecular alterations, 
including the KRAS mutation and CIMP phenotype (Inamura, 2018; Karakas et al., 2006). The 
possible prognostic and predictive value of the PIK3CA mutation in mCRC is not yet established, but 
data suggest that the PIK3CA mutation is a negative predictive factor for EGFR-inhibitors (Jhawer 
et al., 2008).  
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Nonsteroidal anti-inflammatory drugs might supress colorectal cancer progression through the 
inhibition of cyclooxygenase-2 and synthesis of prostaglandin E2, which are enhanced by activated 
PI3K signalling (Domingo et al., 2013). The use of aspirin for the chemoprevention of CRC has been 
studied in several trials (Algra and Rothwell, 2012; Rothwell et al., 2012) and prospective randomised 
trials are ongoing to define the true impact of aspirin in PIK3CA mutated tumours 
(www.clinicaltrials.gov).  
 Tumour sidedness in first-line therapy 
Two randomised phase III trials investigated the use of the biological agents, cetuximab and 
bevacizumab with chemotherapy in first line treatment. The FIRE-3 study (n=493 KRAS exon 2 wild-
type patients) compared the use of FOLFIRI plus cetuximab and that of FOLFIRI plus bevacizumab; 
the primary endpoint of the study was RR, and PFS and OS were the secondary endpoints. No 
differences were observed in RR or mPFS (10.0 vs. 10.3 months, respectively, P= .55) between arms, 
but the mOS was significantly longer in the cetuximab arm (28.7 vs 25.0 months, HR 0.77, CI95% 
0.62–0.96) (Heinemann et al., 2014). In a following analysis that was limited to all the RAS wild-
type patients, the OS benefit was more pronounced with the use of cetuximab.  
In the CALGB 80405 study (n=1137 KRAS exon 2 wild-type patients), first-line treatments with 
FOLFOX/FOLFIRI with bevacizumab or cetuximab were compared. There were no statistically 
significant differences in PFS or OS that were observed between treatment regimens. The mOS was 
30.0 months in the cetuximab-chemotherapy arm and 29.0 months in the bevacizumab-chemotherapy 
arm (HR=0.88 CI95% 0.77–1.01) (Venook et al., 2017). The mPFS was 10.5 months in the cetuximab-
chemotherapy arm and 10.6 months in the bevacizumab-chemotherapy arm (HR CI95% 0.84–1.08). 
The RR in the cetuximab and bevacizumab arms was 59.6% and 55.2%, respectively; thus, the values 
were similar (difference, 4.4%, CI95% 1.0%-9.0%, P = .13). In patients treated with FOLFOX and 
cetuximab, the mOS was 30.1 months and in patients treated with FOLFOX and bevacizumab, the 
mOS was 26.9 months (P = .09). In FOLFIRI-treated patients, the trend was reversed; the mOS was 
33.4 months with the use of bevacizumab and 28.9 months with that of cetuximab (P = .28). Based 
on results from these two trials both ESMO and NCCN guidelines concluded that bevacizumab and 
EGFR-inhibitors are equally effective options that can be used for first-line therapy in mCRC patients. 
The general recommendations regarding targeted therapy were changed after retrospective analyses 
of the primary tumour location had showed that sidedness is a significant, independent prognostic 
and predictive factor (Tejpar et al., 2016). Tumours that originate in the splenic flexure, descending 
colon, sigmoid colon, rectum, or distal one-third of the transverse colon are classified as left-sided, 
distal tumours (Stintzing et al., 2017a). They are derived from the embryonic hindgut, whereas 
tumours that originate in the appendix, cecum, ascending colon, hepatic flexure, or two-thirds of the 
transverse colon are derived from the embryonic midgut and are classified as right-sided, proximal 
tumours. There are several differences in the epidemiology, pathology, mutation profile, and clinical 
presentation of proximal and distal tumours, probably due to their distinct embryologic origins. 
Proximal tumours account for approximately 30% of CRCs and are more common in older females 
who often present with a higher TNM stage, as compared to that observed for distal tumours (Mik et 
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al., 2017). Proximal tumours exhibit microsatellite instability, poor differentiation, mucinous 
histology, CIMP-high status, serrated pathway signature, CMS1 (immune) and CMS3 (metabolic) 
subtypes, and BRAFV600E mutations more often than distal tumours. Distal tumours are observed more 
often in men with CIMP-low status, classical chromosomal instability, and CMS2 (canonical) and 
CMS4 (mesenchymal) subtypes. Regardless of the treatment used, recent meta-analyses have 
consistently demonstrated that OS is significantly worse in patients with proximal tumours, as 
compared to that of those with distal tumours (Arnold et al., 2017; Holch et al., 2017; Petrelli et al., 
2016). It was reported in CALGB 80405 that in all KRAS wild-type patients with distal tumours, the 
OS was significantly longer, as compared with that observed for proximal tumours (33.3 vs. 19.4 
months; HR, 1.55; P < .0001) (Venook et al., 2017). 
The strongest evidence of sidedness was obtained from the CALGB 80405 trial, conducted with the 
largest number of patients (n=1139) (Venook et al., 2017). In all RAS wild-type patients with left-
sided tumours, the mOS was 39.3 months in the cetuximab arm, as compared to that of 32.6 months 
in the bevacizumab arm (HR 0.77, CI95% 0.59-0.99), regardless of the chemotherapy backbone. In 
contrast, in all RAS wild-type patients with right-sided tumours, the mOS was 13.6 months in the 
cetuximab arm, and 29.2 months in the bevacizumab arm (HR 1.36, CI95% 0.93-1.99). Two meta-
analyses conducted after pooling data from several trials confirmed this; RAS wild-type left-sided 
tumours have a significantly greater survival benefit from anti-EGFR treatment, as compared to that 
observed with anti-VEGF treatment, when included along with standard chemotherapy (Arnold et al., 
2017; Tejpar et al., 2016). Patients with tumours originating from the right side of the colon seem to 
benefit from bevacizumab treatment, but EGFR inhibitors might be associated with even detrimental 
effect and according to recent guidelines EGFR-inhibitors should not be used in first-line treatment 
in proximal tumours (Arnold et al., 2017; Benson and Venook, 2018a; Yoshino et al., 2018).  
5.11 Consensus molecular subtypes 
CMS was first described in early-stage CRC cohorts, but the association between CMS and treatment 
outcome in mCRC patients is not established yet (Mooi et al., 2018). It is now being intensively 
researched and validated in large patient cohorts, but increasing amounts of evidence already suggest 
that CMS classification is both a prognostic and predictive factor in CRC (Lenz et al., 2017; Mooi et 
al., 2018; Okita et al., 2018; Stintzing et al., 2017b).  
In the original study by Guinney et al., important associations between CMS groups and clinical 
variables were reported (Guinney et al., 2015). CMS1 (immune subtype) tumours were frequently 
right-sided and diagnosed more frequently in females, and had a higher histopathological grade. The 
CMS1 population showed very poor survival after relapse, which is associated with a number of 
BRAF mutations and patients with MSI in this subtype. CMS2 (canonical subtype) tumours were 
mainly left-sided, showed superior survival after relapse and this subtype was observed in a larger 
proportion of long-term survivors. CMS4 (mesenchymal) tumours tended to be diagnosed at more 
advanced stages and displayed the worst OS and RFS, both in univariate and multivariate analyses 
(adjustment for clinicopathological features, MSI, and BRAF and KRAS mutations).  
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The clinical relevance of the CMS classifications in the adjuvant setting was evaluated in the 
PETACC-8 cohort (Marisa et al., 2017), which was a phase III trial that compared adjuvant FOLFOX  
with or without cetuximab in stage III CRC patients. Samples from PETACC-8 were assigned to 
different consensus molecular subtypes; 17%, 34%, 4%, and 45% of samples were assigned to CMS1, 
CMS2, CMS3, and CMS4 groups, respectively. It was observed that the subtype was significantly 
associated with treatment outcome in multivariate analysis. Individuals whose samples were included 
in the CMS4 group had the shortest OS (HR=1.7, P= .021), which is in line with the findings of the 
study by Guinney et al. The effect of treatment with cetuximab was worse than that of treatment with 
FOLFOX alone in CMS1 tumours, which is probably associated with the large number of right-sided 
tumours in this subtype.  
With regard to metastatic disease, the CALGB 80405 trial reported that the patients with the CMS2 
subtype had the best outcome and those with the CMS1 subtype showed the worst outcome (Lenz et 
al., 2017). Patients with CMS1 tumours who were treated with bevacizumab had a significantly longer 
OS, as compared to that of those treated with cetuximab, but patients with CMS2 tumours who 
received bevacizumab treatment tended to have a shorter OS than those who received cetuximab. A 
study by Okita et al. reported that the effects of irinotecan based chemotherapy were significantly 
superior to those associated with the use of oxaliplatin, in terms of PFS and OS, in patients with the 
CMS4 tumour subtype (Okita et al., 2018). In patients treated with EGFR inhibitors, patients who 
had the CMS1 subtype showed a worse PFS and OS, but those with CMS2 showed a particularly 
good efficacy, as compared to that of other subtypes. It was previously reported after the AGITG 
MAX trial that there was an improvement in PFS, after the addition of bevacizumab to capecitabine 
+/- mitomycin (Tebbutt et al., 2010). A subset of samples from this study were classified according 
to CMS groups, and it was observed that CMS subtypes were prognostic of survival, and that while 
CMS2 was associated with the best outcome, CMS1 was associated with the worst outcome (Mooi et 
al., 2018). According to these results, patients with CMS2 and possibly those with CMS3 tumours 
could derive benefits from the addition of bevacizumab to first-line capecitabine-based 
chemotherapy, but no such benefit was seen for those with CMS1 and CMS4 tumours in this study. 
5.12 Liquid biopsies 
Cell-free DNA (cfDNA) has gained attention in the field of oncology, after it was discovered that a 
part of it originates from tumour cells and can be isolated from any of the body fluids; isolation is 
mostly performed using the peripheral blood and urine (Babayan and Pantel, 2018). The blood-
derived circulating tumour DNA (ctDNA) contains tumour-specific genetic and epigenetic alterations 
that reflect the intra- and inter-tumoural heterogeneity, which are not detected by tissue biopsies (Diaz 
et al., 2012; Katsiampoura and Kopetz, 2014; Misale et al., 2012). This method has gained increased 
interest and might mark the start of a new era in personalized medicine. If the liquid biopsy method 
would be established in further studies to be clinically feasible and reliable, it can represent a modality 
for improving personalized medicine. It is studied as a tool for screening, and for monitoring the risk 
of relapse after surgery, treatment efficacy, clonal evolution, and emerging therapy resistance in real-
time (Babayan and Pantel, 2018). 
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Several studies suggest that liquid biopsies could be utilized for the management of CRC at different 
stages (Babayan and Pantel, 2018). There are studies demonstrating that ctDNA can predict 
recurrence after surgery in early stage CRC (Tie et al., 2016). The detection of ctDNA after the 
resection of stage II CRC was predictive for recurrence in a prospective study by Tie et al (n=230). 
CtDNA was detected post-operatively in 7.9% of the patients who were not treated with adjuvant 
chemotherapy. Of these, recurrence was observed in 79% of the patients, but recurrence was observed 
in only 9.8% of patients with negative ctDNA (HR=18 CI95% 7.9-40). In patients treated with adjuvant 
therapy, the presence of ctDNA after the completion of chemotherapy was associated with an inferior 
RFS, as compared to that of patients in whom ctDNA was not detected (HR=11 CI95%, 1.8-68) (Tie 
et al., 2016).  
The clinical decision to use EGFR-inhibitors is based on RAS analysis, conducted with a tissue 
biopsy. However, it is an invasive method and it is not always possible to retain a representative 
histological biopsy. In addition, its sensitivity is limited, as only a small portion of a tumour is 
commonly biopsied. It is not possible to detect genetic heterogeneity within or between lesions or the 
evolution of new mutations during therapy using tissue biopsies (Katsiampoura and Kopetz, 2014). 
It has been shown that in tumours that were initially considered to be RAS wild-type tumours, there 
are pre-existing RAS-mutant subclones, and resistance has been acquired towards EGFR-inhibitors, 
due to the presence of these resistant subclones (Diaz et al., 2012; Misale et al., 2012). There has been 
an increase in the level of interest in studying liquid biopsies for monitoring treatment efficacy and 
evolution of RAS-mutant clones during EGFR-containing therapy (Diaz et al., 2012; Katsiampoura 
and Kopetz, 2014). These RAS-mutant clones emerge during anti-EGFR treatment and the number 
of clones present declines when treatment is suspended; acquired resistance might therefore be 
delayed or avoided by taking breaks from the use of EGFR-inhibitors (Goldberg et al., 2018).  
The phase II CRICKET trial (n=28) was designed to investigate the activity of the re-challenge with 
cetuximab and irinotecan in initially RAS/BRAF wild-type mCRC patients who had progressed 
during cetuximab and irinotecan containing first-line therapy (Rossini et al., 2018). The role of liquid 
biopsies as a tool for identifying patients that were more likely to benefit from the re-challenge 
strategy was investigated and liquid biopsies were performed. Patients with RAS wild-type ctDNA 
had a significantly longer PFS than those with RAS mutated ctDNA (3.9 vs. 1.9 months; HR 0.48 
CI95% 0.20-0.98) and in none of the patients with PR RAS mutations were detected in baseline liquid 
biopsies.  
A phase III trial, FIRE-4 is ongoing to evaluate the significance of treatment holidays from EGFR-
therapy and to investigate the use of liquid biopsies for tracking and identifying patients with 
emerging and acquired resistance (www.clinicaltrials.gov).  
5.13 Quality of life (QOL) 
Quality of life (QOL) assessment is a multidimensional concept that includes an evaluation of the 
physical, functional, social and emotional well-being of an individual (Anonymous, 1947; Post, 
2014). As more patients treated with adjuvant therapy survive cancer and thus continue to live years 
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after cessation of therapy, and as patients with metastatic disease live longer with the aid of palliative 
therapies, the level of interest in measuring QOL both in cancer patients on treatment and in long-
term survivors continues to increase. The incorporation of QOL measurements into clinical trials is 
therefore nowadays a well-established practice. At present, Patient-reported Outcome Measures 
(PROMS) are being focused upon, because it is established that there is often a discrepancy between 
the NCI-CTCAE grading of adverse events and PROMs (Van Cutsem et al., 2017). 
 Assessment of QOL 
There are several validated, standardized, disease specific and general QOL questionnaires in use 
today. The University of Oxford has conducted a review that provided a list of the most promising 
generic and cancer-specific instruments that have been evaluated in CRC patients 
(http://phi.uhce.ox.ac.uk/pdf/CancerReviews). Four general questionnaires on the list were: Medical 
Outcomes Study 36-Item Health Survey (SF-36), Medical Outcomes Study 12-Item Health Survey 
(SF-12), European Quality of Life Questionnaire (EQ-5D), and EORTC Quality of Life 
Questionnaire (EORTC QLQ-C30). In addition, two CRC-specific instruments were identified, the 
Colorectal Cancer Specific Quality of Life Questionnaire (EORTC QLQ-CR38) and Functional 
Assessment of Cancer Therapy – Colorectal (FACT-C).  
SF-36 is a questionnaire comprising of 36 items, and is used in a wide range of conditions and in the 
general population. SF-12 contains 12 items and was developed from SF-36, because of the need for 
a shorter, less intensive questionnaire that could be completed more rapidly (Sprangers et al., 1999). 
EQ-5D was developed to provide an instrument for economic evaluation (Anonymous, 1990). 
However, one drawback of these general questionnaires is the risk of ignoring cancer specific 
symptoms; therefore, QLQ-C30 was developed by EORTC, initially for evaluating the QOL of cancer 
patients participating in clinical trials (Bergman et al., 1994). Today, the EORTC QLQ-30 is probably 
the most used questionnaire in cancer studies. It is translated into several languages and has been 
validated in patients with several cancer types (http://qol.eortc.org/). It contains nine multi-item 
scales, as there are five functional scales (physical, role, cognitive, emotional, and social), three 
symptom scales (fatigue, pain, and nausea and vomiting) and a global health and quality-of-life scale. 
Several single-item symptom measures are also included (http://qol.eortc.org/). 
In the same manner in which general questionnaires can ignore cancer specific symptoms, the general 
cancer specific questionnaire can ignore some disease specific aspects; therefore, QLQ-C30 contains 
cancer specific sub-scales. QLQ-C38 is a questionnaire for CRC patients that contains 38 CRC 
specific questions, to be delivered in addition to the QLQ-C30 questionnaire (Sprangers et al., 1999). 
The 38 items are added to the 30 core items of the QLQ-C30, resulting in a questionnaire with 68 
items. Like QLQ-C30, QLQ-C38 consists of both multi-item scales and single-item measures. It 
includes two functional scales (body image and sexual function), seven symptom scales (micturition 
problems, gastrointestinal tract symptoms, chemotherapy side effects, defecation problems, stoma-
related problems, and male and female sexual problems), and three single-item measures (sexual 
enjoyment, weight loss, and future perspective) (http://qol.eortc.org/). 
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The FACT-C is a 7 item colorectal cancer-specific module that supplements the functional assessment 
of cancer therapy – General (FACT-G) questionnaire and assesses the following four domains 
investigated by FACT-G: physical, emotional, functional, and social/family wellbeing (Ward et al., 
1999). In addition, FACT-C assesses nine CRC-specific items: swelling/cramping in the stomach 
area, weight loss, control of bowels, digestion, diarrhoea, appetite, body image of all CRC patients, 
in addition to attitudes towards ostomy and difficulty with ostomy care.  
 Assessment of neuropathy 
Peripheral neurotoxicity is a common side effect caused by several chemotherapeutic agents, 
especially vinca-alkaloids, taxanes, and platinum compounds, such as oxaliplatin, which is one of the 
most neurotoxic agents in oncology (Addington and Freimer, 2016; Mols et al., 2014). Interest 
towards oxaliplatin induced long-term neuropathy and its effect on QOL has gained increased 
interest, as it was observed that neuropathy seemed to be under-reported in clinical randomised trials 
(Beijers et al., 2014).  
Several grading scales have been developed to assess the development and severity of the neuropathy 
induced by chemotherapeutic agents, but there is no consensus regarding the most preferable and 
appropriate scales that should be used for conducting an assessment of oxaliplatin induced neuropathy 
(Alberti et al., 2014; Lavoie Smith et al., 2013). Different scales have their strengths and weaknesses, 
but an increasing level of emphasis is placed on patient reported outcome measurements (Lavoie 
Smith et al., 2013; Postma et al., 2005). It is shown that physician reported outcome underestimates 
subjective adverse events (i.e. fatigue, nausea) and a patient reported outcome reveals the worsening 
of a symptom before a physician reported outcome (Mayor, 2015). A study by Alberti concluded that 
both subjective and objective measures should be combined to enhance the validity of the 
measurement (Alberti et al., 2014). 
As with other adverse events, the most commonly used scale to assess neuropathy has been the NCIC-
CTC grading scale (Postma and Heimans, 2000). It requires sensory and motor symptoms to be 
graded separately, even though motor function is rarely affected by oxaliplatin treatment. The NCIC-
CTC sensory scale is based on the subjective evaluation of the presence of paraesthesia and sensory 
loss (grade 1), their interference with function (grade 2), interference with activities of daily living 
(grade 3) and toxicity including permanent symptoms with interference with function or activity of 
daily living (grade 4). As oxaliplatin has a unique toxicity profile that results in both cumulative 
peripheral sensory neuropathy and acute reversible cold-allodynia, a specific Levi grading scale was 
developed to assess oxaliplatin induced neurotoxicity (Levi et al., 1992). It assesses both the intensity 
and the duration of neuropathic symptoms. The widely used functional assessment of cancer-
gynecologic oncology group-neurotoxicity (FACT/GOG-NTX) questionnaire (Huang et al., 2007) 
has also been used in the SCOT, a substudy of the IDEA collaboration, to assess both acute and long-
term neuropathy (Iveson et al., 2018). The total neuropathy score (TNS) is a complex assessment of 
neuropathy that includes objective measures, such as pin pricks, vibration thresholds, and nerve 
conduction studies, in combination with a subjective report of sensory, motor, and autonomic items 
(Cavaletti et al., 2003). Due to the objective measurements, it is not feasible to use the TNS in every 
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day clinical practice; shorter versions have been developed to evaluate only the clinical signs and 
symptoms of neuropathy. 
At present, the patient reported outcome that is used most commonly for evaluating neuropathy is 
probably the EORTC CIPN20 (Lavoie Smith et al., 2013; Postma et al., 2005). It contains 20 items 
assessing sensory (9 items), motor (8 items), and autonomic symptoms (3 items) and it uses a 4-point 
scale for assessing symptom severity during the past week (1 = “not at all,” 2 = “a little,” 3 = “quite 
a bit,” and 4 = “very much”) (http://qol.eortc.org/). As observed for QLQ-C30, all scale scores are 
linearly converted to a 0–100 scale, with higher scores indicating a greater symptom burden. 
 Prediction and prevention of CIPN 
Despite intensive research, no factors that can predict the development or severity of CIPN have been 
identified (Pulvers and Marx, 2017). Data published are partly contradictory, but most studies have 
identified an association between acute and long-term neuropathy and the cumulative dose (Park et 
al., 2011; Stefansson and Nygren, 2016; Tournigand et al., 2006). The Southwest Oncology Group 
examined their database to identify patients that had been treated with taxane therapy (Hershman et 
al., 2016). They noted an association between age and neuropathy, and reported that significantly 
more neuropathy was observed in patients with complications because of diabetes, as compared with 
that in patients with no diabetes. However, this study included only patients with an age of over 65 
years and other studies have reported about conflicting results with regard to both age and diabetes 
(Pulvers and Marx, 2017). Interestingly, patients with a history of autoimmune disease were half as 
likely to experience neuropathy (Hershman et al., 2016). However, in conclusion, no baseline factors 
that can act as predictors for neuropathy have been established.  
OPTIMOX 1 study  intermittent use of oxaliplatin,  the “stop and go” strategy, which is 
currently a recommended treatment strategy with the administration of oxaliplatin (Benson and 
Venook, 2018a; Benson and Venook, 2018b; Van Cutsem et al., 2016). In OPTIMOX 1 (n=620),  
FOLFOX was provided until progression in one treatment arm and in another one FOLFOX was  
provided for 6 cycles, followed by maintenance with 5-FU/LV alone for 12 cycles, after which 
FOLFOX was reintroduced (Tournigand et al., 2006). The median PFS and OS were 9.0 and 
19.3 months, respectively, in patients treated with FOLFOX until progression, as compared with 
those of 8.7 and 21.2 months, respectively, in patients treated using the stop-and-go strategy (P = not 
significant). Oxaliplatin was reintroduced in only 40.1% of the patients, but response or stabilization 
of the disease was achieved in 69.4% of patients in whom oxaliplatin was reintroduced. Results show 
that administering oxaliplatin using the the stop-and-go strategy did not compromise RR, PFS, and 
OS. Lower rates of  grade 3 neuropathy were reported in patients treated using the stop-and-go 
strategy (13% vs 19%; P = .0017) (Tournigand et al., 2006). 
The OPTIMOX 2 phase II trial (n=216) randomised patients to either 5-FU/LV maintenance or a 
treatment holiday between FOLFOX administration (Chibaudel et al., 2009). The primary endpoint, 
duration of disease control (calculated as the sum of the duration of PFS in the initial FOLFOX 
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therapy and with the subsequent reintroduction of FOLFOX), was better in the continued treatment 
arm (13.1 months vs 9.2 months, P=0.046), as was the PFS.  
According to ESMO guidelines, patients receiving FOLFOX or CAPOX plus bevacizumab should 
be considered for maintenance therapy with fluoropyrimidine plus bevacizumab, after an induction 
phase of 8 or 6 cycles, respectively (Van Cutsem et al., 2016).  
In addition to the use of the stop-and-go strategy, no agents have been recommended for the 
prevention or treatment of neuropathy. There were high expectations from the study of calcium-
magnesium infusions, but it turned out negative. Some results were obtained with the use of 
venlafaxine in the prevention of CIPN, but data is insufficient to  recommend any agent in the 
prevention of CIPN (Durand et al., 2012; Jordan et al., 2016). A phase III study is currently ongoing, 
after promising results were obtained with calmangafodipir (Karlsson et al., 2017). With regard to 
the treatment of chronic, painful neuropathy, the best data support was available for carrying out 
treatment with duloxetine (Smith et al., 2017). 
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6. AIMS OF THE THESIS 
The present study, including its four substudies was conducted to find the answers for the following 
questions: 
Study I: Is HTN associated with treatment outcome in mCRC patients treated with bevacizumab 
containing chemotherapy?  
Study II: Is H. Pylori infection predictive of chemotherapy induced gastrointestinal toxicity 
during 5-FU based adjuvant chemotherapy in CRC patients?  
Study II: Does H. Pylori interfere with primary CRC diagnostics?  
Study III: Are haematological or non-haematological adverse events predictive of the efficacy 
of 5-FU based adjuvant chemotherapy in CRC patients? 
Study IV: What is the incidence of acute and long-term neuropathy in CRC patients treated with 
adjuvants FOLFOX or CAPOX? 








7. MATERIAL AND METHODS 
7.1 Patient material and ethical aspects 
An overview of study characteristics is presented in Table 5. Study I included 101 patients who had 
received palliative treatment for mCRC, and studies II-IV included 79, 1033, and 144 patients 
respectively, who received adjuvant treatment after radical resection for stage II-III CRC. 
Study I was a retrospective study based on information in hospital charts, and it was performed with 
institutional approval from the department of Oncology at HUCH, without obtaining formal patient 
consent. In studies II-IV, the Ethical Review Board at HUCH had approved the protocols and written 
informed consent had been obtained from all patients. 
Table 5. Study characteristics 












stage II/III/IV  
No 
 
Yes Yes Yes 
Non-resectable 
metastatic disease  


























Toxicity assessment NCI-C CTCv.2 NCI-C CTCv.2 NCI-C CTCv.1 
in French NCI-
C CTCv.2 in 
Finnish 





Study I included all consecutive mCRC patients treated with bevacizumab containing chemotherapy 
between April 2004 and December 2005 at the Helsinki University Central Hospital (HUCH) Cancer 
clinic. There were 114 bevacizumab treated patients identified from the patient charts, of which 101 
patients with evaluable disease had received treatment with bevacizumab. These 101 patients were 
eligible for efficacy assessment. 
Study II included 79 radically operated CRC patients with H. pylori serology and lactose intolerance 
assessment (stage II-III n=73, stage IV n=6). These patients were the first patients from the 
randomised LIPSYT trial that included a total of 153 patients. The LIPSYT was an open, prospective, 
randomised single institution study conducted using radically operated CRC patients, and it is 
registered on http://www.controlled-trials.com/ISRCTN98405441. The primary endpoint of the 
LIPSYT was treatment tolerability and toxicity.  
Concerning study II, there were 37 seronegative and 42 seropositive patients at diagnosis of CRC. 
Serum samples were collected to study the H. pylori status prior to adjuvant treatment, and during 
and after treatment (at 2, 4, and 6 months), and at 8 and 12 months from the date of initiation of 
treatment. In addition, 77 out 79 patients were evaluated for lactose intolerance, using an oral lactose 
tolerance test at the baseline and at 4 and 8 months after the initiation of adjuvant chemotherapy. With 
regard to the diagnostic delay, patients were asked about the duration for which they had had cancer 
related symptoms before surgery and the main symptom because of which the patient visited a doctor. 
The time to diagnosis was calculated as the time from the beginning of the symptoms to the date of 
surgery. All patients (n=79) were included in the toxicity analysis, but six patients were excluded 
from the analysis of diagnostic delay since it was not possibly to determine the time from the onset 
of symptoms to diagnosis in these patients. Only stage II-III patients were included in the efficacy 
analysis of DFS and OS. 
Study III consisted of 1033 patients with radically operated stage II or III CRC. To increase the 
statistical power of the study we pooled data from two prospective, randomised trials; the Finnish 
LIPSYT (n=153) and French GERCOR C96.1 (n=880). In original GERCOR C96.1 primary end-
point was DFS between bolus and infusional regimens in the adjuvant setting. All patients with 
complete data on toxicity and survival were included and therefore not all patients from the GERCOR 
C96.1 were eligible (905 patients in the original trial). 
In study IV, we included 144 patients. All stage II and III CRC patients who were treated with the 
adjuvant CAPOX (n=72) at the HUCH department of oncology between 1.1.2000 - 31.9.2009 were 
identified from hospital files and matched with comparative FOLFOX controls from the same 
register. All patients who were alive were sent the EORTC QLQ-C30 questionnaires and two 
reminders. An extensive interview was performed with consenting patients (n=92). During the phone 
interview, the EORTC CIPN20 questionnaire was filled-in, to assess long-term neuropathy. By the 
time of the study, CIPN20 was not yet translated into Finnish or Swedish; therefore, instead of sending 
questionnaires in English, a phone interview was performed after obtaining permission from EORTC. 
Six patients were excluded during the interviews, due to different confounding factors and one was 
excluded, because he was not skilled enough to communicate effectively in English or Finnish. At 
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the end of the process, there were 92 patients who had consented, and for whom complete data, 
including both filled-in QLQC-30 and CIPN20 forms were available (Figure 1). 
 






































144 stage II or III CRC patients were 
retrospectively identified and all these 
patients were evaluated for survival analysis 
132 patients were alive out of 144 and  
were sent the QLQ-C30  
102 patients (77%)  
returned the QLQL-C30  
Excluded: 
5 patients undergoing therapy for 
metastatic CRC, 
1 spinal stenosis patient, 
1 excluded due to language barrier 
92 eligible patients provided comprehensive 
QLQ and neuropathy data. 
 (57% females and 43% males) 
12 (8%) had died 
28 did not return the QLQL-
C30, even after two reminders  
(16/28 were survivors) 
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7.2 Treatment regimens  
In study I, any chemotherapy regimen containing bevacizumab was allowed; the most commonly 
used regimens included those of FOLFIRI (n=60), CAPIRI, or irinotecan (n=21), CAPOX or 
FOLFOX (12), and 5-FU/LV or capecitabine (n=7) (Osterlund et al., 2011).  
Adjuvant chemotherapy regimens in studies II and III included either the Mayo (or modified Mayo 
with 3- to 5-min intravenous 5-FU bolus 370–425 mg/m2 and LV infusion 10–20 mg/m2) or the 
LV5FU2 in France or simplified LV5FU2 in Finland (Andre et al., 2003; Osterlund et al., 2007).  
In study IV, all patients were treated with either CAPOX or FOLFOX (Haller et al., 2011b; Soveri et 
al., 2018). 
7.3 Assessment of adverse events 
In study I, the recorded adverse event of interest was HTN, and it was graded retrospectively from 
the patient charts. Blood pressure was measured by a nurse at the baseline and before each 
bevacizumab infusion. Blood pressure values were recorded at every assessment and the highest 
grade was recorded every three months. Three months was chosen, because there were patients with 
both 2- and 3-week long dosing schedules, and all patients started a new treatment cycle every three 
months.  
In study II, the adverse events of interest included functional dyspepsia, stomatitis, diarrhoea, 
constipation, flatulence, nausea, and the worst oro-gastrointestinal toxicity. All these toxicities were 
recorded in a patient diary and graded according to the NCI-C CTC version 2. The worst toxicity 
grade of each specific adverse event during adjuvant chemotherapy was considered in the analysis.  
In study III, the adverse events studied included anaemia, neutropenia, thrombocytopenia, the 
category of worst haematological toxicity, HFS, diarrhoea, nausea/vomiting, mucositis, category of 
other toxicities (i.e. alopecia and fatigue) and the category of worst non-haematological toxicity. 
These adverse events were recorded for every cycle and the worst grade of all cycles was considered 
in the analysis. In the French study, toxicities were recorded using NCI-C CTC version 1, and they 
were recorded in the Finnish study using version 2, but there are no significant differences in the 
grading of the studied events between these two versions.  
In study IV, the adverse events of interest were acute and long-term neuropathy. Both acute and long-
term neuropathy were recorded and graded by experienced consultants according to NCI-CTCAE v 
3.0. Data for acute toxicity were collected by one researcher (Ulrika Hänninen) and data for long-
term neuropathy were collected by the author LMS. Both the sensory and motor neuropathy grades 
were denoted, but the sensory grade was worse than motor in all the cases, and the sensory neuropathy 
grade was used in analyses. In addition, CIPN20 was used to assess long-term neuropathy, as a patient 
reported outcome (PROM). 
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8. Statistical analysis 
In all the four studies, we used Graph Pad Prism version 6.00 (GraphPad Software, La Jolla, 
California, USA), Sigmaplot version 11.0 (Systat software Inc, USA), or SPSS version 24.0 (IBM 
Corp., IBM SPSS Statistics for Windows, Version 24.0 Armonk, NY, USA) for conducting statistical 
analyses. 
Statistical analyses in study I and III were performed by the statistician Tuija Poussa, researchers Pia 
Österlund, and the author, and those for study II were performed by the statisticians Tuija Poussa and 
Emmanuel Quinaux, researchers Thierry Andre, Aimery de Gramont, Pia Österlund, and the author; 
those for study IV were performed by the statisticians Markku Karhunen and researchers Annamarja 
Lamminmäki, Pia Österlund, and the author.  
In all studies, the significance level was set at α = 0.05. DFS was defined as the time from diagnosis 
to the date of relapse, while PFS was defined as the time from the initiation of treatment to the time 
of progression or death because of any cause; OS was defined as the time from diagnosis to the date 
of death or date of last follow up. RR was used as the endpoint in study I, according to RECIST 1.1 
criteria (Eisenhauer et al., 2009).  
Power analyses were performed by the statistician for study II. For study I, III, and IV all patients 
were included and no retrospective power calculations were performed. 
8.1 Study I 
It was hypothesised that an association between HTN and treatment outcome in mCRC patients 
treated with bevacizumab containing chemotherapy might exist. The association between PFS, OS, 
and HTN was assessed by Kaplan-Meier analysis and the comparison between groups was done by 
the log-rank test. The landmark survival analysis was performed to eliminate the bias caused by the 
time-dependent definition of HTN and the landmark point was set at three months, when a majority 
of patients had developed HTN. Cox proportional hazard models were used to perform univariate 
analyses and the HTN status used was that of the landmark time. Crude models were first constructed 
using baseline characteristics (age, gender, primary tumour site, line of treatment, WHO performance 
status, number of metastatic sites), and the significant of these were added as covariates together with 
the HTN status in the multivariate Cox model. The variables with non-normal distributions were 
compared using the Mann–Whitney U-test, and the χ2-test was used for categorical variables. 
8.2 Study II 
In the second study, it was hypothesised that the H. Pylori infection might increase chemotherapy 
induced gastrointestinal toxicity during 5-FU based adjuvant chemotherapy and that H. Pylori might 
interfere with primary CRC diagnostics. Binary logistic regression analysis was performed to 
compare the toxicities between groups. The chemotherapy regimen was included as a categorical 
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covariate due to randomization. The interaction between H. pylori positivity and chemotherapy 
treatment was tested in the beginning and in the case of interaction, the association between H. pylori 
and a symptom was assessed in both treatment groups separately but otherwise omitted. The results 
are presented as adjusted odds ratios with 95% confidence intervals (CI95%). DFS and OS were 
assessed by using Cox regression analysis. The log-rank test was used to study the diagnostic delays. 
For patient characteristics between H. pylori-seropositive vs. -seronegative patients the χ2 and Mann-
Whitney U tests were used.   
8.3 Study III 
The aim of the study was to determine if the occurrence of haematological or non-haematological 
adverse events could predict the efficacy of 5-FU based adjuvant chemotherapy in CRC patients. Two 
types of treatment regimens were used; therefore, possible interactions between the treatment regimen 
and adverse events were first examined, but as no interactions were observed (P > 0.05 for interactions 
for all adverse events), only the treatment regimen was included in the models. Cox proportional 
regression analysis was used to study the association between DFS, OS, and adverse events. In 
univariate crude analysis, the age, stage, and histologic differentiation were significant and therefore 
included further in multivariate Cox proportional hazards regression analyses. A stepwise 
multivariate Cox proportional regression analysis was performed using forward selection for 
assessing which of the significant adverse events was the most important prognostic factor (model 
was adjusted for age, stage, and histologic differentiation). Cox proportional regression analyses and 
Kaplan–Meier survival curves were used to evaluate how the number of different significant adverse 
events predicted DFS and OS. Survival curves were constructed using the Kaplan–Meier method and 
to estimate the survival rates at 5 years and at the end of 8.2 years (the longest follow-up time in 
GERCOR C96.1 study) 
8.4 Study IV 
The aim of the study was to assess the incidence of acute and long-term neuropathy in CRC patients 
treated with adjuvant FOLFOX or CAPOX and evaluate if long-term neuropathy had an impact on 
the QOL in CRC survivors. A neuropathy of grade ≥ 2 was considered clinically significant; therefore, 
grades 0-1 versus 2-4 were used as cut-offs for acute and long-term neuropathy. Chi-square and the 
non-parametric Mann–Whitney U tests were used for comparing the baseline characteristics and the 
outcome variables between the groups. Spearman’s rho test was used to test the correlations between 
continuous variables. Logistic regression analysis was used to test the predictive value of different 
variables for acute neurotoxicity and long-term neuropathy. No adjustments were made for 
conducting multiple comparisons. Time to event distributions were estimated using Kaplan-Meier 






9.1 Study I: “Hypertension and overall survival in metastatic colorectal cancer patients 
treated with bevacizumab-containing chemotherapy”  
 All patients 
In all the 101 patients, the median follow-up time was 63.5 months. By the time of analysis, 100 
(99%) of these patients had progressed and 90 (89%) of them had died. The RR was 50% and disease 
control rate was 89%. In all patients, the median PFS was 8.8 months (range, 8.0–9.6) and OS was 
18.9 months (range, 15.1–22.7). The median duration of bevacizumab-containing chemotherapy was 
8.6 months (range, 1.2–70.5) 
 Effect of HTN on outcome 
Patient characteristics (age, gender, tumour site, treatment line, WHO performance status, 
chemotherapy used) were well balanced and there were no significant differences except for the 
number of metastatic sites (P= .002) between hypertensive and normotensive patients. 
A total of 57 (56%) patients were diagnosed with any grade of HTN (n=26 grade 1, n=28 grade 2 and 
n= 3 grade 3), during bevacizumab treatment, while 44 (44%) patients remained normotensive (grade 
0). Forty-two (74%) out of 57 patients that developed HTN while receiving the therapy, were 
normotensive at the baseline, and had no previous history of hypertension. Fifteen (26%) patients 
were normotensive with antihypertensive medication at the baseline, but HTN recurred during 
bevacizumab treatment. 
The median time from the start of bevacizumab treatment to the onset of HTN was 1 month (range, 
1–15) and the onset of HTN was observed within 6 months from the start of treatment in 95% of the 
patients. The mPFS (5.3 vs.  10.5, P= .008), mOS (11.7 vs. 25.8, P< .001), and RR (20 vs. 30%, P= 
.025) were significantly higher in hypertensive patients. 
 Significance of early HTN for survival 
To avoid the bias due to the time-dependent definition of HTN and determine whether early HTN 
was predictive of survival within three months of treatment, we performed the landmark analysis, in 
which the HTN status of each patient was determined at three months and survival was calculated 
from that time point onwards. One patient had already died and was excluded from the analysis. At 
three months, 48 patients were hypertensive and 53 were normotensive. At 3 months, the mOS in 
hypertensive patients was 19.9 (range, 15.7–24.1), compared to 12.3 months (range, 6.9–17.7, P= 
.020) in normotensive patients.  
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Univariate analysis was performed using the Landmark model. The HTN within 3 months, 
performance status, line of treatment, number of metastatic sites, and type of chemotherapy were all 
statistically significant for survival. In multivariate analysis, HTN was an independent predictor of 
survival (HR 0.53; P= .007), together with the line of treatment and number of metastatic sites.  
 HTN, OS, and treatment line 
All eligible patients (n=101) for whom bevacizumab treatment was started during April 2004 and 
December 2005 were included in the study. Thirty-three patients were treated in the first line, 39 in 
the second line and 29 patients were treated in the third or later line. The median duration of 
bevacizumab-containing chemotherapy in first-line treatment was 12.0 months (range, 1.2–68), and 
that in the second line of treatment was 7.5 (range, 1.3–70.5), while it was 6.6 months (range, 1.9–
27) in the third or later lines of treatment.  
An association between HTN and OS benefit was observed, regardless of the treatment line. After 
first-line treatment, the mOS for hypertensive patients was 28.8 months (range, 12.8–44.8) and that 
for normotensive was 15.3 months (range, 14.0–16.6) months, P= .291. In second-line treatment, 
there was an equally significant difference between hypertensive and normotensive patients with 
regard to the mOS, which were 30.3 (range, 19.8–40.9) and 10.9 (range, 0.36–21.5) months (P= .028), 
respectively. In the third or later lines of treatment, the mOS was 18.1 (range, 12.1–24.0) months for 
hypertensive and 11.4 months (range, 7.5–15.3) for normotensive patients (P= .007). 
9.2 Study II: ““Helicobacter pylori-related gastrointestinal symptoms in diagnostics and 
adjuvant chemotherapy of colorectal cancer” 
 Symptoms of CRC present at diagnosis and diagnostic delay 
The most common symptoms of CRC included altered bowel habits (diarrhoea, constipation, 
alternating function, or mucous faeces) in 53 (73%) patients, blood in the stool in 36 (49%) patients, 
functional dyspepsia (postprandial fullness, nausea, belching, early satiety, epigastric pain, and 
burning) in 26 (35%) patients, occlusion/perforation in 10 (14%) patients, and infectious symptoms 
in 10 (14%) patients. Regardless of the symptoms present, the median time from the onset of 
symptoms to surgery of the primary tumour in 73 patients was 6 months (range, 4–11) and the longest 
time was 42 months in one H. pylori seropositive patient.  
In patients presenting with bowel symptoms, blood in the stool, occlusion/perforation or infectious 
symptoms, the median time to diagnosis for CRC from the onset of symptoms was 5 months (range, 
2–8). In patients presenting with functional dyspepsia, the median time to diagnosis from the onset 




Time to diagnosis was also significantly longer in 35 H. pylori-seropositive patients, as compared to 
that in 38 seronegative patients. The median time to diagnosis of CRC from the onset of symptoms 
was 6 months (range, 4–12) in H. pylori-seropositive, as compared to 5 months (range, 4–8) in H. 
pylori-seronegative patients (P= .012). In six (17%) seropositive patients, but in none of the 
seronegative ones, the time to diagnosis for CRC from the onset of symptoms was greater than 18 
months.  
Diagnostic delays did not turn into a statistically significant inferior survival at the minimum follow-
up time of 120 months. The DFS rates in stage II and III patients (n=73) were 61% and 67% in H. 
pylori-seropositive and seronegative patients, while the corresponding OS rates for these patients 
were 61% and 69%, respectively.  In the entire cohort of 79 patients, the DFS rate was 64% and OS 
was 65%. 
We also assessed lactose intolerance using an oral test in 77 (97%) of the patients. There were 14 
(18%) patients diagnosed with hypolactasia (blood glucose increase > 1.1 mmol/L and 12 patients 
(16%) had borderline hypolactasia (blood glucose increase 1.1-1.6). Hypolactasia and H. 
pylori seropositivity were not correlated (P= .20) with each other and hypolactasia or borderline 
hypolactasia did not interfere with diagnostics. 
 Adverse events in H. pylori-seronegative and H. pylori-seropositive patients 
Adverse events during 5-FU adjuvant treatment were compared between H. pylori-seronegative and 
H. pylori-seropositive patients. The adverse events studied included stomatitis, functional dyspeptic 
symptoms (including postprandial fullness, belching, early satiety, epigastric pain, and burning), 
diarrhoea, constipation, flatulence, nausea, and the category of the worst oro-gastrointestinal toxicity. 
No statistically significant differences were noted in functional dyspeptic or gastrointestinal toxicities 
between H. pylori-seronegative and H. pylori-seropositive patients. 
9.3 Study III: “Association of adverse events and survival in colorectal cancer patients treated 
with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? 
 Univariate analysis 
DFS and OS were assessed in 1033 patients treated with 5-fluorouracil as bolus or LV5FU2. Median 
follow-up was 6.05 years. In univariate analysis significant predictors for DFS or OS were 
neutropenia, nausea/vomiting, mucositis and worst non-haematological toxicity and these were used 
in further analysis.  
Patients presenting without any toxicity had the worst outcome, but there was no linear improvement 
in the outcome with an increase in the toxicity level. Patients with grade 1 nausea/vomiting, grade 2 
neutropenia, grade 2 mucositis, or grade 2 of the worst non-haematological toxicity had the best 
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survival. Frequencies for predefined toxicities and the association with DFS and OS are presented in 
Table 2. 
 Survival analysis 
Cox regression analysis was performed dichotomizing between grade 0 vs grade 1-4 toxicity. As 
observed in the univariate analysis, leukopenia, thrombocytopenia, the worst haematological toxicity, 
diarrhoea, HFS, or other toxicities were not associated with DFS or OS (all P values >0.10). 
Neutropenia, mucositis, nausea/vomiting, and the worst non-haematological toxicities were 
significant, both in unadjusted and adjusted cox regression analysis (adjusted for other significant 
predictors, age, stage, and histological differentiation). Any grade of neutropenia was associated with 
an improved DFS but not with OS, in both non-adjusted and adjusted models, whereas mucositis, 
nausea/vomiting and the worst non-haematological toxicity were significantly associated both with 




Table 6. Frequency of significant adverse events and association with DFS and OS for 
separate grades, and for grades 0 versus grades 1-4  
  Frequency Disease-Free Survival Overall Survival 
Adverse Event Grade n (%) HR 95% CI P value HR 95% CI P value 
Neutropenia 0 537 (53) 1.00   1.00   
n=1022 1 204 (20) 0.79 0.60-1.05 0.10 0.81 0.58-1.13 0.22 
 2 153 (15) 0.74 0.54-1.02 0.06 0.77 0.53-1.13 0.19 
 3 90 (9) 0.88 0.60-1.29 0.52 1.00 0.65-1.54 1.00 
 4 38 (4) 1.03 0.60-1.77 0.92 1.26 0.70-2.27 0.44 
 1-4*  0.76 0.61-0.95 0.02 0.82 0.64-1.06 0.13 
Nausea/vomiting 0 474 (46) 1.00   1.00   
n=1032 1 379 (36) 0.78 0.62-0.99 0.04 0.60 0.45-0.79 <0.001 
 2 141 (14) 0.76 0.54-1.06 0.10 0.59 0.39-0.88 0.01 
 3 38 (4) 0.98 0.57-1.69 0.94 0.96 0.53-1.73 0.90 
 4 0 (0)       
 1-4*  0.74 0.59-0.92 0.008 0.58 0.45-0.75 <0.001 
Mucositis 0 587 (57) 1.00   1.00   
n=1031 1 229 (22) 0.84 0.65-1.09 0.19 0.78 0.57-1.06 0.12 
 2 149 (15) 0.52 0.36-0.75 <0.001 0.48 0.31-0.75 0.001 
 3 52 (5) 0.97 0.61-1.55 0.90 1.15 0.69-1.89 0.59 
 4 14 (1) 0.93 0.38-2.26 0.88 0.89 0.33-2.40 0.81 
 1-4*  0.70 0.56-0.88 0.003 0.67 0.52-0.88 0.003 
Worst non- 0 143 (14) 1.00   1.00   
haematological  1 300 (29) 0.75 0.55-1.03 0.08 0.70 0.48-1.00 0.05 
toxicity 2 371 (36) 0.54 0.39-0.75 <0.001 0.48 0.33-0.70 <0.001 
n=1031 3 181 (18) 0.83 0.59-1.17 0.28 0.73 0.49-1.09 0.12 
 4 36 (3) 0.73 0.39-1.36 0.33 0.77 0.39-1.52 0.44 
 1-4*  0.65 0.49-0.86 0.003 0.57 0.41-0.79 0.001 
*Adjusted for age, stage, and histological differentiation, which were significant in univariate analysis. 
 
The co-occurrence of all the significant adverse events (neutropenia, nausea/vomiting, and mucositis) 
was significantly associated with the best survival. In patients presenting with only one adverse event 
(seen in 33%), the HR for DFS was 0.86 (CI95% 0.66–1.14, P= .30), while in patients presenting with 
two adverse events (seen in 28.2%), the HR was 0.64 (CI95% 0.47–0.86, P= .003); in patients 
presenting with all three adverse events (seen in 18.5%), the HR was 0.61 (CI95% 0.44–0.80, P= .004).  
In patients presenting with only one adverse event, the HR for OS was 0.74 (CI95% 0.53–1.01, P= 
.06), while in patients presenting with two adverse events, the HR was 0.59 (CI95% 0.42–0.84, P= 
.003); in patients presenting with three adverse events, the HR was 0.49 (CI95% 0.33–0.74, P= .001). 
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We also investigated which of the significant adverse events was the strongest predictor of survival, 
using a stepwise multivariate COX proportional regression analysis. Any grade of mucositis or 
nausea/vomiting was statistically significant in this model. With regard to mucositis, the HR for DFS 
was 0.71 (CI95% 0.57–0.90, P = .004) and that for OS was 0.71 (CI95% 0.54–0.93, P = .01). With 
regard to nausea/vomiting, the HR for improved DFS was 0.79 (0.63–0.99, P = 0.04) and that for OS 
was 0.61 (0.46–0.79, P < 0.001). Thus, nausea/vomiting was the strongest predictor of OS.  
9.4 Study IV: “Long-term neuropathy and quality of life in colorectal cancer patients treated 
with oxaliplatin-containing adjuvant chemotherapy 
 Acute and long-term neuropathy 
Sensory neuropathy of any grade was observed during chemotherapy in 136 (94%) out of 144 
patients; grade 1, grade 2, grade 3, and grade 4 neuropathy was observed in 24%, 45%, 25%, and 1% 
of the patients, respectively. Long-term neuropathy was observed in in 69% (grade 1/2/3/4 in 
36/24/8/1%) of patients at a median follow-up at 4.2 years. There was a significant association 
observed between acute neurotoxicity during treatment and long-term neuropathy during follow-
up.There were no differences in acute or long-term neuropathy between treatment regimens (CAPOX 
vs FOLFOX) and no differences in CIPN20 scores were noted. No baseline factor was associated 
with long-term neuropathy, with the exception that a performance status of ECOG 1 at the baseline 
predicted the occurrence of long-term neuropathy (OR 3.9, CI95% 1.3-12.2). No differences were 
observed in the long-term neuropathy between patients who had treatment durations of ≥3 months vs. 
< 3 months. 
 Neuropathy and QOL 
Grade 2-4 long-term neuropathy associated with impaired physical and role functioning and with 
higher rates of diarrhoea, but it did not affect global health status. In patients with grade 3-4 long-
term neuropathy QOL scores for role functioning and financial problems were affected, but the global 
health status was not affected in these patients either compared to patients with grade 0-2 neuropathy. 
There were no differences between QLQ-C30 subscales among treatment regimens.  
 Seasonal variation 
As Finland has a sub-arctic climate, we studied whether the mean outside temperature has an effect 
on neuropathy. There were no seasonal variations, as treatment in coldest winter months was not 
significantly associated with grade 2-4 neuropathy and the severity of long-term neuropathy was not 
associated with the month during which oxaliplatin treatment was started or stopped. 
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 Acute neuropathy and survival 
We studied whether acute neuropathy predicted survival. There were no statistically significant 
differences in the DFS or OS of patients presenting with grade 0-1 neuropathy and those with 2-4 
neuropathy, but the trend towards superior OS was observed in patients presenting with grade 2-4 
neuropathy (Figure 2). 
 
Figure 2. Overall survival in 92 stage II or III colorectal cancer patients treated with 
FOLFOX or CAPOX, divided based on neuropathy grade 0-1 versus 2-4. 
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Neurotoxicity gr 0-1 during therapy, censored 69%




 Treatment regimen and survival 
There was numerical but not statistically significant difference in DFS (Figure 3A.) and OS (Figure 
3B) favouring CAPOX treatment.   
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Figure 3. Disease-free survival (A. upper panel) and overall survival (B. lower panel) in 144 
CAPOX and FOLFOX-treated stage II and III colorectal cancer patients. 
Time in months











FOLFOX treatment, n=72, censored 63%















FOLFOX treatment, n=72, censored 68%







10.1 What does this thesis mean for a clinician? 
This study was performed to answer the following clinically relevant questions:  
 Does H. pylori interfere with CRC diagnostics?  
 Does H. pylori increase acute oro-gastrointestinal toxicity during 5-FU-based adjuvant 
chemotherapy?  
 Are common treatment-related adverse events associated with treatment outcome and could 
those be considered as clinically feasible predictive biomarkers?  
 How common is long-term neuropathy after oxaliplatin-based adjuvant chemotherapy and 
does it impair QOL in CRC survivors?  
10.2 Diagnostic delay in CRC  
CRC is a major public health problem. If it is metastatic and incurable, it causes suffering and results 
in considerable economic burden for the individual and the health care system.  
The major solution to this is early diagnosis. The role of the primary care physician cannot be 
emphasised enough and is essential in the early diagnosis and treatment of gastrointestinal diseases 
(Gikas and Triantafillidis, 2014). Unfortunately, it is also shown that the diagnostic delay in CRC due 
to physician and health care system issues (Walter et al., 2016) can be longer than that observed due 
to patient-related factors (Turunen and Peltokallio, 1982), and is also longer than that of other 
common cancers (Korsgaard et al., 2008; Mitchell et al., 2008; Van Hout et al., 2011).  
Our study established in line with most previous studies the fact that clear, severe symptoms such as 
bowel obstruction, anaemia, and intestinal bleeding lead to colonoscopy and the diagnosis of CRC. 
However, signs of CRC can be vague and sometimes mimic those of upper GI-tract complaints 
(O'Reilly and Long, 1987). We observed that in H. pylori positive patients and in patients presenting 
with dyspepsia, colonoscopy was postponed and the diagnosis of CRC was significantly delayed. The 
delay was one month in H. pylori positive patients and 2.5 months in patients presenting with 
dyspepsia, as compared with that for patients presenting with bowel obstruction, anaemia, and 
intestinal bleeding. In contrast to H. pylori infection, we observed that lactose intolerance did not 
interfere with diagnostics. It can be speculated that this is due to small number of patients in our 
study; with a larger number of patients, the results would have been different, because of the high 
prevalence of lactose intolerance as a gastrointestinal comorbidity worldwide. To the best of our 
knowledge, our study is one of the few to explore the significance of H. pylori and lactose intolerance 
in CRC diagnostics, for which comparative data is scarcely available.  
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The diagnostic delay in the group of H. pylori positive patients did not result in inferior survival 
during the follow-up duration of 10 years. Even though it has been shown that the screening and early 
detection of CRC decreases mortality (Shaukat et al., 2013), the results of most other studies are in 
line with ours, and suggest that symptom duration has no apparent impact on survival in CRC patients 
(McDermott et al., 1981). Several studies have reported a U-shaped association between diagnostic 
interval and mortality in CRC patients, i.e., either very short or long diagnostic delays are associated 
with increased mortality (Torring et al., 2012). A prospective population-based Danish study by 
Tørring et al. showed that the mortality rates were significantly higher for patients presenting with 
alarming symptoms that suggested cancer occurrence, and with those showing the shortest and 
longest diagnostic intervals (Torring et al., 2011). However, there were no statistically significant 
associations between diagnostic interval and mortality in patients presenting with vague symptoms, 
which was in line with the results of our study. Similar results about survival and the nature of CRC 
symptoms have also been reported by another study that pooled data from three population-based 
CRC studies in Denmark and the United Kingdom (Torring et al., 2013).  
The association of a short diagnostic delay with increased mortality can be explained by the fact that 
patients presenting with alarming symptoms showed an advanced stage of metastasis, probably in 
part because acute surgery, which is a known risk factor for impaired outcome, had been performed 
in these patients (Jeong et al., 2017). It can also be possible that these patients present with a more 
biologically aggressive disease. A diagnostic delay could be attributable to either a patient or doctor 
in patients with a long diagnostic interval and increased mortality, which leads to diagnosis being 
performed at a more advanced stage and an inferior treatment outcome. 
In our study, diagnostic delays are modest in number, but clinically relevant. Most importantly, our 
observations highlight the importance of performing a thorough diagnostic work-up, even though 
comorbidities are present. The clinicians responsible for the diagnostics should be aware of the vague 
nature of CRC symptoms. In a patient presenting with anaemia or abdominal discomfort, gastroscopy 
is often the first examination to be performed, but in a high-income country such as Finland, CRC is 
much more common than gastric cancer (Bray et al., 2018; Cancer_registry, 2018). Therefore, 
according to our results, colonoscopy should always be considered for a patient presenting with 
gastrointestinal symptoms; regardless of the symptoms present and concern about limited resources, 
it might be more reasonable to recommend colonoscopy before gastroscopy. According to our results, 
in patients that are diagnosed with H. pylori infections, a colonoscopy should be performed despite a 
diagnosis of an H. pylori infection. 
 H. pylori and survival 
We did not observe statistically significant differences in survival between H. pylori positive and 
negative patients, but we observed a trend towards inferior survival in H. pylori positive patients. The 
emergence of data has shown that the microbiota is a driver of CRC carcinogenesis and modulator of 
the toxicity and efficacy of chemotherapeutic agents. Data concerning H. pylori infections in the 
context of CRC are still contradictory and scarce. There are studies demonstrating the association 
between H. pylori infection and CRC (Chen et al., 2013; Rokkas et al., 2013; Wu et al., 2013), but 
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there is a lack of prospective longitudinal data that would thoroughly prove the causality. The sample 
size in our study is too small to draw conclusions or find significant differences in survival, but we 
can speculate whether the inferior trend in survival in H. pylori positive patients is truly due to the 
infection, diagnostic delay, or the possible modulation of the efficacy of chemotherapy by H. pylori 
and its toxins. It is unknown whether the antibiotics or proton pump inhibitors used to treat H. pylori 
infections modified the gastrointestinal microbiota, which lead to dysbiosis and the carcinogenesis of 
CRC. No such data exist, to the best of our knowledge. 
Increasing amounts of evidence have suggested that oro-gastrointestinal microbiota are an important 
driver of carcinogenesis and play a significant role in modulating treatment efficacy and treatment 
related toxicity. Mycoplasmas are bacteria that abundantly express thymidine phosphorylase and 
are associated with several cancers (Bronckaers et al., 2008). As the efficacy of capecitabine is 
dependent on thymidine phosphorylase activity, the presence of M. hyorhinis was shown to 
enhance the cytotoxic effect of capecitabine. The presence of M. hyorhinis in the tissues might 
therefore modify the efficacy and toxicity of capecitabine. To the best of our knowledge, there is 
a limited availability of data about H. pylori and its capability to modify the effect of 
chemotherapy; it would be interesting to study this topic further.  
Recently, it was demonstrated that gut microbiota play a significant role in the immunotherapy 
treatment response in melanoma patients (Gopalakrishnan et al., 2018). A study by Gopalakrishnan 
et al. observed that there were notable compositional differences in melanoma patients who 
responded to immunotherapy with PD1-blockade, as compared to those who were non-responsive. 
Patients with the highest diversity of gut microbiota showed the best outcome. The Ruminococcaceae 
family was enriched in responders and was responsible for a greater level of T cell penetration into 
tumours; higher levels of circulating T cells were observed in these patients. Patients with abundant 
levels of Bacteriodales spp. had higher levels of circulating regulatory T cells, myeloid-derived 
suppressor cells, and a blunted cytokine response, which resulted in the dampening of anti-tumour 
immune responses. A favourable microbiota was also associated with increased levels of antigen 
processing and presentation by the immune system at the tumour site. A study by Matson et al. 
showed as well, . that a significant association was observed between commensal microbial 
composition and clinical response  in melanoma patients treated with immunotherapy with PD1-
blockade (Matson et al., 2018).  
A major drawback in the treatment of CRC has been the modest response of immunotherapy in 
MSS patients, as opposed to significant benefits noted in MSI-H tumours (Kalyan et al., 2018). 
Unfortunately, the number of patients exhibiting MSI-H represents less than 5% of patients with 
mCRC. Early phase data suggested that combination therapy with PD-L1 inhibitor atezolizumab 
and MEK inhibitor cobimetinib improved OS, as compared to that observed with regorafenib in 
heavily pretreated mCRC patients with MSS tumours (Bendell et al., 2018b). It is shown that 
cobimetinib favourably alters the tumour microenvironment and T-cell responses that enhance anti-
tumour immune activity, by inhibiting MEK1/MEK2 in the MAPK pathway. It was therefore 
hypothesized that a combination of atezolizumab and cobimetinib would enhance immune 
recognition and contribute to greater anti-tumour activity, but no enhanced efficacy was noted in a 
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phase III trial (Bendell et al., 2018a). Since we now know that the microbiota plays a crucial role in 
modifying immune responses, it is interesting to speculate whether it would be possible to enhance 
the response generated after immunotherapy in MSS patients in the future, by altering the 
microbiota. Gut microbiota would probably present a target for personalized cancer therapy in the 
future, as discussed by Petrosino as well (Petrosino, 2018).  
 Acute chemotherapy-related adverse events and H. pylori 
The association between acute chemotherapy-induced toxicity and H. pylori in CRC patients is a 
topic that has been rarely investigated, and to the best of our knowledge, our paper is still one of the 
few to focus on H. pylori and chemotherapy-related toxicity in CRC patients. Our study was based 
on the hypothesis that H. pylori might increase oro-gastrointestinal toxicity induced by 5-FU-based 
chemotherapy and that the eradication of H. pylori before therapy might be recommended. The use 
of 5-FU is associated with high rates of gastrointestinal toxicity (Macdonald, 1999) and H. pylori is 
equally associated with such symptoms (Malfertheiner et al., 2012), i.e., symptoms such as dyspepsia 
and nausea could be attributable to H. pylori and chemotherapy.  
We showed that H. pylori seropositivity was not associated with treatment-related gastrointestinal 
toxicity during 5-FU-based adjuvant therapy. Since we included only 79 patients in our study, it is 
difficult to make definitive conclusions; results contradictory to ours have been published recently. 
A Chinese study reported significantly higher rates of nausea in H. pylori-infected patients with 
metastatic gastric cancer or mCRC patients treated with oxaliplatin and irinotecan-based combination 
chemotherapy, as compared to uninfected patients (Yao et al., 2017). As H. pylori is a significant 
carcinogen associated with gastric cancer (Herrero et al., 2014), it causes gastric complaints 
(Malfertheiner et al., 2012); in addition, because the toxicity attributable to combination 
chemotherapy differs from that to single agent 5-FU, it is not possible to directly compare our results 
with those of the Chinese study. Additionally, an essential difference between the studies is that we 
graded toxicities using NCI-CTCAE v2, but the Chinese study used PROMs. It is challenging to grade 
nausea objectively; therefore, it is interesting to speculate whether our results would have been 
different if we had used direct PROMs instead of a patient diary. In addition, a small study (n=79) 
reported that significantly more thrombocytopenia was observed in H. pylori-infected stage III CRC 
patients during chemotherapy, as compared to that observed in non-infected patients (Tanriverdi, 
2014). We focused on oro-gastrointestinal toxicity in our study, but with regard to the results obtained 
by Tanriverdi et al., it would be interesting to analyse the haematological toxicity as well.  
Based on our results, we cannot recommend the routine screening and eradication of H. pylori before 
5-FU-based chemotherapy. However, due to the inclusion of a small number of patients in the study, 
it would be interesting to repeat our study design after the inclusion of a larger number of patients, 
because though H. pylori is not a major health problem in Finland, it is a major problem globally. 
There are also other interesting aspects that require further investigation. All our patients were treated 
intravenously with 5-FU. Because orally ingested drugs reach the gastrointestinal tract and are 
exposed to the microbiota in the stomach and gut, it is questionable whether the increased toxicity 
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in H. pylori seropositive patients had also been observed with the use of capecitabine. To the best of 
our knowledge, no such data has been published yet. 
10.3 Adverse events as biomarkers of the outcome  
 HTN as a biomarker in bevacizumab treatment 
HTN is a typical treatment-related adverse event of all drugs with VEGF/VEGFR inhibition (Launay-
Vacher and Deray, 2009). Bevacizumab-induced HTN was first considered a harmful adverse event, 
but HTN and its association with outcome were widely investigated in several tumour types 
eventually. Increasing amounts of data suggest that HTN induced by the inhibition of VEGF/VEGFR 
could act as an easily monitored biomarker for efficacy in e.g. glioblastoma, breast, renal, ovarian 
and lung cancer (Gampenrieder et al., 2014; Lombardi et al., 2013; Zhong et al., 2015). 
By the time our study was completed, the association between HTN and treatment outcome had been 
studied, mainly in renal cell carcinoma (mRCC) patients. Rini et al published a meta-analysis of 
sunitinib-treated patients, which demonstrated that patients who developed HTN after the first cycle 
of sunitinib treatment showed significantly improved mPFS, mOS, and RR, as compared to that in 
normotensive patients (Rini et al., 2011). Rini et al also showed that mRCC patients presenting with 
grade ≥ 2 HTN that were treated with interferon-α plus bevacizumab showed a significantly improved 
mPFS and mOS, as compared to normotensive patients (Rini et al., 2010). Bono et al. had also 
reported about similar results for bevacizumab-treated mRCC patients (Bono et al., 2009). 
These findings enhanced our interest in the study of HTN and outcome in mCRC patients. By this 
time, Scartozzi et al had reported small, retrospective study of 39 mCRC patients treated with 
bevacizumab-containing chemotherapy. They noted that mCRC patients presenting with HTN (n=8) 
during therapy showed a significantly improved PFS and OS, as compared with that of normotensive 
patients (Scartozzi et al., 2009). Our study was the largest when it was published, and identified 57 
out of 101 patients with HTN, enabling us to make a larger comparison. We observed that HTN was 
a significant, independent predictive factor for improved RR, PFS, and OS, despite the line of 
treatment. Tahover et al. observed significant improvement in the mPFS (29.9 vs. 17.2 months, P= 
.024) and OS (median not reached vs. 36.8 months, P= .029) in hypertensive bevacizumab-treated 
mCRC patients (Tahover et al., 2013), which was in line with the findings of our study. These findings 
by our and Tahover’s group were further established in a meta-analysis, in which the occurrence of 
bevacizumab-induced HTN was associated with significant improvements in the PFS (HR = 0.57, 
CI95% 0.46–0.72), OS (HR = 0.50, CI95% 0.37–0.68) and RR (RR = 1.57, CI95% 1.07–2.30) (Cai et al., 
2013). A retrospective Japanese study evaluated the effect of bevacizumab-induced HTN and 
prognosis in a large population of CRC patients (n=315) and non-small cell lung cancer patients 
(n=317) (Nakaya et al., 2016). Again, with this larger sample size, it was found that OS of both CRC 
and NSCLC patients was significantly prolonged if they developed HTN during early bevacizumab 
treatment, as compared to that of normotensive patients.  
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Thus, an increasing level of evidence suggests that HTN is a predictive biomarker, but large 
prospective trials that support this finding have not yet been conducted. Those would be required to 
conclusively establish that HNT is a surrogate marker for efficacy. It would be interesting to continue 
to conduct research on this topic, because it would be easy to monitor HTN, when it is considered to 
be a biomarker in every day clinical practice and the monitoring of HTN is a part of normal clinical 
practice. Because economic constraints need to be taken into account, the cost-effectiveness of 
bevacizumab has been questioned on some occasions (Goldstein et al., 2017; Lange et al., 2017). 
Effective patient selection is therefore of the utmost importance. If HTN is established as a predictive 
biomarker for efficacy, it would allow us to choose the correct patients for continued bevacizumab 
therapy. It would help us to reduce healthcare costs; most importantly, the risk of unnecessary adverse 
events for a patient would be reduced. In addition, when it is unclear whether VEGF inhibition should 
be continued during the second line of treatment, HTN monitoring could enable us to reach and 
support a decision, as according to our results, the level of HTN was significant, regardless of the line 
of treatment.  
The major problem with using HTN as a predictive factor might be the level of reliability for carrying 
out assessments. HTN is easy to grade objectively, according to the NCI-CTCAE grading scale, but 
environmental and psychological factors easily bias HTN, as it is affected by the timing and manner 
of measurement, which leads to wide variations in values (Vischer and Burkard, 2017). Currently 
there are no specific guidelines to treat bevacizumab-induced HTN (Syrigos et al., 2011). It is not 
known if a certain type of medication should be favoured; the impact that the medication might have 
on outcome over the long term remains unknown. Our study was too small for us to definitively 
conclude about this aspect; therefore, larger trials need to be conducted.  
According to our results, HTN strongly supports the continuation of bevacizumab-containing therapy. 
HTN is not a reason to terminate therapy, but it should be treated according to common treatment 
practices for HTN treatment. 
 Haematological toxicity as a biomarker for survival 
Saarto et al had already studied the association between haematological toxicity and survival in breast 
cancer patients in the 1990s (Saarto et al., 1997). They demonstrated the association between a low 
leucocyte nadir and improved survival in 211 breast cancer patients treated with doxorubicin-based 
adjuvant chemotherapy. This association was also shown by Poikonen et al. in a subsequent study in 
breast cancer patients treated with adjuvant CMF (cyclophosphamide, methotrexate, and fluorouracil) 
(Poikonen et al., 1999). These were one of the first studies investigating the topic, but since then, the 
association between haematological toxicity and survival has been widely studied and shown in 
several tumour types. 
To the best of our knowledge, data for chemotherapy-treated CRC patients were scarcely available 
by the time we published our study, at least in the adjuvant setting, and the number of reports is still 
limited (Rambach et al., 2014; Shitara et al., 2009; Shitara et al., 2011; Sunaga et al., 2014). A meta-
analysis that was performed with data obtained from 9,528 patients with different malignancies in 
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thirteen trials had previously demonstrated that the mortality was reduced (HR=0.69, CI95%, 0.64-
0.75) in patients with grade 3-4 leucopoenia or neutropenia, as compared to that in patients with a 
lower-grade or complete lack of cytopenia (Shitara et al., 2011). This meta-analysis also included 
data from a study with 153 mCRC patients treated with FOLFOX during first-line treatment (Shitara 
et al., 2009). There was a significant level of association between neutropenia and OS; the risk of 
death was reduced by 45% in patients with grade 1-2 neutropenia (HR=0.55 CI95% 0.31-0.98) and by 
65% in patients with grade 3-4 neutropenia (HR=0.35 CI95% 0.18-0.66).  
Another study with 399 mCRC patients treated with at least one line of chemotherapy was published 
in concordance with our paper (Rambach et al., 2014). This was a retrospective analysis similar to 
ours, which demonstrated an association between any grade of neutropenia and OS (HR=0.55, CI95% 
0.43-0.70, P< .0001) and thrombocytopenia and OS (HR=0.70 CI95% 0.56-0.88, P= .025) that 
occurred during the first two lines of chemotherapy. In contrast to the results of our study, anaemia 
during chemotherapy was significantly associated with inferior OS (HR=1.9 CI95% 1.22-2.97, P= 
.005) in their study. In our study, thrombocytopenia and anaemia were insignificant.  
Sunaga et al have also retrospectively investigated the association between neutropenia and survival 
in 123 CRC patients with stage III disease receiving uracil and tegafur/LV as adjuvant chemotherapy 
(Sunaga et al., 2014). They demonstrated a significant improvement in the DFS in neutropenic 
patients, as compared to that in non-neutropenic patients (3-year DFS 81.2% versus 57.3%, P= 
.0213), but there were no statistically significant differences in the OS; these results were in line with 
those obtained in our study. However, Rambach et al and Shitara et al demonstrated the association 
between neutropenia and OS in metastatic disease. It is possible that haematological toxicity acts as 
a predictive factor in patients with advanced disease, but not for OS in the adjuvant setting. A 
limitation of our study was the unavailability of nadir counts in the bolus arm. It can be speculated 
that with nadir values, the DFS benefit would have turned into a significant OS benefit as well. Since 
the use of 5-FU as a single therapy does not typically lead to a considerable level of cytopenia, non-
complicated neutropenia is probably not detected. The strength of our study was its large sample size.  
 Non-haematological toxicity as a biomarker for survival 
Most trials have focused on studying the association between haematological toxicity and survival, 
which is understandable, since haematological toxicity is easy to monitor objectively. We were 
interested in studying non-haematological toxicity, which is a comparatively less studied topic. 
According to our results, non-haematological toxicity is especially associated with improved survival 
in patients treated with 5-FU-based chemotherapy. To the best of our knowledge, our study was one 
of the first to report the association between non-haematological toxicity and survival in CRC 
patients. 
Chemotherapy-induced gastrointestinal toxicity has mainly been attributed to the disruption of the 
mucosal barrier, which lines the entire alimentary tract (Lee et al., 2014). In our study, we refer to 
oro-gastrointestinal mucositis, including that occurring in the mucosal lining of the upper as well as 
the lower gastrointestinal tract. Today, it is increasingly recognised that the pathobiology of mucositis 
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is complex, and involves not only the mucosal barrier injury, but also the mucosal immune system 
and that an important role is played by the release of pro-inflammatory cytokines (Lee et al., 2014). 
It is increasingly being recognised that these inflammatory processes, which contribute to the oro-
gastrointestinal toxicity of chemotherapeutic agents, play an essential role in the development of anti-
tumour immunity, reduction of the risk of recurrence, and improvement of patient survival. With 
regard to these data, it is rational to consider mucositis as a surrogate marker for efficacy, especially 
since 5-FU is associated with a notable level of mucosal injury. Hence, we expected to discover an 
association between diarrhoea and outcome, but did not do so.  
Instead, we saw a strong association between nausea/vomiting and outcome. The association was so 
strong that it is hard to preclude that it was a coincidence, but equally hard to explain; data regarding 
this association are scarcely available, but the symptom of nausea probably reflects the occurrence of 
mucosal injury throughout the gastrointestinal tract, and can therefore be considered a predictive 
factor. A report by the European Osteosarcoma Intergroup showed in line with our findings that in 
osteosarcoma patients treated with doxorubicin and cisplatin in addition to surgery for localised 
disease, grade 3-4 oral mucositis (HR=0.51, CI95% 0.29-0.91), grade 1-2 nausea/vomiting (HR 0.37, 
CI95%0.16-0.85), and grade 1-2 thrombocytopenia (HR 0.49, CI95%0.27-0.87) were associated with 5- 
and 10-year survival rates in a multivariate analysis (McTiernan et al., 2012). On the other hand, a 
meta-analysis published as an abstract by the North-Eastern German Society of Gynecological 
Oncology (NOGGO) reported that grade 3-4 nausea/ vomiting significantly decreased both PFS and 
OS in patients with ovarian cancer (n=1213) (Woopen et al., 2017). Observations by NOGGO 
emphasize the importance of receiving supportive care along with chemotherapy. Grade 3-4 
nausea/vomiting not only reflects the excessive toxicity of therapy, but compromises the well-being 
of a patient with a high risk of termination of the therapy. 
Twelves et al. demonstrated in a post-hoc analysis of the X-ACT trial that HFS was associated with 
improved outcome in patients treated with capecitabine (Twelves et al., 2012).The association 
between HFS and survival was also established (Hofheinz et al., 2012) in a pooled dataset from AIO 
KRK-0104 and the Mannheim rectal cancer trials. In this study, patients with any grade of HFS 
showed a significantly improved PFS/DFS (29.0 vs. 11.4 months; HR=0.69, P= .015) as well as OS 
(75.8 vs. 41.0 months; HR=0.56, P= .001). No difference was noted between patients presenting with 
HFS at the beginning of therapy or those that developed HFS later. In patients presenting with HFS, 
a significantly higher rate of any grade of diarrhoea, stomatitis/mucositis, and fatigue was reported, 
but no similar correlation with haematological toxicity was found. It had been interesting to know if 
diarrhoea, stomatitis/mucositis, and fatigue were associated with outcome in capecitabine treated 
patients. With regard to our observations, it might be speculated that both the mucosal lining and the 
skin are more susceptible to injury from 5-FU than haematopoiesis. This could also explain why 
haematological toxicity, at least in the adjuvant setting, does not seem to be as strong a predictor of 
survival as non-haematological toxicity. Enhancing the effect of registered chemotherapeutic and 
biological agents 
Despite the improved prognosis for patients with early stage CRC, disease recurrence occurs in 30-
50% of patients (Koo et al., 2013). Therefore, tools to further improve the treatment outcome in the 
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adjuvant setting are needed. Irinotecan and the biological agents have failed to show efficacy in early-
stage disease and no new drugs are in sight at least shortly. Thus, we need to investigate whether it 
might be possible to improve treatment outcome by enhancing the cytotoxic effect of 5-FU both in 
the adjuvant and metastatic settings.  
In clinical practice, patients undergoing chemotherapy that do not experience adverse events 
sometimes enquire whether the treatment is beneficial at all, and based on our results and the 
published data, this question is highly relevant. We know that it is possible to improve outcome and 
decrease treatment-related toxicity using pharmacokinetically guided dose escalation, but 
pharmacokinetic measurements are cumbersome, and therefore cannot be performed easily in clinical 
practice (Saif et al., 2009). This explains why we do not use pharmacokinetically guided dose 
escalation in the clinic, but the author of this thesis wonders whether we have focused so intensively 
on the development of new agents that such a “simple” approach is forgotten.  
Tumour sidedness has been a topic that has attracted great interest in CRC oncology lately, but it had 
already been reported in 1990 that there are major differences in the underlying pathogenesis of 
proximal and distal tumours (Bufill, 1990). It took 15 years for this topic to attract higher levels of 
interest, and our treatment practices have now drastically changed. Tumour sidedness does not require 
complicated measurements to guide the therapy. Likewise, though follow-up of adverse events is 
carried out in everyday clinical practice, treatments are currently modified only if the toxicity level 
is high. High toxicity is associated with poorer survival and consequently, the reduction in the dose 
should be performed in time. Probably the best outcomes are achieved when the toxicity level is mild 
or moderate, with or without dose reduction. As observed in our results, patients presenting with 
grade 2 neutropenia, mucositis, and the worst non-haematological toxicity had the most favourable 
outcomes. As discussed, HFS was shown to be associated with the outcome. HFS is a not a life-
threating adverse event; it can easily be monitored and the inconvenience caused because of HFS can 
be relieved by supportive approaches, such as the use of appropriate creams. A difficulty encountered 
while obtaining our results is that adverse events such as mucositis and nausea/vomiting cannot be 
easily or objectively monitored, and even grade 1 nausea or mucositis can be highly inconvenient, 
compromise well-being, and decrease QOL. Therefore, it is difficult to set the dose based on the grade 
of nausea/vomiting, a higher grade of mucositis, or deeper neutropenia, but the capecitabine dose 
could be titrated to ensure at least mild HFS. Skin toxicity is a known predictive factor for EGFR-
antibodies, and therefore the phase II EVEREST trial studied whether the skin toxicity-based dose-
escalation of cetuximab improved outcome (Van Cutsem et al., 2012b). In this study, the cetuximab 
dose was escalated if the patient did not present with at least grade 2 skin toxicity during the first 21 
days of treatment. Dose escalation was proven to result in an improved RR (30% vs. 16%) and disease 
control rate (70% vs. 58%), but did not significantly improve OS. To the best of our knowledge, there 
is scarcity of data with regard to toxicity-based dose escalation and chemotherapeutics in CRC 
patients.  
Henricks et al. recently published results from the first prospective study conducted to investigate the 
effect of dose individualisation on fluoropyrimidine-related toxicity, based on the four best-
recognised DPYD variants (Henricks et al., 2018). They observed that genotype-guided dosing was 
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feasible in clinical practice and dose individualisation reduced the risk of severe 5-FU-related 
toxicities, but they did not evaluate treatment outcome. They did perform pharmacokinetic 
measurements, and the findings suggested that applied dose reductions in DPYD variant allele carriers 
did not result in 5-FU underdosing, but it does not discussed about whether we should screen for fast 
metabolizers to avoid underdosing in these patients.  
To establish the impact of results in study III, a prospective randomised trial using toxicity-based 
dose-escalation needs to be conducted.  
10.4 Neuropathy and Quality of life 
Nowadays, CRC survivors represent the third largest cohort of cancer survivors because of their 
improved survival, which would hopefully improve further (Amstutz et al., 2018). Acute toxicity 
during therapy has been of interest as long as chemotherapeutics have been in use, but the interest in 
long-term toxicities and QOL after therapy in cancer survivors is increasing. Data in the metastatic 
setting suggest that QOL is an independent predictor of improved survival and similar findings have 
currently been observed in early-stage disease (Braun et al., 2011; Maisey et al., 2002; Wong et al., 
2014). The American Society of Clinical Oncology (ASCO) was the first to establish a Cancer 
Survivorship Task Force in 2004, to develop a coordinated strategy for providing follow-up care to 
the growing population of cancer survivors. ASCO has currently established its guidelines for 
survivorship care (El-Shami et al., 2015; McCabe et al., 2013) and ESMO has published a patient 
guide for survivors (www.esmo.org).  
It is known that patients report higher grades of toxicities than doctors, and that patients start to report 
adverse events earlier than doctors (Mayor, 2015). HTN or haematological toxicity is easy to grade 
because the value is dependent on an objectively measured value. On the contrary, the grading of 
nausea, fatigue, diarrhoea, and neuropathy is more complicated, as we know that there is a variation 
between how patients interpret, tolerate, and report their symptoms and how they cope with them in 
everyday life (Bernhard et al., 1999b). Therefore, though PROMs are being focused on and 
commonly incorporated in clinical trials, in clinical practice, we still grade toxicities according to 
versions of NCI-CTCAE. 
In general, the QOL in CRC survivors is reported to be relatively good (Adams et al., 2016; Jansen 
et al., 2010; Ramsey et al., 2000; Ramsey et al., 2002), but advanced age at diagnoses, higher BMI, 
lower education, smoking, and other co-morbidities are associated with a lower QOL (Adams et al., 
2016; Jansen et al., 2010). However, these factors can cause the QOL to deteriorate independently, 
and might not be specifically related to CRC and CRC survivorship. Patients are often fearful about 
stomas in advance and some studies report an inferior QOL in stoma patients (Guren et al., 2005; 
Jansen et al., 2010); however, there are also studies that have shown contrary results (Smith-Gagen 
et al., 2010). The most critical aspect reportedly influenced by the presence of the stoma is the social 
component of QOL, which partially differs based on the gender (Krouse et al., 2009). Females are 
reported to experience more psychological and physical stress due to the stoma, but men report more 
sexual dysfunction (Guren et al., 2005).  
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What is reported about the impact of adjuvant therapy on QOL in CRC survivors? It is known that 
acute toxicity during 5-FU-based adjuvant therapy is reversible and short-lived, and QOL during 
therapy is dependent on the regimen and the acute toxicity profile of the treatment (Chau et al., 2005; 
Chen et al., 2015; Norum et al., 1997). Patients treated with single agent 5-FU do not experience 
long-term toxicities, and deterioration in the long-term QOL is minor, as compared to patients treated 
with surgery alone (Gray et al., 2007; Norum et al., 1997). On the contrary, in patients treated with 
oxaliplatin-based adjuvant chemotherapy, increasing amounts of data suggest that long-term 
neuropathy can be permanent (Grothey et al., 2018; Iveson et al., 2018), but it is not established 
whether it impairs the long-term QOL. An increasing number of studies have reported about 
neuropathy and QOL findings, but the methods to assess neuropathy and follow-up times between 
studies vary, which makes it difficult to conduct comparisons. In addition, the availability of data 
regarding the prevalence and course of neuropathy in a subarctic climate such as that of Finland is 
minimal.  
We studied the prevalence of acute and long-term neuropathy, and impact of long-term neuropathy 
on QOL in CAPOX- and FOLFOX- treated patients in the Finnish sub-arctic climate. Any grade of 
acute neurotoxicity was observed in 96% of the patients included in our study, which is in line with 
the results of some previous studies, which have reported neurotoxicity rates of 92-95% (Andre et al., 
2004b; Ducreux et al., 2011; Farhana et al., 2018). However, we have reported grade 3-4 neuropathy 
during adjuvant therapy in 26% of the patients, which is more than reported in large phase III adjuvant 
studies such as MOSAIC (FOLFOX, 12.5%), XELOXA (CAPOX, 11%), and NSABP C-07 (FLOX, 
8.4%), but in line with that of smaller studies (Argyriou et al., 2012; Ducreux et al., 2011; Farhana et 
al., 2018). We have also reported about grade 2-4 acute toxicity in 71% of the patients, which is more 
than that reported by the IDEA study in the six-month arm (FOLFOX arm 48% and CAPOX arm 
45%) (Grothey et al., 2018). We did not observe differences between treatment regimens with regard 
to the prevalence of acute neuropathy. Our observations might be attributed to the subarctic climate. 
With regard to long-term neuropathy, we have reported any grade and grade 2-4 of long-term 
neuropathy in 68% and 33% of patients, respectively, at a median follow-up time of 4.2 years. 
MOSAIC has reported about any grade of neuropathy in 24% of patients becoming grade 3 in 0.7% 
of patients at 18 months (Andre et al., 2004a). Further, MOSAIC has reported neuropathy grade 1 in 
12%, grade 2 in 3%, and grade 3 in 0.7% of patients at year 4 of follow-up (André et al., 2009). The 
NSABPC-07 trial has reported about persistent neuropathy at 27 months in 10% of patients (Land et 
al., 2007). Thus, the patients in our study demonstrate more long-term neuropathy than those in two 
large, randomised trials, but our results are in line with those of a small Australian study (n=25), 
which showed that oxaliplatin-induced nerve damage did not get resolved during a median follow-up 
of 2 years, and that significant clinical and neurophysiological deficits persisted in 79 % of patients 
(Park et al., 2011). Notably, the Australian and our studies specifically assessed neurotoxicity using 
neurophysiological tests or deep interviews, which can explain the differences observed, as compared 
to pure toxicity grading using NCI-CTCAE in clinical trials. We did not observe differences between 
treatment regimens with regard to the prevalence of long-term neuropathy or in CIPN20 subscales.  
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After the publication of the IDEA results (Grothey et al., 2018), the duration of adjuvant therapy in 
low-risk patients was reduced to three months, but the recommended duration for high-risk patients 
is still six months. Our study is of value, as it demonstrates that the development of neuropathy is 
hard to predict and long-term severe neuropathy can be observed during treatments conducted for a 
duration that is ≤ 3 months. There was statistically more long-term neuropathy observed in patients 
presenting with acute grade 2-4 neurotoxicity. We observed that an ECOG performance status that 
was > 0 was associated with long-term neuropathy and to the best of our knowledge, the availability 
of such data is scarce. Medicated diabetes was not associated with neuropathy in our patients. Apart 
from ECOG performance status, our findings are in line with most previous studies demonstrating 
that no baseline factor predicts long-term neuropathy (Brouwers et al., 2009; Uwah et al., 2012).  
The risk of long-term neuropathy has been associated with a cumulative dose of oxaliplatin in most 
previous studies (Beijers et al., 2015; Park et al., 2011), though not by all (Brouwers et al., 2009; 
Stefansson and Nygren, 2016). Data supporting the association between cumulative dose and 
neuropathy come partly from pivotal metastatic trials, but a growing body of evidence from adjuvant 
trials has shown that lower cumulative doses of oxaliplatin result in less acute and long-term 
neuropathy. In the IDEA trial, grade 2-4 acute neurotoxicity was reported in 17% of the patients 
treated with FOLFOX and in 15% of patients treated with CAPOX in the three month arm, which is 
significantly less than that observed in the six month arm (48% vs. 45%, respectively) (Grothey et al., 
2018). In addition, of the three pivotal adjuvant trials, the least long-term neuropathy was reported 
with NSAPB C-07, with the smallest cumulative dose of oxaliplatin (25% less in FLOX as compared 
to that in FOLFOX and CAPOX) (Andre et al., 2004a; André et al., 2009; Haller et al., 2011a; Land 
et al., 2007). We did not see a significant association between the cumulative dose of oxaliplatin and 
risk of acute or long-term neuropathy in our study. The high cumulative dose used in our study (770 
mg/m2) and the small patient number might explain this. 
The strength of our study is the long follow-up and assessment time, for the objective NCI-
CTCAEv3.0 and PROMs in the form of CIPN, as well as the assessment of both acute and long-term 
neuropathy. We also have data for all consecutive CAPOX patients with matched FOLFOX controls, 
which would enable us to perform a direct head-to-head comparison. Methodological challenges were 
encountered, as the CIPN20 was not available in Finnish or in Swedish and was therefore filled-in 
during the interview together with the patient, which affected the results either way. The interviews 
really gave us a deep insight into the phenomenon known as reframing means, during which the 
perception of QOL is affected by the life-threating disease, i.e., cancer and its treatment (Bernhard et 
al., 1999a). Most people think that it is of utmost importance to survive cancer; even though the cost 
of QOL would be high and they would remain symptomatic, they still considered the QOL to be 
relatively good.  
Some studies have shown that neuropathy has a negative influence on QOL (Mols et al., 2014; 
Stefansson and Nygren, 2016; Tofthagen, 2010), but most studies have investigated QOL and 
neuropathy separately. Mols et al. conducted a systematic review of 14 studies, in which three of 
these studies did not find an association between neuropathy and QOL, while the other 11 concluded 
that more neuropathy is associated with a lower QOL. However, it is difficult to associate the meta-
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analysis with our study, as it included many cytotoxins, different tumours, and treatment indications 
(Mols et al., 2014).  
The biggest study conducted in CRC patients is a population-based Dutch study (n=1643), which 
reported about health-related QOL (HRQOL) and chemotherapy-induced neuropathy findings in 
CRC survivors, 2 to 11 years after diagnosis (Mols et al., 2013). HRQOL was assessed with QLQ-
C30, while neuropathy was assessed with CIPN20. In all patients, the most common neuropathy-
related symptoms reported in CIPN20 were erectile problems (42% of men), trouble hearing (11%), 
trouble opening jars or bottles (11%), tingling in the toes/feet (10%), and trouble walking on stairs or 
standing up (9%). Patients who received oxaliplatin reported significantly more tingling (29% vs. 8%; 
P= .001), numbness (17% vs. 5%; P= .005), and an aching or burning pain (13% vs. 6%; P= .03) in 
the toes/feet, as compared to that in patients not treated with chemotherapy at all. In addition, it was 
studied whether there was a difference between patients treated with chemotherapy, with or without 
oxaliplatin. Patients treated with oxaliplatin reported more frequent tingling in the toes/feet (29% vs. 
14%; P= .0127), as compared with patients treated with fluoropyrimidines alone. As discussed by the 
authors, the most common symptoms reported are those types that can be commonly caused by 
several other conditions as well by cancer or its treatment. It was expected that patients treated with 
oxaliplatin would report significantly more tingling, numbness, and aching/burning pain, as compared 
with patients that were not treated with chemotherapy. Only tingling was observed to be significantly 
increased in a comparison between chemotherapy groups that did or did not receive oxaliplatin, which 
might be explained by the small number of chemotherapy patients (162 oxaliplatin-receiving, 118 
other chemotherapy-receiving) included in the study, as discussed in the report. In addition, patients 
exhibiting the maximum number of neuropathy symptoms reported significantly and clinically 
relevant worse HRQOL scores on all EORTC QLQ-C30 subscales (all P< .01). 
A cross-sectional patient series in 111 CRC survivors demonstrated that oxaliplatin-induced 
neuropathy impairs the emotional and physical well-being of patients, and thus affects the QOL 
(Tofthagen et al., 2013). This is in line with the impaired physical functioning noted in our study. In 
addition, our findings demonstrate that patients with long-term neuropathy exhibit impaired role 
functioning, which is in line with the findings of the Swedish study (Stefansson and Nygren, 2016). 
In our material, long-term neuropathy was associated with more diarrhoea, but in other subscales, we 
did not find any associations. An important observation is that the global health scale is not affected 
by long-term neuropathy, which is in line with the findings of the Swedish study (Stefansson and 
Nygren, 2016), but contrary to those of the studies by Tofthagen and Mols (Mols et al., 2013; 
Tofthagen et al., 2013). Even severe, grade 3-4 neuropathy did not impair the global health status in 
our study. This can be explained by the reframing process observed during the interviews. As a patient 
who was retired owing to impaired dexterity told us, “Neuropathy is a low price to pay for being 
alive.”  
Our study has a significant value because it was conducted in a sub-arctic climate. To the best of our 
knowledge, such data are scarcely available. Altaf et al. reported that in a Danish patient material , 
patients who received oxaliplatin during the coldest months of Danish winter (December-February) 
required more dose reductions during their first cycle, as compared to those required for patients 
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treated outside this period (Altaf et al., 2014). The Danish study did not provide long-term neuropathy 
data. As mentioned previously, a Swedish study reported that there is no association between the 
cumulative dose of oxaliplatin and long-term neuropathy, which is in line with our findings; this poses 
a question about whether acute and long-term neuropathy are triggered at lower doses in a subarctic 
climate (Stefansson and Nygren, 2016). We observed no difference in acute or long-term neuropathy 
in patients treated during the coldest months (January-February), and received the bulk of their 
treatment in winter, as compared to patients treated outside this period. Stefansson et al. do not report 
neuropathy grades, only CIPN20 scores, which makes direct comparison challenging. They have also 
not reported about any data related to acute toxicity, climate, and temperature. Therefore, our study 
is one of the few to report neuropathy findings in relation to temperature, in a subarctic climate. We 
noted no seasonal variation, but this might be attributable to the small number of patients and the fact 
that the mean temperature in a sub-arctic climate is low around the year.  
To conclude the findings of the substudy III, it is notable that in a subarctic climate such as that of 
Finland, it is not possible to eliminate the risk of grade 2-4 long-term neuropathy by reducing the 
duration of therapy to three months. Even though the global health status was not deteriorated in 
patients suffering from grade 2-4 long-term neuropathy, our observations establish that long-term 
neuropathy is present in a significant number of patients, and because we cannot treat neuropathy, we 








 The assessment and eradication of H. pylori before the initiation of adjuvant 5-FU-based 
treatment cannot be recommended.  
 An important message to clinicians is that H. pylori and related symptoms might interfere with 
CRC diagnostics. Even if a diagnosis of H. pylori infection has been made, colonoscopy should 
always be considered in differential diagnostics. 
 Patients who develop or require intensified treatment for HTN during bevacizumab treatment 
might survive longer and HTN might be a predictive surrogate marker for treatment efficacy and 
continued care. 
 Neutropenia is associated with significantly improved DFS in patients treated with FU-based 
adjuvant chemotherapy. 
 Mild or moderate non-haematological toxicity is a strong predictor of improved DFS and OS in 
patients who received FU-based adjuvant chemotherapy; mucositis and nausea/vomiting seem to 
be especially predictive. No treatment-related toxicity associated with the poorest survival. 
 The prevalence of long-term neuropathy after oxaliplatin-based adjuvant chemotherapy seems to 
be higher than expected in real-life patient populations.  
 Long-term neuropathy did not deteriorate the global QOL, but had an impact on physical and role 
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